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Previous findings have suggested that functional variants within collagen encoding 
genes are associated with several musculoskeletal soft tissue injuries and other 
exercise-related phenotypes. Specifically variants within the functional COL5A1 3’-
untranslated region (UTR) have previously been associated with (1) chronic Achilles 
tendinopathy, (2) Anterior Cruciate Ligament (ACL) ruptures in females, (3) 
endurance running performance and (4) range of motion (ROM). Since this gene 
encodes for an important structural component of the collagen fibril it has been 
hypothesised that variants within other collagen fibril encoding genes, such as 
COL3A1, COL6A1 and COL12A1, will also be associated with these and/or other 
musculoskeletal soft tissue injuries and exercise-related phenotypes. 
 
The COL5A1 rs12722 and COL12A1 rs970547 gene variants have been previously 
associated with risk of ACL ruptures in females [153;154] and/or chronic Achilles 
tendinopathy [131;181]. The first aim of this thesis was therefore to investigate the 
COL3A1 rs1800255 and COL6A1 rs35796750 gene variants as risk factors for these 
musculoskeletal soft tissue injuries. The objectives to address this aim were: 
 
 To investigate the COL3A1 rs1800255 and COL6A1 rs35796750 gene 




 To investigate the COL6A1 rs35796750 gene variant as a risk factor for 
Achilles tendinopathy in independent SA and Australian cohorts. 
 
Since the COL5A1 rs12722 variant was previously associated with endurance 
performance and ROM, the second aim of this thesis was to further investigate the 
COL3A1, COL6A1, and COL12A1 genes for associations with these exercise-related 
phenotypes. Therefore, the objectives to address this aim were: 
 
 To investigate the COL3A1 rs1800255, COL6A1 rs35796750 and COL12A1 
rs970547 gene variants as intrinsic factors for ROM in a SA cohort. 
 To investigate the COL3A1 rs1800255, COL6A1 rs35796750 and COL12A1 
rs970547 gene variants as intrinsic factors for endurance performance in 
participants of the SA Ironman triathlon. 
 
The third aim of this thesis was the investigation of COL3A1 rs1800255, COL5A1 
rs12722, COL6A1 rs35796750 and COL12A1 rs970547 in novel exercise-related 
phenotypes, namely exercise associated muscle cramps (EAMC) and rugby union 
playing level and position. The objectives to address this aim were: 
 
 To investigate the COL3A1 rs1800255, COL5A1 rs12722, COL6A1 
rs35796750 and COL12A1 rs970547 gene variants as risk factors for EAMC 
in a South African cohort. 
 To investigate the COL3A1 rs1800255, COL5A1 rs12722, COL6A1 




rugby union playing level and position in professional SA Super 15 rugby 
union players. 
 
Since COL6A1 rs35796750 has previously been predicted to be functional, the final 
aim of this thesis was to investigate the expression of the COL6A1 gene in 




Participants within several phenotypic groups were previously recruited. These 
groups include; (1) participants with diagnosed ACL rupture and matched controls 
(2) participants with diagnosed chronic Achilles tendinopathy and matched controls, 
(3) participants that were measured for range of motion, (4) participants from the 
South African Ironman triathlon, (5) participants with a history of EAMC and matched 
controls and (6) professional South African Super 15 rugby union players. All 
participants were genotyped, where appropriate, for COL3A1 rs1800255, COL5A1 
rs12722, COL6A1 rs35796750 and COL12A1 rs970547 using standard PCR based 
methods. Furthermore, to address the final aim of this thesis primary skin fibroblasts 
were cultured, from participants with known COL6A1 rs35796750 genotypes, and 









This thesis identified a novel independent association between COL5A1 rs12722 
and past history of EAMC but not for rugby union playing level and position. 
Specifically the COL5A1 rs12722 CC genotype was significantly under-represented 
(p=0.031, OR=2.2, 95% CI 1.1–4.5) in the EAMC group (CC genotype 11.1%) when 
compared to the control group (CC genotype 21.8%). 
 
COL12A1 rs970547 
Although this COL12A1 variant was previously associated with ACL ruptures in 
females, no additional significant independent associations were identified between 
COL12A1 rs970547 and any of the exercise-related phenotypes (ROM, EAMC, 
endurance performance and rugby union) investigated in this thesis. 
 
COL6A1 rs35796750 
An additional novel finding of this thesis was that the COL6A1 rs35796750 gene 
variant was independently associated with endurance cycling performance in 
Ironman triathletes. Specifically, participants with the COL6A1 rs35796750 TT 
genotype were significantly faster than those with a TC or CC genotype in the bike 
component of the triathlon (p=0.014). No other independent associations were 
identified between this variant and any of the other musculoskeletal soft tissue 





Novel functional analysis of the COL6A1 rs35796750 variant revealed, for the first 
time, that participants with a COL6A1 rs35796750 T allele (TT or TC genotype) had 
significantly higher levels of COL6A1 gene expression than their CC genotype 
counterparts. Specifically, participants with a T allele had a 1.8 fold increase in 
COL6A1 expression (p=0.001) when compared to participants with a CC genotype.  
 
COL3A1 rs1800255 
The COL3A1 rs1800255 gene variant was significantly independently associated 
with the male forwards rugby union positional sub-group. Specifically, the COL3A1 
rs1800255 GG genotype was significantly (p=0.047) under-represented in the 
forwards rugby union position sub-group (39.6%, n=38) when compared to controls 
(53.5%, n=76). No other independent associations were identified between this 
variant and any of the other musculoskeletal soft tissue injuries and exercise-related 
phenotypes investigated in this thesis. 
 
In addition to the independent associations identified, a final novel finding of this 
thesis was that a number of inferred pseudo-haplotypes, constructed from COL3A1 
rs1800255, COL5A1 rs12722, COL6A1 rs35796750 and/or COL12A1 rs970547, 




This thesis identifies a number of collagen gene variants which are associated with 
various musculoskeletal soft tissue injuries and other exercise-related phenotypes. 




the phenotypes investigated in this thesis. Furthermore, as initially hypothesised, the 
mechanism for most of these associations is consistent with that previously 
proposed for COL5A1 rs12722 [41]. Future studies are required to investigate and 
understand the contrasting and unique results identified for COL6A1 rs35796750. 
The COL3A1 rs1800255 variant was associated with a number of phenotypes, while 
no additional independent associations were identified for COL12A1 rs970547. In 
addition, varying gene-gene interactions were identified between the four variants 
and six phenotypes investigated in this thesis. These results highlight the complexity 
in identifying genetic, and other, markers for the inter-individual predisposition to 
musculoskeletal soft tissue injuries and other exercise-related phenotypes. 





INTRODUCTION AND SCOPE OF THE THESIS 
 
Collagen proteins are important structural components of the collagen fibril and 
building blocks of musculoskeletal tissues. Rare mutations within collagen encoding 
genes, such as COL1A1, COL3A1, COL5A1, COL6A1 and COL12A1, cause 
debilitating musculoskeletal disorders. These disorders include but are not limited to, 
osteogenesis imperfecta [144;147], chondrodysplasias [205], Ehlers-Danlos 
syndrome [34;121;122;124;186;218], Bethlem Myopathy [17;161] and Ullrich 
Congenital Muscular Dystrophy [17;161]. These severe clinical disorders highlight 
the importance of this protein family in the normal structure and function of 
musculoskeletal tissues and suggest a lack of biological redundancy within the 
collagen fibril [41]. Musculoskeletal tissues, are not only common sites of injury 
during participation in physical and certain occupational activities, they also play an 
important role in contributing to athletic performance. Many of these collagen fibril 
encoding genes are therefore ideal candidates for association with less severe 
multifactorial exercise-related phenotypes [163]. 
 
Changes to types III, V, VI and XII collagen levels within the collagen fibril result in 
changes to its architecture and organisation which may modulate the biomechanical 
properties of tissue containing these proteins [19;21;78;110;133;207]. It has 
therefore been proposed that common variants, like the previously studied COL5A1 
Chapter 1   
2 
 
rs12722 [1;2;28;29;40;107;131;151;153;156;179] and COL12A1 rs970547 [154;181] 
single nucleotide polymorphisms, within the genes that encode these collagens may 
be associated with seemingly unrelated musculoskeletal soft tissue injuries and other 
exercise-related phenotypes, such as range of motion and athletic performance [41]. 
The COL5A1 and COL12A1 genes encode for the α1(V) and α1(XII) chains of types 
V and XII collagen respectively [18]. It has been previously proposed that the 
associated collagen gene variants will, at least in part, directly or indirectly alter 
collagen fibril architecture and structure and, thereby, the mechanical properties of 
musculoskeletal soft tissue [41]. This thesis will therefore examine the hypothesis 
that common variants within several collagen-encoding genes are associated with 
musculoskeletal soft tissue injuries and other exercise-related phenotypes.  
 
The COL5A1 rs12722 variant was previously shown to be associated with chronic 
Achilles tendinopathy [131;179] and anterior cruciate ligament (ACL) ruptures in 
females [153], while the COL12A1 rs970547 variant was only associated with ACL 
ruptures in females [154], but not Achilles tendinopathy [181]. The first aim of this 
thesis was therefore to further investigate the association of common variants within 
the COL3A1 and COL6A1 genes as additional risk factors for chronic Achilles 
tendinopathy and ACL ruptures. These genes encode for the α1 chains of types III 
and VI collagen respectively. In addition, the COL5A1 rs12722 variant was also 
previously shown to be associated with range of motion [1;28;29;40] and athletic 
performance [1;28;151]. The second aim of this thesis was therefore to investigate 
the COL3A1, COL6A1 and COL12A1 genes and these exercise-related phenotypes. 
The third aim of this thesis was to investigate the collagen genes, specifically 
COL3A1, COL5A1, COL6A1 and COL12A1, for associations with novel exercise-
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related phenotypes, namely exercise associated muscle cramps and rugby union 
playing level and position. The final aim of this thesis was to investigate the 
functional effects of the COL6A1 rs35796750 variant in order to further the 
understanding, and determine biological mechanisms, of how this gene variant may 
modulate exercise-related phenotypes.  
 
In preparation for the exploration and further discussion of the experimental chapters 
of this thesis, Chapter 2 will provide a focussed review of collagens, their genes, as 
well as the role of collagen gene sequence variants in the aetiology of exercise-
related phenotypes. The rationale for the collagen gene sequence variants 
investigated in this thesis will also be provided. Subsequent experimental chapters 
(Chapters 3 to 8) will use a candidate gene approach to achieve the primary, 
secondary and tertiary aims of this thesis. The final aim of this thesis will be achieved 
through the use of specific molecular assays and techniques as outlined in chapter 
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 CHAPTER 2 
 
COLLAGEN GENE SEQUENCE VARIANTS AND EXERCISE-
RELATED PHENOTYPES: A REVIEW 
 
2.1 AN OVERVIEW OF COLLAGENS AND THE STRUCTURE OF THE 
COLLAGEN FIBRIL 
 
Collagens are a family of twenty-eight structurally and functionally diverse proteins 
which consist of three polypeptide α-chains wound in a characteristic uninterrupted 
or interrupted left-handed triple helical structure [84;114]. The majority of these 
proteins are important for tissue assembly or maintenance [84]. Furthermore, many 
are the major macromolecular building blocks of the collagen fibril, which is the 
structural component of tendons, ligaments, bone, cartilage and connective tissue 
structures in muscle and other tissues (Figure 2.1) (Section 2.5.1). Although some 
collagen types, such as type XI collagen [16], are structural components or 
associated with the collagen fibril in both types of tissues, non-cartilaginous 
connective tissues generally contain a different set of collagen proteins when 
compared to cartilage (Table 2.1) (Figure 2.1) [9;84]. Since the collagen fibril within 
The information presented in this chapter has been published in a condensed 
form in the peer-reviewed article: O'Connell K, Saunders CJ, Collins M. Collagen 
Gene Sequence Variants in Exercise-Related Traits. Central European Journal of 
Sports Science and Medicine 2013; 1: 3-17 
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the musculoskeletal system is an important structure in injury and exercise-related 
phenotypes, this review will focus predominately on the structural collagens of the 
non-cartilage and, to a lesser extent, the cartilage fibril as well as those collagens 
that are directly associated with these fibrils. The structure and functions of the entire 
collagen family has been previously reviewed [84;164].  
 
 
Figure 2. 1. A schematic diagram of the collagen fibril 
Figure 2.1. A schematic diagram of the collagen fibril, adapted from Collins and Posthumus 
[41]. The major fibrillar type I (solid white cylinders) and III (hatched cylinders) collagen 
molecules comprise the majority of the non-cartilaginous fibril. The minor fibrillar type V 
collagen (solid black cylinders with globular ends) is embedded within the fibril with a 
protruding amino terminal end. Type XII and XIV collagen (solid black cylinders with forked 
ends) belong to the fibril-associated collagens with interrupted triple helices (FACITs) sub-
family. Beaded non-fibrillar type VI collagen (solid grey circles) interacts, at the surface of the 
fibril, with the other collagens that make up the fibril. Collagen types listed in parentheses 
are the cartilage specific collagens equivalent to those they are listed under. The proteins in 
this diagram are not drawn to scale. 
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Table 2.1. The classification of collagens within the non-cartilage and cartilage fibril, as well 
as, the basement membrane (BM) area.  
 
  Non-cartilage Cartilage BM Area 
Fibrillar Major I, III II III 2 
 Minor V XI 1  
 “Non-classical” XXIV 3 XXVII 3  
Non-fibrillar FACITs 4 XII, XIV, XVI 
5, 
XX 6, XXI 7 IX, XX 
6 XIX 7, XXII 8 
 Beaded filament   VI 9, XXVIII 10 
 Network forming   IV 
 Short chain VIII X VIII, X 
 Anchoring fibrils   VII 11 
 Multiplexins 12   XV 13, XVIII 
 
Transmembrane 
domains   
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Collagens listed in italic typeset and underlined are not, or have not been shown to be, 
involved in the musculoskeletal system. 
1 also expressed in the developing tendon 
2 reticular fibres 
3 not classical fibrillar collagens, expressed primarily in cartilage and sites of transition from 
cartilage to bone 
4 fibril associated collagens with interrupted triple helices 
5 high levels have been detected in fibroblasts, keratinocytes and smooth muscle [89] 
6 prevalent within corneal epithelium but has also been identified in embryonic skin and 
tendons [97] 
7 been identified within skeletal muscle amongst other tissues [54;132] 
8 expressed in myotendinous junctions [99] 
9 predominately expressed in the basement membranes of skeletal muscle [109]  
10 expressed in the skin and calvaria [202]. 
11 expressed only in the retina [149] 
12 contains multiple triple-helix domains interrupted by non-collagenous domains 
13 mainly derived from muscle cells and fibroblasts [68] 
14 specifically expressed in the ovary and testis [169] 
Table 2. 1. The classification of collagens within the non-cartilage and cartilage fibril, as well as, the basement membrane (BM) 
area. 
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The collagen family can be divided into two groups based on their structure and 
function: (i) the fibrillar, or fibril-forming, collagens which form the fibrillar scaffolding 
for the extracellular matrix and, (ii) the non-fibrillar collagens which include, amongst 
others, the fibril associated collagens with interrupted triple helices (FACITs), beaded 
filament collagens, network forming collagens, short chain collagens, anchoring 
fibrils, multiplexin and transmembrane domains (Table 2.1) [84;166]. The different 
musculoskeletal collagen types, with a focus on collagens found within tendons, 
ligaments and/or connective tissue layers of skeletal muscle, will be reviewed in the 
following sections. 
 
2.1.1 Classical Fibrillar Collagens 
 
The classical fibrillar collagens are further sub-divided, based on quantity, into the 
major (types I, II, III) and minor (types V, XI) fibrillar collagens [84]. The predominant 
major fibrillar collagen is type I collagen consisting of two α1(I) and one α2(I) chains.  
It is responsible for the hierarchical structure and mechanical strength of non-
cartilage connective tissue [52;75;162]. Type II collagen, a homotrimer consisting of 
three α1(II) chains, is the equivalent main structural collagen in cartilage [86]. Type 
III collagen, which consists of three α1(III) chains, is also a major fibrillar collagen 
which forms heterotypic fibrils together with type I collagen, and is important in 
healing and during fibrillogenesis [9;114]. It is thought that type III collagen regulates 
the diameter of type I collagen fibrils during development and healing by limiting 
lateral growth [9]. Tissues with elastic properties, such as skin and arteries, also 
have a higher type III collagen content than less elastic tissues [60]. Type III collagen 
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is also known to form a fine supporting meshwork known as the reticular fibres within 
the basement membranes of soft tissues [200]. 
 
Type V collagen is a minor fibrillar collagen which is co-expressed with types I and III 
collagen and also plays a role in the regulation of type I collagen fibril diameter 
[18;201]. The predominant isoform of type V collagen is a heterotrimer of two α1(V) 
and one α2(V) chains, however other isoforms, which may contain α3(V) chains, also 
exist [18]. Type XI collagen is traditionally considered the minor fibrillar collagen co-
expressed with type II collagen in cartilage [84;201]. Recent investigations on the 
function of type V collagen in tendon development suggest a synergistic role with 
type XI collagen in the regulation of fibrillogenesis and growth of mature tendon 
fibrils [207]. Types XXIV and XXVII collagen, although not classical fibrillar collagens, 
are nevertheless also fibrillar collagens expressed primarily in cartilage and sites of 
transition from cartilage to bone [23;74;98;144], while type XXVII collagen is also 
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2.1.2 Fibril-Associated Collagen with Interrupted Triple Helices (FACITs) 
 
The “classical” well characterised FACITs, which include types IX, XII and XIV [60], 
are important non-fibrillar collagens in mediating cell-matrix interactions between the 
collagen fibres and cell surfaces [166], and during stabilisation of the attached 
collagen triple helices [25;164]. Figure 2.2 shows the structure of these “classical” 
FACITs, as well as how they affect cell-matrix interactions. Type IX collagen plays a 
role in the mechanical stability and resistance to swelling of the collagen type II fibril 
framework of cartilage [209]. One of the short isoforms of type XII collagen, XIIB-1, is 
predominately expressed in tendons and ligaments [85]. Type XIV collagen is also 
shown to be expressed in skeletal muscle connective tissue after denervation and 
during muscle fibre regeneration [195]. 
 
Other lesser characterised FACITs include types XVI, XX, XXI, XIX and XXII 
collagens. High levels of type XVI collagen have been detected in fibroblasts and 
keratinocytes, as well as smooth muscle [89]. Type XX collagen is prevalent within 
corneal epithelium but has also been identified in embryonic skin and tendons [97]. 
Types XIX and XXI collagen have been identified within skeletal muscle amongst 
other tissues [54;132], while type XIX collagen is also expressed in the skin [132]. 
Furthermore, investigation of the myotendinous junctions has revealed that muscle 
cells produce collagen XXII, which acts as a cell adhesion ligand for skin epithelial 
cells and fibroblasts [99]. 
  

















Figure 2.2. A schematic diagram showing the structures of types IX, XII and XIV collagen, 
adapted from Gordon and Hahn [64]. The cell-matrix interaction of FACITs is also shown. 
The FACITs are required for fibril fusion and interaction, however too many FACITs will 
adversely affect fibril fusion and interaction. 
 
2.1.3 Non-fibrillar Beaded Filament Collagens 
 
Type VI collagen (Figure 2.3), a non-fibrillar beaded filament collagen, is 
predominately expressed as a microfibrilllar network in close association with the 
basement membranes of skeletal muscle [109], and also facilitates fibrillar interaction 
with the extracellular matrix through interactions with types I, V, and XII collagens 
[129;190;201]. In addition, abnormal collagen fibrillogenesis in Col6a1 deficient mice 
highlights the potential importance that type VI collagen may have in this biological 
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process [78]. Type VI collagen is predominately a heterotrimer made up of one 
α1(VI), one α2(VI) and one α3(VI) chain, encoded by the COL6A1, COL6A2 and 
COL6A3 genes respectively. More recently, heterotrimers containing α4(VI), α5(VI) 
and α6(VI) chains, encoded by the COL6A4, COL6A5 and COL6A6 genes, have 
also been identified [55]. Type XXVIII collagen is a beaded filament collagen 
restricted in expression to the skin and calvaria (skullcap), specifically to the dorsal 


















Figure 2. 3. A schematic diagram of the type VI collagen beaded filament, adapted from Lampe and Bushby. 
 
 
Figure 2.3. A schematic diagram of the type VI collagen beaded filament, adapted from 
Lampe and Bushby [109]. The α1(VI), α2(VI) and α3(VI) chains assemble intracellularly and 
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2.1.4 Other Non-fibrillar Collagens 
 
Other non-fibrillar collagens include the network forming (IV), short chain (XVIII, X), 
anchoring fibrils (VII), multiplexins (XV, XVIII), transmembrane domains (XIII, XVII, 
XXIII, XXV) and those with unknown function (XXVI). Although type IV collagen isn’t 
a structural component of the fibril, it does form a major part of the basement 
membrane, which surrounds and anchors the cellular component of musculoskeletal 
tissues, and maintains tissue architecture during development and wound healing 
[84;194]. In particular, the basement membranes are connected to cells by receptors 
which specifically bind to type IV collagen and other proteins.   
 
The short-chain collagen types VIII and X form networks in the basement 
membranes of non-cartilaginous and cartilaginous tissues respectively [84]. Type VII 
collagen, the only anchoring fibril, is expressed only in the retina [149]. Multiplexins, 
types XV and XVIII collagen, contain multiple triple-helix domains interrupted by non-
collagenous domains. Type XV collagen is mainly derived from muscle cells and 
fibroblasts [68], and the absence of type XV collagen results in skeletal myopathy 
and cardiovascular defects in mice [49]. Less is known about type XVIII collagen, 
however lack of type XVIII collagen leads to ocular defects as a result of aberrant 
blood vessel formation and integrity [211]. 
 
Although all transmembrane domain collagens, types XIII, XXIII and XXV share 
structural similarity, all differing to type XVII collagen. Type XIII collagen has high 
expression during development and growth which decreases during adulthood and is 
expressed in the basement membrane of myotendinous and neuromuscular 
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junctions, amongst other tissues [72;189]. Type XXV is also necessary for the 
normal functioning of the neuromuscular junction [192]. Type XXIII collagen shows a 
greater diversity of expression and has been identified in the basement membrane of 
lung, cornea, skin, tendon and kidney tissue [100]. Unlike types XIII, XXII and XXV 
collagen, type XVII collagen is  not implicated in the musculoskeletal system but is 
instead necessary for the normal supply of melanocytes to the epidermis [65]. The 
non-fibrillar collagens are further reviewed by Ricard-Blum et al. [164]. 
 
2.1.5 Collagen Synthesis 
 
Typically, the polypeptide α-chains of the fibrillar collagens comprise approximately 
1000 amino acids in an uninterrupted repeating triplet, which contains a glycine 
amino acid in every third position with proline and 4-hydroxyproline residues in the 
other two positions (Gly-X-Y) [84]. These repeating triplets are essential for the 
formation of the uninterrupted and interrupted triple helical domains in all the 
collagens (Figure 2.4) [84]. Most collagens occur as homotrimers of three identical α-
chains, however heterotrimers of two or three different α-chains are also common 
[84]. These α-chains are wound together in a left-handed triple helix and, in the 
major fibrillar collagens (I, II and III), the globular amino- and carboxy-terminal 
domains flanking the uninterrupted triple helix are post-translationally cleaved prior to 
their aggregation into collagen fibrils (Figure 2.4) [9;84;136]. Only the carboxy-
terminal globular domains of the minor fibrillar collagens (V and XI) are post-
transnationally cleaved. The triple helical domains of types V and XI collagens are 
imbedded in the non-cartilaginous and the cartilaginous fibrils respectively. The 
amino-terminal globular domains of these molecules protrude from the surface of the 
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fibril where they play an important role in regulating fibrillogenesis (Figure 2.1). The 


















Figure 2.4. A schematic diagram of collagen fibril assembly. The polypeptide α-chains of the 
fibrillar collagens comprise an uninterrupted repeating triplet, which contains a glycine amino 
acid in every third position with proline and 4-hydroxyproline residues in the other two 
positions (Gly-X-Y). This is indicated by the hydroxyl (-OH) groups on the type I collagen α-
chains. These repeating triplets form the triple helical domains in all the collagens. In the 
major fibrillar collagens, including type I collagen, the globular carboxy- and amino-terminal 
domains flanking the triple helix are post-translationally cleaved prior to their aggregation 
into collagen fibrils. Post-translational cleavage of the amino-terminal domain does not occur 
in some of the minor fibrillar (type V collagen) and non-fibrillar (type XII and XIV collagens) 
collagens. Type I and type XII collagen have been used as examples for the collagen fibril 
assembly process. The molecules and proteins in this diagram are not drawn to scale. 
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Although several collagen types are expressed in tendons, ligaments and the 
connective tissue structures within skeletal muscle, this thesis will focus on types I, 
III, V, VI and XII collagen. These collagens will be further reviewed in section 2.3 and 
2.6 of this chapter, as well as, the introductions of the results chapters of this thesis. 
 
2.2 MENDELIAN AND MULTIFACTORIAL COLLAGEN RELATED 
DISORDERS 
 
The major structural domains of collagen proteins are typically highly conserved 
across species, and each polypeptide α-chain is encoded by a specific gene (Table 
2.2). In the case of homotrimeric collagens, all three α-chains are encoded by the 
same gene. For example, the α1 chains of type II collagen are encoded by the 
COL2A1 gene.  In heterotrimeric collagens, each different α-chain is encoded by a 
different gene. The COL1A1 and COL1A2 genes, for example, encode the α1 and 
α2 chains of type I collagen respectively. Rare mutations in many of these genes 
result in serious musculoskeletal disorders including, amongst others, osteogenesis 
imperfecta [144;147], chondrodysplasias [205] and Ehlers-Danlos syndrome 
[34;121;122;124;186;218] (Table 2.2). Symptoms of these disorders include bone 
fragility, joint hypermobility, skin hyperextensability and abnormal wound healing 
[124;147]. These severe clinical disorders highlight the importance of this protein 
family in the normal structure and function of musculoskeletal tissues.  
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Table 2.2. Disorders resulting from rare mutations or common variants in the collagen 
gene(s) that encode for the non-cartilage and cartilage fibril, as well as the collagen network 
around the fibril producing cells. 
Type Gene(s) Mendelian Disorder(s)
a
 Complex Multifactorial Disorder(s) 
I COL1A1 
COL1A2 
Osteogenesis imperfecta, EDS, 
Infantile Cortical Hyperostosis  
Osteoporotic Fractures, Osteoarthritis, 
Myocardial Infarction, Lumbar Disc 
Disease, Stress Urinary Incontinence 
II COL2A1 Collagenopathy, types II and III 
Mild Spondyloepiphyseal Dysplasia 
Congenita, Nonsyndromic Cleft Palate, 
Osteoarthritis, Myopia 
III COL3A1 EDS (Hypermobility type; type 3), EDS (Vascular type; type 4) 
Mitral Valve Prolapse, Pelvic Organ 
Prolapse, Cervical Artery Dissection, 
Rupture of Intracranial Aneurysms 
IV COL4A1 
COL4A6 
Porencephaly, Alport Syndrome, 







EDS (Classic type; types 1 and 2) 
Central Corneal Thickness, Ischemic 
Heart Disease, Cervical Artery 






Bethlem Myopathy, Ullrich Congenital 
Muscular Dystrophy  
Ossification of the Posterior 
Longitudinal Ligament (OPLL) and the 




Posterior Polymorphous Corneal 
Dystrophy, Fuchs' Endothelial Corneal 
Dystrophy 
Primary Open Angle Glaucoma, 





Epiphyseal Dysplasia, Stickler 
Syndrome 
Osteoarthristis, Lumbar Disc 
Degeneration 





Fibrochondrogenesis, Marshall Syn., 
Stickler Syn., Weissenbacher-
Zweymuller Syn., Deafness, 
Otospondylomegaepiphyseal 
Dysplasia 
Lumbar Disc Herniation, Limbus 
Vertebra, Lumbar Spine Stenosis, 
OPLL, Rheumatoid Arthritis 
XII COL12A1 EDS, Developmental Delay, Mild Dysmorphism, Lax Connective Tissue 
Abnormal Corneal Endothelial 
Maturation 
XIV COL14A1 Punctate Palmoplantar Keratoderma, Recurrent Strokes  
Abnormal Corneal Endothelial 
Maturation 
XXVII COL27A1 None identified to date Tourette's Syndrome 
 
EDS, Ehlers-Danlos Syndrome; OPLL, Ossification of the Posterior Longitudinal Ligament.  
a as listed in the OMIM database [142] 
Table 2. 2. Disorders resulting from rare mutations or common variants in the collagen gene(s) that encode for 
the non-cartilage and cartilage fibril, as well as the collagen network around the fibril producing cells. 
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Since rare mutations within most of the genes encoding the collagens in the fibril 
cause severe disorders, it has been hypothesised that there is a lack of biological 
redundancy within the collagen fibril [41].  In support of this hypothesis, in addition to 
these severe rare Mendelian disorders, common variants within the collagen genes 
are also associated with a multitude of anomalous connective tissue phenotypes 
(Table 2.2). Therefore, it is possible that a continuum of associated phenotypes may 
exist for the range of genetic variation within these genes encoding the fibrillar and 
non-fibrillar collagens.  An example of this genetic continuum was recently proposed 
to describe phenotypes associated with variation within the COL5A1 gene (Figure 
2.5) [41]. Two functional copies of the COL5A1 gene are required for normal 
development, structure and function of the connective tissue. Mutations that 
inactivate both copies of COL5A1 result in death in utero [206], while mutations, 
which inactivate a single copy of the gene (haploinsufficiency) will result in classical 
types of Ehlers-Danlos syndrome (EDS) [124]. At this end of the continuum the 
mutations in COL5A1 result in death or EDS, which occur regardless of 
environmental exposure and independent of other non-genetic risk factors [41].  At 
the opposite end of the continuum, functional common variants within COL5A1 
contribute to more complex and less severe phenotypes, and do not result in 
disorders. These multifactorial phenotypes arise as a result of the interaction 
between genetic and non-genetic factors modifying physiological responses to 
environmental exposures [41].  
 
Lethal mutations have also been described within other fibrillar collagen encoding 
genes, such as COL1A1, COL1A2 and COL2A1, and severe musculoskeletal tissue 
disorders caused by non-lethal mutations within most of the genes encoding 
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components of the collagen fibril have also been reported (Table 2.2). As with the 
COL5A1 genetic continuum, these mutations result in death or severe disorders 
which occur regardless of environmental exposure and independent of other non-
genetic risk factors (Figure 2.5).  At the opposite end of the continuum, it may be 
proposed that common variants within the same collagen genes contribute to less 
severe phenotypes, including exercise-related phenotypes, by modifying the effects 
of environmental exposures (Figure 2.5). This proposal is supported by experimental 
studies investigating common variants in genes encoding fibrillar and fibrillar-
associated collagens with exercise-related phenotypes and will be expanded on in 













Figure 2.5. A proposed general genetic continuum for collagen genes, adapted from Collins 
and Posthumus [41]. The black shading represents the lethal or severe phenotypes due to 
mutations in the collagen genes. At this end of the continuum a single mutation results in the 
disorder. The white shading represents the most beneficial “versions” of the collagen genes. 
At this end of the continuum variants within collagen genes collectively contribute to the 
aetiology of the phenotype. The COL5A1 gene and rs12722 gene variant are used as 
examples at each stage of the continuum.   
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2.3 FIBRILLAR AND FIBRIL-ASSOCIATED COLLAGEN GENES AND 
EXERCISE-ASSOCIATED PHENOTYPES  
 
2.3.1 Type I Collagen 
 
Type I collagen, encoded by the COL1A1 and COL1A2 genes, is the predominant 
fibrillar collagen in non-cartilage connective tissues [52;75;162]. Several polymorphic 
regulatory elements have been identified within the promoter and first intron of the 
COL1A1 gene, which result in differing transcription factor binding affinities and in 
turn regulate α1(I) chain production [81;126]. One of the most extensively 
investigated functional polymorphic transcription factor binding sites is the Sp-1 
binding site variant (rs1800012, G/T) within the first intron of the COL1A1 gene 
(Figure 2.6). The G allele of this variant produces normal levels of COL1A1 mRNA 
and the heterotrimeric protein consisting of two α1(I) and one α2(I) chains.  However, 
the T allele has been shown to functionally increase the binding of the transcription 
factor Sp-1 to its binding element within the first intron thereby increasing COL1A1 
mRNA transcription and translation, resulting in the proposed formation of α1(I) 
homotrimers from the excess α1(I) chains produced. It has been proposed that 
tissues consisting of both hetero- and homotrimeric type I collagen are produced, 
which have different mechanical properties to the normal tissue only consisting of 
heterotrimers [81;126].   
 
The association of this functional Sp-1 binding site variant with cruciate ligament 
injuries has been investigated in Swedish [91], South African [152] and Polish [53] 
cohorts (Table 2.3). In all three studies the rare TT genotype was under-represented 
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in participants with diagnosed cruciate ligament (predominately ACL) ruptures when 
compared to apparently healthy control participants with no history of cruciate 
ligament injuries [53;91;152]. In a combined analysis of all three published studies 
and a second unpublished South African ACL cohort (H Knight, personal 
communication), which all had similar genotype distributions, the TT genotype was 
significantly over-represented (p<0.0001, odds ratio 23.8, 95% confidence interval 
3.2 to 176.2) in the control groups (26 TT, 4.3%; 161 GT, 26.4% and 428 GG, 
70.3%) when compared to the cruciate ligament rupture groups (1 TT, 0.2%; 168 









Figure 2. 6. A schematic representation of the exon and intron boundaries of the human COL1A1 gene, which contains 52 
exons. 
 
Figure 2.6. A schematic representation of the exon (vertical lines) and intron (horizontal 
lines) boundaries of the human COL1A1 gene, which contains 52 exons. The Sp1 
transcription factor binding site, which has been enlarged, is located within intron 1 and 
contains the rs1800012 G/T variant. The rs1800012 T allele increases the binding affinity of 
Sp1 thereby increasing COL1A1 mRNA and type I collagen protein translation. This variant 
is associated with cruciate ligament ruptures [53;91;152] and has been investigated as risk 
factor for other musculoskeletal soft tissue injuries [51;91;155]. 
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Table 2.3. A comparison of the genotype frequency distributions for COL1A1 rs1800012 
(G/T) between anterior cruciate ligament (ACL) and control (CON) groups within the 
Swedish (SW), South African (SA) and Polish (PL) cohorts. 
 
 
COL1A1 rs1800012 Genotype 
n Ref 
GG GT TT 
SW CL a 69.5 (162) 30.0 (70) 0.5 (1) 233 
[91] 
SW CON 70.7 (230) 25.6 (83) 0.7 (12) 325 
SA ACL 65.9 (139) 34.1 (72) 0.0 (0) 211 
[152]b 
SA CON 69.4 (102) 25.2 (37) 5.4 (8) 147 
PL ACL 71.4 (65) 28.6 (26) 0.0 (0) 91 
[53] 
PL CON 67.1 (96) 28.7 (41) 4.2 (6) 137 
Table 2. 3. A comparison of the genotype frequency distributions for COL1A1 rs1800012 (G/T) between the Swedish, South African and Polish cohorts. 
Values are expressed as percentages with the number of participants indicated in 
parentheses. The total number (n) of participants genotyped in each individual or combined 
cohort is also indicated. 
a This study did not distinguish between posterior and anterior cruciate ligament ruptures 
and merely grouped them together as cruciate ligament (CL) ruptures 
b The published SA data was pooled with a second unpublished SA ACL cohort (H 




The most recent investigation of the Sp1 binding site variant (rs1800012) also 
reported an interaction between this variant and another polymorphic regulatory 
element in the COL1A1 promoter (rs1107946, G/T, position −1997) in modulating 
risk of ACL injury [53]. Specifically, the haplotype constructed from the rs1800012 T 
and rs1107946 G alleles, both known to functionally increase expression of COL1A1, 
was over-represented in the control participants when compared to individuals with 
cruciate ligament ruptures [53] [81].   
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In the original Swedish study the intronic COL1A1 rs1800012 TT genotype also 
showed a tendency to be under-represented (p=0.123) in participants with shoulder 
dislocations (0.8%) compared to controls (3.7%) (Table 2.4) [91]. In addition, the 
COL1A1 Sp1 binding site variant was also investigated for risk of both acute Achilles 
tendon ruptures (n=41) and chronic Achilles tendinopathy (n=83) in a South African 
cohort (Table 2.4) [155]. Although no significant associations were identified for 
either the acute or chronic injuries, it is interesting to note that the TT genotype was 
absent in individuals diagnosed with acute Achilles tendon ruptures (0.0% ruptures, 
2.4% tendinopathy and 4.8% controls) [155]. This variant was also recently shown 
not to be associated (p=0.170) with tennis elbow (lateral epicondylitis), although the 
TT genotype frequency was lower in the tennis elbow group (1.9%) when compared 
to the control group (6.8%) (Table 2.4) [51].  
 
Furthermore, studies have shown an increase in type I collagen mRNA expression in 
tendinopathic tendons [165], while differential expression of type I collagen in 
anterior cruciate ligaments is associated with the degree of healing after a rupture 
[117]. These findings highlight the potential differences in the genetic and 
biochemical components contributing to risk of acute and chronic injuries and require 
further investigation.  
 
In addition to this injury mechanism specific association, it is also interesting to note 
that the TT genotype is associated with increased risk in a number of other 
pathologies, such as osteoarthritis, osteoporotic fractures and lumbar disc disease 
(Table 2.2) [80]. This highlights that certain gene variants may affect the aetiology of 
phenotypes in different ways. The reasons for these differences remains unknown, 
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however it may be the result of interactions with other gene variants, interactions 
with environmental stimuli and/or changes to the mechanical properties of the tissue 







Table 2.4. A summary of the associations investigated between COL1A1 rs1800012 and 




Associated Studies Ref 
ACL Ruptures Yes 3 [53;152] 
Shoulder Dislocations ? 1 [91] 
Achilles Ruptures ? 1 [155] 
Achilles Tendinopathy No 1 [155] 
Lateral Epicondylitis 
(Tennis Elbow) No 1 [51] 
    
? These studies show tendencies towards an association but larger cohorts are needed to 
determine whether a true association exists. 
 
Tab 
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2.3.2 Type V Collagen 
 
As mentioned previously, type V collagen is known to interact with types I and III 
collagen and plays a role in the regulation of collagen fibrillogenesis [18;201].  The 
rs12722 T/C variant within the 3’-untranslated region (UTR) of the COL5A1 gene, 
which encodes the α1 chain of type V collagen, was the first collagen gene variant 
reported to be associated with Achilles tendon injuries [131]. Specifically, the CC 
genotype was significantly over-represented in physically active healthy control 
participants with no self-reported history of Achilles tendon injury when compared to 
participants with clinically diagnosed chronic Achilles tendinopathy in independent 
South African and Australian cohorts (Figure 2.7) [131;179]. Several other variants, 
rs71746744 (-/AGGG), rs169399 (ATCT/-) and rs1134170 (A/T), within the COL5A1 
3’-UTR were also found to independently associate with risk of Achilles tendinopathy 
in the same Caucasian South African and Australian cohorts [2]. Specifically, the 
COL5A1 rs71746744 AGGG/AGGG, rs169399 -/- and rs1134170 TT genotypes 
were significantly over-represented in the participants with clinically diagnosed 
Achilles tendinopathy when compared to the controls in both cohorts as well as in 
the combined cohorts (Figure 2.7) [2]. 
 
Interestingly, one study has also investigated a variant, COL5A1_01 G/A, within 
intron 65 of the equine COL5A1 gene for an association with superficial digital flexor 
(SDF) tendinopathy [199]. Specifically, horses with the AA genotype were 
significantly (p=0.010) over-represented in the SDF tendinopathy group when 
compared to yard-matched controls [199]. Other equine COL5A1 variants which 
were located upstream of the associated polymorphism were however not 
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independently associated with SDF. Both the human and equine associated variants 
are located within the 3’-end of the gene suggesting that this region of the COL5A1 
gene within both species could contain important elements directly involved in the 
















Figure 2.7. A schematic representation of the exon (vertical lines) and intron (horizontal 
lines) boundaries of the human COL5A1 gene, which contains 66 exons. Every 5th exon is 
labelled. Exon 66, which has been enlarged, encodes for the terminal amino acids of the 
α1(V) chain (black box), the stop codon and the 3’-untranslated region (UTR) (clear box). 
The four variants (i) rs12722 (T/C), (ii) rs71746744 (-/AGGG), (iii) rs169399 (ATCT/-) and (iv) 
rs1134170 (A/T) previously shown to be associated with risk of Achilles tendinopathy 
[2;131;179] and other exercise-related phenotypes [28;29;40;151;153] are all located within 
the 3’-UTR (indicated by arrows and dotted lines). The alleles in green typeset were 
associated with reduced risk of Achilles tendinopathy. The alleles in red typeset were 
associated with increased risk of Achilles tendinopathy. Also noted within the 3’-UTR region 
are an expressed sequence tag (EST; ENSESTG00000033016, function unknown) and 
three putative polyadenylation signals (A, multiple lines). 
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Posthumus et al. [153] further investigated the COL5A1 rs12722 T/C variant for an 
association with risk of ACL injuries in a Caucasian South African cohort. The CC 
genotype was also significantly over-represented in apparently healthy female 
control participants (27.3%, 23 of 84) when compared with female participants with 
ACL ruptures confirmed at surgery (5.4%, 2 of 37), but not in a male cohort [153]. 
The reasons for this gender specific association remain unknown. 
 
Since the 3′-UTR of eukaryotic genes contains elements which are emerging as 
important post-transcriptional regulators [127;210], it has been suggested that the 
COL5A1 3’-UTR plays a role in the regulation of the COL5A1 mRNA stability and by 
implication type V collagen production. In support of this, two major functional allelic 
forms of the COL5A1 3’-UTR, namely the C- and T-forms, have been identified and 
show significant differences in mRNA stability, with the T-form having increased 
stability (Figure 2.8) [107]. The T- and C-allelic forms were predominately identified 
in participants diagnosed with Achilles tendinopathy and asymptomatic controls 
respectively [107]. The differences in the sequence of the two functional forms of the 
3’-UTR is determined by seven variants which include the four variants, rs12722 
(T/C), rs71746744 (-/AGGG), rs169399 (ATCT/-) and rs1134170 (A/T), shown to be 
independently associated with chronic Achilles tendinopathy (Figure 2.8) [107]. 
Based on these findings, Collins and Posthumus [41] proposed that the relative 
content of type V collagen in tendons, ligaments and other tissues alters the fibril 
diameters and packing density within these tissues. This will alter their mechanical 
properties, and therefore their susceptibility to injury and other exercise-related 
phenotypes (Figure 2.8). Based on their hypothesis [41], COL5A1 3’-UTR variants 
have also been investigated for associations with other exercise-related phenotypes, 
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including range of motion (ROM) measurements [1;28;29;40;196] and endurance 


















Figure 2.8. A schematic diagram showing the proposed functionality of the COL5A1 3’-UTR 
and its effects on the collagen fibril, adapted from Hay et al. [71]. A functional region with the 
COL5A1 3’-UTR (1), containing a number of gene variants which compose a C- and T-form, 
is known to alter the secondary structure of the COL5A1 mRNA (2). This altered structure is 
proposed to result in altered mRNA stability (3 right panel). The T-form is proposed to result 
in increased levels of type V collagen within the fibril (4 right panel), which results in smaller 
more densely packed fibrils (5 right panel). Conversely, the C-form is proposed to produce 
less stable COL5A1 mRNA (3 left panel), resulting in lower levels of type V collagen in the 
fibril (4 left panel) and therefore larger less densely packed fibrils (5 left panel). The C-form, 
in green typeset, is associated with reduced risk of Achilles tendinopathy, while the T-form, 
in red typeset, is associated with increased risk of Achilles tendinopathy.  
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Mutations within COL5A1 cause classic EDS, a condition that is characterized by 
joint hypermobility [124]. Furthermore, it was proposed that COL5A1 is associated 
with benign joint hypermobility syndrome [66]. Altered musculotendinous flexibility, 
which is defined as ‘‘the ability to move a joint through its complete range of motion’’ 
(ROM), has been cited as an intrinsic risk factor for many injuries [95;96;103], 
including tendon and ligament injuries. Although flexibility can be improved through 
regular stretching, it is at least in part also determined genetically [69]. Since variants 
within COL5A1 may affect tissue architecture and biomechanical properties [41], 
variants within this gene were investigated for associations with ROM 
measurements. The COL5A1 rs12722 variant was associated with lower limb ROM 
measurements in a mixed injured/uninjured cohort [40]. In addition, a follow up study 
in an independent, larger cohort of apparently healthy physically active Caucasian 
South Africans reported that the COL5A1 rs12722 CC genotype protected 
participants against an age-related decline in sit-and-reach ROM [29]. More recently, 
the COL5A1 rs12722 CT genotype was also significantly over-represented in a 
cohort of Italian high-level international rhythmic gymnasts when compared to an 
active control group, further implicating this variant in modulation of joint mobility 
[196]. Since this functional variant was associated with sit-and-reach ROM, it was 
recently investigated for effects on the mechanical properties of human tendons in 
vivo [58;104]. The results of these studies will be discussed in section 2.5.2. 
 
Reduced ROM, specifically sit-and-reach ROM, has also been associated with 
improved endurance running economy and performance [45;82]. This relationship is 
proposed to result from reduced aerobic demand due to increased elastic return and 
may result in improved performance [82]. Given that the COL5A1 rs12722 variant is 
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associated with sit-and-reach ROM [29;40], it is not surprising that this variant was 
also associated with endurance running performance. The TT genotype of this 
variant was associated with faster run times in South African Ironman triathletes 
while triathletes with the CC genotype were over-represented in the slowest tertile for 
the run stage of this triathlon [151]. The TT genotype was also associated with faster 
performance in a 56km ultra-marathon road race [28].  Furthermore, when these 
endurance runners were divided into four quadrants (Fast and inflexible, fast and 
flexible, slow and inflexible, slow and flexible) based on both their race finishing 
times and sit-and-reach ROM measures, runners with the COL5A1 rs12722 T allele 
were over-represented in the fast and inflexible quadrant.  
 
A second COL5A1 variant located within the functional COL5A1 3’-UTR, rs71746744 
(-/AGGG), was later shown to be associated with both endurance running 
performance and sit-and-reach ROM measures in 56km ultra-marathon runners [1]. 
Specifically, the rs71746744 AGGG/AGGG genotype was associated with increased 
performance and reduced sit-and-reach ROM, similar to the rs12722 TT genotype. 
Interestingly the rs71746744 AGGG and rs12722 T alleles contribute to the 
functional T-form as described above. 
 
2.3.3 Type XI Collagen 
 
Type XI collagen has been suggested to interact with type V collagen in the 
regulation of fibrillogenesis during tendon development [207], and sequence variants 
within the genes encoding the α-chains of type XI collagen have also been 
investigated for association with Achilles tendinopathy in Caucasian South African 
  Review 
31 
 
and Australian populations [71]. Although there were no independent genotype 
associations with risk of chronic Achilles tendinopathy for the COL11A1 rs3753841 
(T/C), COL11A1 rs1676486 (C/T) and COL11A2 rs1799907 (T/A) variants, 
significant gene-gene interactions in modulating risk of Achilles tendinopathy were 
observed [71]. Specifically, the TCT inferred pseudo-haplotype constructed from 
rs3753841, rs1676486 and rs1799907 was significantly over-represented in 
participants with clinically diagnosed Achilles tendinopathy (25.9%) when compared 
to control participants (17.1%) in a combined Caucasian South African and 
Australian cohort [71]. Similarly the TCT pseudo-haplotype was significantly over-
represented in the Achilles tendinopathy participants when the South African and 
Australian cohort were analysed separately [71]. Furthermore, the TCT(AGGG) 
pseudo-haplotype constructed from the type XI collagen genes and independently 
associated COL5A1 rs71746744 (-/AGGG) variant was also significantly over-
represented in the Achilles tendinopathy participants (25.2%) compared to the 
controls (9.1%) [71].  
 
The T allele of COL11A1 rs1676486 results in reduced COL11A1 expression [159]. 
The proposed effects of the variants with known function, COL5A1 rs12722 and 
COL11A1 rs1676486, that contribute to the inferred pseudo-haplotypes mentioned 
above have been previously reported (Figure 2.9) [71]. Based on the functional 
effects of these variants it was hypothesised that this interaction between COL11A1 
and COL5A1 may modulate risk of chronic Achilles tendinopathy by affecting mRNA 
stability, thereby altering type V and/or XI collagen production, which in turn 
regulates collagen fibril diameter and changes the biomechanical properties of the 
collagen fibril [71]. In addition, this interaction further corroborates the evidence 
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Figure 2. 9. A hypothetical schematic diagram illustrating the proposed mechanism of how polymorphisms within COL5A1 and 
COL11A1 potentially affect fibrillogenesis.  
 
Figure 2.9. A hypothetical schematic diagram illustrating the proposed mechanism of how 
polymorphisms within COL5A1 and COL11A1 potentially affect fibrillogenesis, adapted from Hay et al. 
[71]. Although there is no evidence that type XI collagen is produced in the mature, diseased and/or 
healing tendon, it is produced and functional during tendon development.  
(A) The COL5A1 rs71746744 (-/AGGG) and COL11A1 rs1676486 (C/T) polymorphisms are part of an 
inferred pseudo-haplotype that is associated with chronic Achilles tendinopathy. The COL5A1 
rs71746744 - allele and the COL11A1 rs1676486 T allele are both believed to be associated with 
increased mRNA degradation (increased mRNA degradation is indicated in the left panel, while 
decreased mRNA degradation is indicated in the right panel).  
(B) The altered mRNA stability associated with these polymorphisms is believed to result in altered 
α1(V) and α1(XI) chain and types V and XI collagen production (decreased in left panel and increased 
in the right panel).  
(C) Types V and XI collagen regulates collagen fibril assembly and diameter and thus the mechanical 
properties of tendons. There is an inverse relationship between the types V and XI collagen content of 
the fibril and its diameter. Thinner more densely packed collagen fibrils are produced due to the 
increased production of types V and XI collagen (right panel). It has previously been proposed that 
the thinner fibrils are associated with chronic Achilles tendinopathy. 
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2.3.4 Type XXVII Collagen 
 
As previously mentioned, the fibrillar type XXVII collagen is expressed primarily in 
cartilage and sites of transition from cartilage to bone, but also in skeletal muscle 
[23;74;144]. Recently, Saunders et al. [171] investigated variants within the 
neighbouring COL27A1 and TNC genes as risk factors for chronic Achilles 
tendinopathy in Caucasian South African and Australian populations. Both of these 
genes are also situated close to COL5A1 on chromosome 9 (Figure 2.10), and a 
variant within the TNC gene was previously associated with chronic Achilles 
tendinopathy [130;171]. Although no independent associations were identified for 
COL27A1 rs946053 (G/T), this variant was implicated in a haplotype, with the TNC 
rs13321 and rs2104772 variants, associated with risk of chronic Achilles 
tendinopathy [171]. This finding highlights the possibility that variants in COL27A1 
and its neighbouring genes also play a role in modulating the risk of chronic Achilles 
tendinopathy and suggests that COL27A1 variants may be useful candidates in the 
investigation of other exercise-related phenotypes.  
  












Figure 2. 10. A schematic representation of human chromosome 9 showing the relative positions of the COL27A1, TNC, ABO 




Figure 2.10. A schematic representation of human chromosome 9 showing the relative 
positions of the COL27A1, TNC, ABO and COL5A1 genes (adapted from September et al. 
[182]). The centromere binds with the nuclear spindle during mitosis and meiosis. The 
telomeres refer to the end regions of the chromosome. The chromosome is comprised of a 
short arm (p) and a long arm (q). The dark and light areas reflect the unique banding pattern 
of chromosome 9 when stained using cytogenetic techniques. The nomenclature of each 
band is indicated on the right side of the chromosome. A segment within the long arm of 
chromosome 9 (9q32–q34), which encompasses the COL27A1, tenascin C (TNC), ABO and 
COL5A1 genes, is also shown. The vertical lines represent the relative position of each 
gene, while the arrows indicate the direction of their transcription. Mb, megabase  
 
 
The equine TNC gene, like the equine COL5A1 gene as mentioned in section 2.3.2, 
was also investigated for risk of SDF tendinopathy in horses [199]. The TNC BIEC2-
696469 T/C variant was found to be associated with SDF tendinopathy. Specifically 
the CC genotype was significantly (p=0.010) under-represented in SDF tendinopathy 
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group when compared to yard-matched controls [199]. As in humans, the COL27A1 
gene is upstream of the TNC gene on chromosome 25 in horses 
(http://www.ncbi.nlm.nih.gov/gene/). These results further highlight the potential to 
investigate the effects of variants on tissues containing these variants in equine 
models for tendinopathy and other phenotypes. 
 
2.4 GENES ENCODING THE FACITS  
 
2.4.1 Type XII and XIV Collagen 
 
FACIT collagens, such as types XII and XIV collagen, mediate cell-matrix 
interactions between the collagen fibres and cell surfaces [166], and assist with 
stabilisation of the attached collagen triple helices by bridging with adjacent fibrils, 
thereby resisting shear forces [25;164]. Furthermore, these collagens play a similar 
role to type V collagen in regulating collagen fibril assembly and diameter [213]. The 
COL12A1 gene encodes the α1(XII) chains of long (XIIA) and short (XIIB) 
homotrimeric isoforms of type XII collagen (Figure 2.11). Interestingly the short 
isoform is predominately expressed in both tendons and ligaments in response to 
mechanical loading [85]. The α1(XIV) chains of type XIV collagen are encoded for by 
the COL14A1 gene (Figure 2.11). As such, September et al. [181] investigated 
variants within both COL12A1 and COL14A1 for associations with risk of Achilles 
tendinopathy in a South African population. However, no significant associations 
between COL12A1 rs240736 (T/C), COL12A1 rs970547 (G/A), COL14A1 rs4870723 
(A/C) and COL14A1 rs1563392 (T/A) and risk of Achilles tendinopathy were 
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observed [181]. The COL12A1 rs970547 and rs240736 variants were also 
investigated for an association with risk of ACL rupture in a Caucasian South African 
cohort [154]. Interestingly, a significant association was again only identified after 
gender stratification of the participants. The COL12A1 rs970547 AA genotype was 
significantly over-represented in female participants with clinically diagnosed ACL 















Figure 2.11. A schematic representation of the (A) COL12A1 and (B) COL14A1 genes, 
adapted from September et al. [181]. The COL12A1 gene has two transcripts, a short (top 
panel A) and a long (bottom panel A) variant. The exon (vertical lines) and intron (horizontal 
lines) boundaries are shown. The four variants, COL12A1 rs240736 and rs970547 and 
COL14A1 rs4870723 and rs1563392, investigated by September et al. [181] for associations 
with Achilles tendinopathy are boxed. The rs970547 associated with risk of ACL ruptures is 
circled in red [154]. 
A 
B 
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2.5 COLLAGEN FIBRIL ORGANISATION AND THE MECHANICAL 
PROPERTIES OF MUSCULOSKELETAL SOFT TISSUE 
 
2.5.1 The Collagen Component of Tendons, Ligaments and Connective Tissue 
Structures in Muscle and other tissues 
 
Collagen fibres (Figure 2.12) form the structural component of tendons, ligaments 
and connective tissue structures in skeletal muscle. Specifically, these collagen 
fibres account for approximately 85% of the dry weight of the extracellular matrix 
(ECM) of tendons, while other components include 1-5% proteoglycans and 2% 
elastin [83]. Type I collagen fibrils account for 95-99% of the collagen fibres, followed 
by type III collagen which account for approximately 1-5% (Figure 2.1) [75;83]. Other 
minor collagens within the tendon include, amongst others, types IV, V, VI, XII and 
XIV collagen (Table 2.5) [75;83]. Interestingly, expression of these collagens may be 
specific to portions of the tendon (Table 2.5), including the tendon midsubstance, 
myotendinous junction (where the tendon connects to the muscle) and 
osteotendinous junction or entheses (where the tendon connects to the bone). 
Collagen fbrils come together to form fibres which in turn are bundled together to 
form fascicles (Figure 2.12) [165]. Each fascicle is surrounded by a loose connective 
tissue “membrane” called the endotenon [165]. These fascicles are then grouped 
together, and surrounded by another loose connective tissue “membrane” called the 
epitenon, to form the tendon (Figure 2.12) [165]. This results in a highly organised 
structure in which the fibres are all oriented uni-directionally along the long axis of 
the tendon [75;83]. 
 











Figure 2.12. The hierarchical structure of a tendon, adapted from Riley [165]. Collagen 
molecules are grouped together to form the fibril [165]. Fibrils come together to form fibres 
which in turn are bundled together to form fascicles [165]. Each fascicle is surrounded by 
connective tissue called endotenon [165]. These fascicles are then grouped together, and 
surrounded by epitenon, to form the tendon [165]. The hierarchical structure of ligaments is 
similar to that of tendons as shown above [75]. 
 
 
Although there are important functional differences, ligaments and tendons have a 
very similar hierarchical structure (Figure 2.12) [75]. Specifically, collagen fibrils form 
fibres which are then bundled into fascicles, and these fascicles make up the 
ligament [75]. Despite their similarities in structure the composition of ligaments and 
tendons is different. The fibres that make up the ligament are less well organised 
resulting in a multi-directional orientation leading to a weaving pattern [75;83]. 
Furthermore, differences also exist at a molecular level. Unlike tendons, only 70-80% 
of the dry mass of ligaments is made up of collagen fibres, while the remainder of the 
ligament ECM is composed of glycoproteins, proteoglycans and glycosaminoglycans 
[75]. The collagen composition of ligaments is approximately 90% type I collagen, 
10% type III collagen and as much as 12% type V collagen [75]. In addition, the 
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Table 2.5. A summary of “well characterised” collagens identified within tendons, ligaments 







Midsub MTJ OTJ Endo Peri Epi 
Fibrillar        
I √ √ √ √ √ √ √ 
II   √     
III √  √ √ √ √ √ 
V √   √ √ √  
XI    √    
Non-fibrillar        
IV  √   √   
VI  √ √ √ √   
XII √   √  √  
XIV √   √  √  
 
The localisation of collagen types is indicated by “ticks”. The tendon is shown as three 
separate portions; the midsubstance (Midsub), the myotendinous junction (MTJ) and the 
osteotendinous junction (OTJ). The three separate connective tissue subdivisions of skeletal 
muscle are shown; the endomysium (Endo), the perimysium (Peri) and the epimysium (Epi). 
 




In contrast to tendons and ligaments, muscle tissue is composed mainly of myofibres 
(muscle cells) while the intramuscular connective tissue accounts for only 1-10% of 
the tissue dry mass [79;92]. This intramuscular connective tissue is comprised of 
three distinct subdivisions, namely the endomysium, perimysium and epimysium 
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[62]. The endomysium is a load-bearing network that surrounds individual muscle 
fibres and most likely transmits forces generated by the muscle by shear [62]. The 
perimysium surrounds bundles of muscle fibres to form fascicles. Although it is not 
known, it has been suggested that the perimysium may surround a fascicle from the 
muscles origin to its insertion point due to its structure differing from that of the 
mesh-like structure of endomysium. Furthermore, the perimysium may also play a 
role in cellular signalling [62]. Finally the epimysium surrounds the entire muscle and 
is continuous with the tendon at the myotendinous junction [62]. Unlike the endo- or 
perimysium, this subdivision of muscle connective tissue is also known to have 
larger collagen bundles with a similar orientation and organisation to that seen in 
tendons [62]. Interestingly, the collagen content within these three subdivisions has 
also shown to be different (Table 2.5). 
 
In addition to tendons, ligaments and the connective tissue within skeletal muscle, 
collagens are also present, in varying quantity, within the ECM which occupies the 
extracellular space of other tissues. This highlights the importance of the regulation 
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2.5.2 Collagen Levels and their Effects on Fibril Organisation 
 
As previously mentioned, rare mutations in many collagen genes result in serious 
musculoskeletal disorders [34;121;122;124;144;147;186;205;218] (Table 2.2), and 
symptoms of these disorders include, but are not limited to, bone fragility, joint 
hypermobility, skin hyper-extensibility and abnormal wound healing [124;147]. The 
nature of these symptoms highlights the importance of collagen in maintaining the 
normal architecture and mechanical properties of musculoskeletal soft tissues. 
Although no evidence in humans exists, to better understand these disorders and 
their symptoms, a number of studies have used murine and in vitro models to 
determine the effects that collagen gene mutations may have on musculoskeletal 
soft tissue [22;35;78;133;207;213;217].  
 
Investigation of haploinsufficient Col5a1 +/- mice, in comparison to wildtype mice, 
showed that reduced levels of type V collagen resulted in greater numbers of both 
larger and smaller collagen fibrils in the dermis [206]. These haploinsufficient mice 
also showed a reduced dermis fibril density when compared to the wildtype mice 
[206]. These results were later repeated in murine tendon (Figure 2.13) [207]. In 
addition, haploinsufficient Col5a1 +/- and Coll11a1 +/- mice showed a more severe 
phenotype, with aberrant fibril diameter and density, when compared to wildtype and 
Col5a1 +/- only mice (Figure 2.13) [207]. Furthermore, in vitro assays from day 17 
chick embryos also identified reduced collagen fibril diameters when type V collagen 
levels were increased [19].  
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Interestingly, Col6a1 -/- null mice show similar changes to the collagen fibril 
architecture as haploinsufficient Col5a1 +/- mice [78]. Specifically, collagen fibrils 
with smaller diameters and greater density were observed in this knockout murine 
model (Figure 2.14) [78]. Furthermore, the average weekly distance run by these 
Col6a1 -/- mice was consistently less than the wildtype mice [21], highlighting that 











Figure 2.13. Collagen fibril organisation in murine tendon, adapted from Wenstrup et al. 
[207]. The haploinsufficient Col5a1 +/- tendons (B) show a greater numbers of larger and 
smaller collagen fibrils and reduced fibril density (circled in white) when compared to 
wildtype (WT) tendons (A). Tendons from both haploinsufficient Col5a1 +/- and Col11a1 +/- 
mice (C) showed a more severe phenotype with regard to both fibril diameter and density 
(circled in white) when compared to both the wildtype (A) and Col5a1 +/- (B) mice. The white 
arrows highlight the aberrant structure of the “regular” fibrils in these haploinsufficient murine 




In vitro assays have also shown that the levels of types XII and III collagen affect the 
architecture and/or biomechanical properties of the fibril [110;133]. Specifically, 
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increasing levels of the N-terminal NC-3 domain of type XII collagen reduces inter-
fibrillar connections, which may make the matrix surrounding these fibrils more 
pliable in the absence of cellular stress or more rigid if these domains are able to 
facilitate cell-mediated alignment and concentration of banded fibrils [133]. These 
changes to the matrix may then result in fibrils with reduced or larger diameters, 
respectively [133]. Increased levels of type III collagen has also been shown to 











Figure 2.14. Collagen fibril organisation in murine tendon, adapted from Izu et al. [78]. The 
Col6a1 -/- tendons (A) show a greater numbers of smaller collagen fibrils and increased fibril 
density when compared to the Col6a1 +/+ tendons (B). The white circle highlights an 
extreme section of these aberrant small collagen fibrils. 
 
 
2.5.3 The Effects of Fibril Organisation on the Biomechanical Properties of 
Musculoskeletal Soft Tissue 
 
A: Col6a1 -/- B: Col6a1+/+ 
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Structural and architectural changes to the collagen fibrils are known to alter the 
biomechanical properties of their containing tissues [102;143]. The measures used 
to describe the biomechanical properties of these tissues include ultimate tensile 
strength, Young’s modulus and creep [120]. The ultimate tensile strength refers to 
the maximum stress that the tissue can take before failing [120]. Young’s modulus, a 
measure of stiffness, is defined as the ratio of stress (force per unit area) over strain 
(deformation relative to initial length) along a particular axis [120]. Finally, creep is 
the long-term deformation of a tissue due to mechanical stress [120].  
 
An increased mean collagen fibril diameter results in greater ultimate tensile strength 
[143;145]. Furthermore, the larger diameter also increases the surface area per 
collagen fibril resulting in an increased number of covalent crosslinks between the 
adjacent fibrils thereby inhibiting creep [143;145]. A smaller mean collagen fibril 
diameter results in increased fibril density within the fibre and a reduced surface area 
per collagen fibril [143;145].  Although the surface area per fibril is reduced, the 
increased density of smaller fibrils results in a larger overall surface area per unit 
mass [143;145]. This overall increase in surface area leads to increased creep, and 
possibly stiffness of the tissue, due to increased electrostatic interactions between 
the fibrils and ground substance [143]. 
 
2.5.4 Effects of the COL5A1 Gene on Fibril Organisation and the Resulting 
Changes to the Biomechanical Properties of Musculoskeletal Soft Tissue 
 
As mentioned above, murine and in vitro models have shown the effects that 
collagen gene mutations may have on musculoskeletal soft tissue, including aberrant 
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changes to collagen fibril size or diameter and fibril density. Therefore, it may be 
proposed that less severe changes to the musculoskeletal soft tissue architecture 
may result in other phenotypic effects. For example, changes to the fibril architecture 
and organisation as a result of functional variants within the COL5A1 gene may 
explain associations identified between this gene and musculoskeletal soft tissue 
injuries and other exercise-related phenotypes (Figure 2.15) [41]. Specifically, 
smaller fibrils with greater density may result in reduced ROM, improved endurance 
running performance and reduced risk of musculoskeletal soft tissue injuries [41]. In 
support of this, one recent in vivo analysis of COL5A1 rs12722 (T/C) in Japanese 
males showed that individuals with the CC genotype had greater mean maximal 
tendon elongation (TT+TC 21.1 ± 5.4 mm, CC 24.5 ± 5.4 mm) and strain (TT+TC 
6.51 ± 1.58 %, CC 7.61 ± 1.62 %), and lower stiffness (TT+TC 78.2 ± 18.5 N.mm-1, 
CC 66.2 ± 19.3 N.mm-1), for their knee extensors when compared to individuals with 
the TT or TC genotypes [104]. No significant differences were recorded for the 
plantar flexors [104]. This study highlights that the level of effect of gene variants 
may differ between tissue structures, possibly due to differences in environmental 
stimuli, and adds further evidence to the proposed genetic continuum model updated 
in figure 2.15 [41;104]. 
 
A second in vivo investigation in male and female Caucasian participants identified 
no associations between the COL5A1 rs12722 genotypes and patellar tendon or 
plantar flexor architecture and mechanical properties, including maximal elongation, 
strain and stiffness [58]. Interestingly, although not significant, the median maximal 
stiffness showed a tendency to be higher in the TT genotype group (TT 855.7 N.mm-
1), followed by the TC genotype (TC 707.6 N.mm-1), while the CC genotype group 
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(CC 555.3 N.mm-1) reported the lowest maximal stiffness. Differences between the 
combined TT+TC genotypes compared to the CC genotype group were however not 
reported. A number of methodological disparities between these studies may explain 
the differences observed. These include ethnic and gender differences between 
study populations, as well as the techniques and methods used to determine the 
dimensional and functional properties of the tendons in vivo [58;104]. Further studies 
are therefore required to determine the exact effects that COL5A1 rs12722 may 
have on tendon architecture and mechanical properties.  
 
Despite the differences in these in vivo tendon analyses, it is known that altered type 
V collagen expression affects collagen fibril architecture and organisation [206;207]. 
Like type V collagen, changes to types XII, III and VI collagen levels also result in 
changes to the fibril architecture and organisation which may affect the 
biomechanical properties of tissues containing these proteins [21;78;110;133]. 
Therefore, it may be proposed that common functional variants, like COL5A1 
rs12722, within the genes that encode these proteins may be associated with 
musculoskeletal soft tissue injuries and other exercise-related phenotypes.  
  
  























Figure 2.15. A proposed general genetic continuum for collagen genes, adapted from 
Collins and Posthumus [41]. The black shading represents the lethal or severe phenotypes 
due to mutations in the collagen genes. At this end of the continuum a single mutation 
results in the disorder. Murine and in vitro models have shown the effects that collagen gene 
mutations may have on musculoskeletal soft tissue, including aberrant changes to collagen 
fibril size or diameter and fibril density [207]. The white shading represents the most 
beneficial “versions” of the collagen genes. At this end of the continuum variants within 
collagen genes collectively contribute to the aetiology of the phenotype. Smaller fibrils with 
greater density, as result of variants such as rs12722, may result in reduced ROM, improved 
endurance running performance and increased risk of musculoskeletal soft tissue injuries 
[41;104].  
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2.5.4 Additional Exercise-Related Phenotypes 
 
As mentioned in section 2.3.2, the COL5A1 rs12722 gene variant was initially 
associated with risk of both Achilles tendinopathy [131;179] and ACL rupture [153]. 
Furthermore mutations within the COL5A1 gene are known to cause classic type 
EDS [124]. Due to the characteristics of EDS, joint hypermobility and hyper-
extensibility, additional studies investigated and identified associations between 
COL5A1 gene variants and ROM [1;28;29;40], and later endurance performance 
[1;151] (Section 2.3.2). It has therefore been proposed that the relative content of 
type V collagen in tendons, ligaments and other tissues alters the fibril diameters and 
packing density within these tissues, and may alter their mechanical properties, and 
therefore their susceptibility to injury and other exercise-related phenotypes [41]. 
Investigation of additional candidate exercise-related phenotypes is required to 
further explore these proposed biomechanical effects.  
 
The altered neuromuscular control hypothesis implicates an increased exercise 
intensity or duration [174;175;183], and possible tissue damage [174] as primary 
factors for the aetiology of exercise-associated muscle cramps (EAMC). As 
mentioned in section 2.3.2, the COL5A1 rs12722 gene variant was associated with 
increased endurance running performance [1;151] and musculoskeletal soft tissue 
injuries [131;153;179], including tendon and ligament injuries. Recently, pre-race 
serum creatine kinase activity (a marker of muscle damage) tended to be higher in 
the 20 athletes who developed EAMC during participation within the 2009 56 km 
Two Oceans ultra-marathon when compared to 29 non-crampers [175]. Furthermore, 
cross-sectional studies have reported an association between a positive family 
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history of EAMC and increased risk of EAMC. A cross-sectional survey study 
highlighted family history of EAMC as a factor that is associated with a past history of 
EAMC in 1300 marathon runners [125]. This association was later confirmed in a 
case-control study of 433 Ironman triathletes where the frequency of a positive family 
history of EAMC was significantly more common in triathletes with a past history of 
EAMC (36.6%) when compared to those with no history of EAMC (16.4%) [183]. 
However, in two subsequent prospective cohort studies, a positive family history of 
EAMC was not associated with the risk of developing EAMC during an event in 
Ironman triathletes [178] and distance runners [175]. Therefore, since an increased 
exercise intensity or duration, muscle damage and a familial predisposition may play 
a role in the aetiology of EAMC, this exercise-related phenotype is a good candidate 
to further investigate COL5A1 rs12722 and other collagen gene variants. 
 
Similarly, since the COL5A1 rs12722 gene variant has been associated with range of 
motion [28;29;40] and endurance running performance [28;151], and may affect 
levels of the type V collagen α1 chain synthesis and thereby modulate fibrillogenesis 
and the biomechanical properties of connective tissues [41], it may be hypothesised 
that COL5A1 rs12722, and other collagen gene variants, may be a good candidate 
for associations with other endurance or power based sports in which muscle tendon 
stiffness may be regarded as an important feature, such as rugby union [41]. A 
number of studies have reported differences in rugby union player characteristics 
between playing positions and playing level [157;158;185]. However, these 
descriptive studies do not help to determine the underlying factors which may 
predispose individuals to particular playing positions or playing levels. Only two 
studies have investigated genetic markers for determining individual playing position 
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[14;15] and playing level [14]. The first of these studies showed that there were 
differences in measures of leg power between forwards and backs when the players 
were grouped according to their ACE rs5186 (I/D) genotypes [15]. A second study by 
the same group investigated the functional ACTN3 rs1815739 (R/X) gene variant as 
a marker of playing position and level [14]. No associations were identified between 
ACTN3 rs1815739 and playing position or playing level [14]. These results highlight 
the involvement of a genetic component in predisposing individuals to particular 
playing positions or playing levels. Therefore this exercise-related phenotype may 
also be a good candidate to further investigate for associations with COL5A1 
rs12722 and other collagen gene variants.  
 
2.6 CANDIDATE COLLAGEN GENES FOR INVESTIGATION 
 
2.6.1 Type V Collagen 
 
Type V collagen is known to interact with types I and III collagen and plays a role in 
the regulation of collagen fibrillogenesis [18;201].  Mutations within the COL5A1 
gene are known to cause EDS [124] and the functional COL5A1 rs12722 T/C variant 
was associated with Achilles tendinopathy [131], ACL ruptures [153], ROM 
[28;29;40] and endurance running performance [1;151]. Based on these findings a 
genetic continuum model was proposed by which common functional variants within 
this gene may contribute to more complex multifactorial phenotypes [41]. The 
COL5A1 rs12722 variant, and others within the COL5A1 gene, is therefore an 
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excellent candidate to investigate in additional exercise-related phenotypes, such as 
EAMC and rugby union. 
 
2.6.2 Type XII Collagen 
 
Type XII collagen, a member of the FACIT collagens sub-family, is important for 
mediating cell-matrix interactions [166], stabilisation of the collagen triple helices 
[25;164], in regulating collagen fibril assembly and diameter [213], in a similar 
fashion to type V collagen. The COL12A1 gene encodes the α1 chain of type XII 
collagen and mutations within this gene have also been shown to cause EDS [218]. 
The COL12A1 rs970547 A/G variant was investigated in the aetiology of Achilles 
tendinopathy and ACL rupture [154;181], but was only associated with risk of ACL 
rupture in Caucasian South African females [154]. In addition, bioinformatic 
functional analysis of COL12A1 rs970547 shows that the resulting glycine to serine 
change is potentially damaging to the COL12A1 peptide and may modulate the 
function of type XII collagen [105]. This variant should therefore be explored in the 
aetiology of additional exercise-related phenotypes. 
 
2.6.3 Type III Collagen 
 
Type III collagen consists of three α1(III) chains and is a major fibrillar collagen which 
forms heterotypic fibrils together with type I collagen [9;114]. Similarly to types I, V 
and XII collagen, type III collagen is also implicated in fibrillogenesis [56;115;141]. 
The α1 chain of type III collagen is encoded by the COL3A1 gene. Like COL5A1 and 
COL12A1, mutations within the COL3A1 gene also result in EDS 
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[33;115;124;186;218]. The non-synonymous COL3A1 rs1800255 A/G variant within 
this gene is also associated with a mitral valve and pelvic organ prolapse [37;39;94]. 
Furthermore, the COL3A1 rs1800255 variant is proposed to be functional [94]. 
Specifically, the alanine to threonine change at position 698 of the COL3A1 peptide, 
as a result of COL3A1 rs1800255, is proposed to affect the tensile strength of type III 
collagen fibres [94]. Therefore, since type III collagen is implicated in fibrillogenesis 
like types I, V and XII collagens, it may be proposed that common potentially 
functional variants within the COL3A1 gene, such as COL3A1 rs1800255, may also 
be associated with musculoskeletal soft tissue injuries and other exercise-related 
phenotypes. 
 
2.6.4 Type VI Collagen 
 
The function of type VI collagen remains largely unknown, however, it is believed to 
play a role at the basement membrane [109;201], and is known to interact with type 
V collagen in the fibril [190]. In additional, rat models have shown co-localisation of 
type III and VI collagen in lung tissue [5]. Mutations within the gene which encodes 
the α1 chain of type VI collagen (COL6A1) have been shown to cause muscle 
diseases such as Bethlem myopathy [17;109] and Ullrich congenital muscular 
dystrophy [17;109;140]. Bonaldo et al. [21] established a model for myopathy in mice 
by knocking out the gene responsible for production of the α1 (VI) chain, the Col6a1 
gene. The average weekly distance run by these myopathic Col6a1 -/- mice was 
consistently less than the wildtype mice [21]. In addition, these Col6a1 null mice 
showed abnormal fibril diameter and density [78], similar to that observed in col5al 
haploinsufficient mice [206] (Section 2.5.2). Sequence variations in the human 
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COL6A1 gene have to date been associated with a number of multifactorial 
conditions, such as ossification of the posterior longitudinal ligament (OPLL) 
[101;191], ossification of the ligamentum flavum (OLF) [101] and diffuse idiopathic 
skeletal hyperostosis (DISH) [197]. Specifically a variant within intron 32 
(rs35796750 T/C) of the COL6A1 gene was found to be significantly associated with 
all of these conditions [101;191;197]. The TT genotype of COL6A1 rs35796750 was 
associated with increased risk of both OPLL [191] and DISH [197] in independent 
Japanese populations. This variant occurs near the branch site of intron 32, where 
the cytosine to thymine transition is proposed to cause aberrant splicing of the 
COL6A1 mRNA [191]. This potentially functional variant is therfore another good 
candidate for investigation in the aetiology of musculoskeletal soft tissue injuries and 
other exercise-related phenotypes. 
 
2.7 AIMS AND OBJECTIVES OF THE THESIS 
 
The COL5A1 rs12722 and COL12A1 rs970547 gene variants have been previously 
associated with risk of ACL ruptures in females [153;154] and/or chronic Achilles 
tendinopathy [131;181]. The first aim of this thesis was therefore to investigate the 
COL3A1 rs1800255 and COL6A1 rs35796750 gene variants as risk factors for these 
musculoskeletal soft tissue injuries. The objectives to address this aim were: 
 
To investigate the COL3A1 rs1800255 and COL6A1 rs35796750 gene variants as 
risk factors for ACL ruptures in a South African cohort (Chapter 3). 
To investigate the COL6A1 rs35796750 gene variant as a risk factor for Achilles 
tendinopathy in independent SA and Australian cohorts (Chapter 4). 




Since the COL5A1 rs12722 variant was previously associated with endurance 
performance and ROM, the second aim of this thesis was to further investigate the 
COL3A1, COL6A1, and COL12A1 genes for associations with these exercise-related 
phenotypes. Therefore, the objectives to address this aim were: 
 
To investigate the COL3A1 rs1800255, COL6A1 rs35796750 and COL12A1 
rs970547 gene variants as intrinsic factors for ROM in a SA cohort (Chapter 5). 
To investigate the COL3A1 rs1800255, COL6A1 rs35796750 and COL12A1 
rs970547 gene variants as intrinsic factors for endurance performance in participants 
of the SA Ironman triathlon (Chapter 6). 
 
Due to the previously mentioned associations between collagen genes and 
musculoskeletal soft tissue injuries and other exercise-related phenotypes, the third 
aim of this thesis was the investigation of COL3A1 rs1800255, COL5A1 rs12722, 
COL6A1 rs35796750 and COL12A1 rs970547 in novel exercise-related phenotypes, 
namely exercise associated muscle cramps (EAMC) and rugby union playing level 
and position. The objectives to address this aim were: 
 
To investigate the COL3A1 rs1800255, COL5A1 rs12722, COL6A1 rs35796750 and 
COL12A1 rs970547 gene variants as risk factors for EAMC in a South African (SA) 
cohort (Chapter 7). 
To investigate the COL3A1 rs1800255, COL5A1 rs12722, COL6A1 rs35796750 and 
COL12A1 rs970547 gene variants as intrinsic factors for rugby union playing level 
and position in professional SA Super 15 rugby union players (Chapter 8). 




A summary of the first, second and third aims of this thesis are provided in table 2.6. 
 
Since the COL6A1 rs35796750 has previously been predicted to be functional, the 
final aim of this thesis was to investigate the expression of the COL6A1 gene in 

















Table 2. 6. A summary of the candidate collagen gene variants and exercise-related phenotypes that will be investigated in this thesis. 
Table 2.6. A summary of the candidate collagen gene variants and exercise-related 
phenotypes that will be investigated in this thesis, as well as those which have been 
previously investigated and published. The chapter in which each phenotype will be 
investigated for associations with these variants is also shown. Prev Pub, previously 
published. 
a Discussed in Section 2.3.2 [1;28;29;40;131;151;153;179]  
b Discussed in Section 2.4.1 [154] 









GENETIC RISK FACTORS FOR ACL RUPTURES  
3.1 INTRODUCTION 
 
Rupture of the anterior cruciate ligament (ACL), which is one of the injuries studied in 
this thesis, occurs as a result of a non-contact mechanism in approximately 70% of 
cases [20]  and is one of the most severe injuries in sports [27]. The exact aetiology 
of ACL ruptures remains unknown. However, a number of extrinsic and intrinsic risk 
factors, including a genetic component, have been identified [67]. Initially familial 
studies showed that the risk of an ACL rupture was more than doubled in individuals 
with a first-degree relative (sibling, parent or child) with history of an ACL rupture 
[57].  More recently, the rare TT genotype of the COL1A1 rs1800012 (G/T) single 
nucleotide polymorphism (SNP) was shown to be under-represented in patients with 
a cruciate ligament rupture in three separate studies [53;91;152].  The COL5A1 
rs12722 (T/C) and COL12A1 rs970547 (G/A) variants have also been shown to 
modulate the risk of ACL ruptures in females in a single cohort [153;154]. 
Specifically, the CC genotype of COL5A1 rs12722 decreased the risk, while the AA 
genotype of COL12A1 rs970547 increased the risk of ACL rupture in females 
[153;154]. The COL1A1, COL5A1 and COL12A1 genes encode for the α1 chains of 
The data presented in this chapter has been accepted for publication in a 
condensed form in the peer-reviewed article: O'Connell K, Knight H, Ficek K, 
Leonska-Duniec A, Maciejewska-Karlowska A, Sawczuk M, Stepien-Slodkowska M, 
O’Cuinneagain D, van der Merwe W, Posthumus M, Cieszczyk P, Collins M. 
Interactions between Collagen Gene Variants and risk of Anterior Cruciate Ligament 
Rupture. European Journal of Sports Science. InPress. 
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types I, V and XII collagen respectively. These collagens make up the majority of the 
solid component of ligaments (Chapter 2 Figure 2.12) [59] and play important roles in 
normal collagen fibrillogenesis [141;213].  
 
Other collagens, such as types III and VI, are also present in the solid component of 
ligaments [59], where they interact with type I, V and XII collagens to facilitate normal 
collagen fibrillogenesis [115;129]. The α1 chains of types III and VI collagen are 
encoded by the COL3A1 and COL6A1 gene, respectively. The non-synonymous 
COL3A1 rs1800255 (G/A) SNP within exon 30 and the intronic COL6A1 rs35796750 
(T/C) SNP are both proposed to be functional [94;191]. The COL3A1 rs1800255 
variant results in an A698T amino acid transition which is proposed to affect collagen 
fibre assembly and tensile strength [94]. The GG genotype of this variant is 
associated with increased risk of mitral valve prolapse [39] while the AA genotype is 
associated with increased risk of pelvic organ prolapse [37;94]. The intronic COL6A1 
rs35796750 variant is located near an intron branch site and is proposed to result in 
aberrant splicing of the COL6A1 mRNA [191], which may result in altered or aberrant 
type VI collagen fibrils. In addition, the TT genotype of this this variant has been 
associated with increased risk of ossification of the posterior longitudinal ligament 
[101;191] and the ligamentum flavum [101], as well as diffuse idiopathic skeletal 
hyperostosis [197].  
 
Since it is already shown that COL1A1, COL5A1 and COL12A1 variants are 
independently associated with risk of ACL rupture, it may be hypothesised that 
COL3A1 and COL6A1 variants, as well as, collagen gene-gene interactions are also 
important modulators of ACL rupture risk. The aims of this study within the thesis 
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were therefore to (i) determine if COL3A1 rs1800255 and COL6A1 rs35796750 are 
independently associated with risk of ACL rupture in a South African cohort, (ii) 
repeat the gender-specific independent associations of COL5A1 rs12722 and 
COL12A1 rs970547 with risk of ACL rupture in a larger South African cohort and (iii) 
investigate gene-gene interactions between collagen variants and risk of ACL 
rupture. Based on previous findings (Chapter 2 Section 2.6), it was hypothesised that 
the COL6A1 rs35796750 TT and COL12A1 rs970547 AA genotypes, in females 
only, would be associated with increased risk of ACL ruptures. Previous findings also 
suggest that either of the COL3A1 rs1800255 genotypes may be associated with 
increased risk of ACL rupture. In addition, the COL5A1 rs12722 CC genotype may 
be associated with decreased risk of ACL injuries in females.  
 
3.2 MATERIALS AND METHODS 
 
This case-control genetic association study was reported using the 
recommendations outlined in the genetic association study specific STREGA 
initiative [113], which adds to the STROBE statement checklist for reporting of 
observational studies in epidemiology [203]. These recommendations were used for 
all subsequent genetic association studies (Chapters 4 to 8) in this thesis. 
3.2.1 Participants 
 
Four hundred and seventy-seven South African self-reported Caucasian were 
recruited and included in this study. Two hundred and forty-two participants (177 
male and 65 female) with surgically diagnosed ACL ruptures (ACL group) were 
recruited from the Sports Science Orthopaedic Clinic in Cape Town, South Africa, as 
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previously described [153]. A subset of the ACL group, 129 (91 male and 38 female) 
participants were previously recruited and have been included in previous genetic 
association studies (ACL subset 1) [152-154]. A second subset of 113 (86 male and 
27 female) additional participants was recruited for this study (ACL subset 2). The 
exact mechanism of injury, as defined by the American Orthopaedic Society for 
Sports Medicine classification system [152], was identified in 161 male (91.0%) and 
59 female (90.58%) participants. The 56% (n=136) of the participants, 103 male 
(58.2%) and 33 female (50.8%), who had ruptured their ACL via a self-reported non-
contact (NON) mechanism were analyzed in this study as a separate sub-group 
(NON sub-group). In addition, 235 previously described apparently healthy 
participants (145 male and 90 female) with no self-reported history of ACL injury 
were previously recruited as controls (CON group) from sports and recreational clubs 
within the greater Cape Town area [152-154]. A breakdown of these groups, as well 
as their subsets, is shown in figure 3.1. 
  
























Figure 3.1. A flow diagram showing the breakdown of the South African participants 
recruited for this study. ACL, Anterior cruciate ligament rupture. CON, control. NON, non-




Chapter 3   
62 
Genotype frequency distributions for COL5A1 rs12722 and COL12A1 rs970547 have 
been published in the 364 previously described South African participants [152-154]. 
To increase the sample size these variants were genotyped in the additional South 
African ACL participants recruited for this study.  
 
Prior to participation in this study, all the participants gave informed written consent 
(Appendix A.3). In addition, each participant completed personal details, medical 
history, as well as a sports participation questionnaire (Appendix A.4). This study 
was approved by the Human Research Ethics Committee of the Faculty of Health 
Sciences within the University of Cape Town, South Africa (Appendix A.1). 
 
3.2.2 Variant Selection 
 
Four independent sequence variants were investigated in this study. Namely 
COL3A1 rs1800255 (Figure 3.2), COL5A1 rs12722 (Figure 3.3), COL6A1 
rs35796750 (Figure 3.4) and COL12A1 rs970547 (Figure 3.5). The COL5A1 rs12722  
variant is associated with chronic Achilles tendinopathy [131;179], anterior cruciate 
ligament ruptures in females [153], range of motion [28;29;40] and endurance 
running performance [1;151], and the region containing this variant is known to be 
functional [107]. Variants within the COL3A1, COL6A1 and COL12A1 genes are 
associated with a number of soft-tissue phenotypes [39;94;101;154;191;197]. 
Furthermore, functionality has been proposed for COL3A1 rs1800255 [94] and 
COL6A1 rs35796750 [191], while bioinformatics analysis suggests that COL12A1 
rs970547 may be functional [105]. 






















Figure 3. 2. Schematic diagram showing the position of type III collagen in the fibril, a diagram of the COL3A1 gene, as well as 
the position of the gene variant rs1800255. 
Figure 3.2. Type III Collagen. (A) A schematic diagram showing the position of type III 
collagen in the fibril. Type III collagen is boxed in red. (B) A schematic diagram of the 
COL3A1 gene, as well as the position of the gene variant rs1800255 within the gene 
(marked by the red arrow). The exon (vertical lines) and intron (horizontal lines) boundaries 
are shown. Every 5th exon is labelled. (C) The flanking sequence for variant rs1800255 
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Figure 3. 3. Schematic diagram showing the position of type V collagen in the fibril, a diagram of the COL5A1 gene, as well as 
the position of the gene variant rs12722. 
Figure 3.3. Type V Collagen. (A) A schematic diagram showing the position of type V 
collagen in the fibril. Type V collagen is boxed in red. (B) A schematic diagram of the 
COL5A1 gene, as well as the position of the gene variant rs12722 within the gene (marked 
by the red arrow). The exon (vertical lines) and intron (horizontal lines) boundaries are 
shown. Every 5th exon is labelled.  (C) The flanking sequence for variant rs12722 (marked 









Figure 3. 4. Schematic diagram showing the position of type VI collagen in the fibril, a diagram of the COL6A1 gene, as well as 
the position of the gene variant rs35796750. 
Figure 3.4. Type VI Collagen. (A) A schematic diagram showing the position of type VI 
collagen in the fibril. Type VI collagen is boxed in red. (B) A schematic diagram of the 
COL6A1 gene, as well as the position of the gene variant rs35796750 within the gene 
(marked by the red arrow). The exon (vertical lines) and intron (horizontal lines) boundaries 
are shown. Every 5th exon is labelled.  (C) The flanking sequence for variant rs35796750 
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Figure 3. 5. Schematic diagram showing the position of type XII collagen in the fibril, a diagram of the COL12A1 gene, as well 
as the position of the gene variant rs970547. 
Figure 3.5. Type XII Collagen. (A) A schematic diagram showing the position of type XII 
collagen in the fibril. Type XII collagen is boxed in red. (B) A schematic diagram of the 
COL12A1 gene, as well as the position of the gene variant rs970547 within the gene 
(marked by the red arrow). The exon (vertical lines) and intron (horizontal lines) boundaries 
are shown. Every 5th exon is labelled.  (C) The flanking sequence for variant rs970547 
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3.2.3 DNA Extraction and Genotyping Methods 
 
Approximately 4.5 ml of venous blood was collected from all participants by 
venipuncture of a forearm vein into an ethylenediaminetetraacetic acid (EDTA) 
vacutainer tube. Blood samples were stored at 4 ˚C until DNA was extracted, as 
previously described [108], with minor modifications [131]. A brief outline of the 
methodology is as follows; Blood samples were transferred to 15ml polypropylene 
tubes and 10ml of TKM1 (10mM Tris-HCl pH 7.6, 10mM KCl, 10mM MgCl2 and 
2mM EDTA) buffer containing 2.5% NP40 was added. This lyses the red blood cells. 
Samples are then incubated and centrifuged at 1200 X g at room temperature for 10 
minutes respectively. The centrifugation causes white blood cells (WBC) to form 
pellets at the bottom the tubes. Following centrifugation the samples were washed 
with 1 volume of TKM1 buffer. Washed WBC pellets were then resuspended in 800μl 
TKM2 (10mM Tris-HCl pH 7.6, 10mM KCl, 10mM MgCl2, 0.4M NaCl2 and 2mM 
EDTA) buffer containing 50μl of 10% SDS and were then incubated for 
approximately 60 minutes at 550C resulting in WBC lysis. The samples were 
vortexed briefly following the addition of 150μl of 5M NaClO4 and 500μl chloroform. 
The sample solutions were then transferred to new 1.5ml microfuge tubes and 
centrifuged at 15000 X g for 5 minutes at room temperature to allow proteins to 
precipitate. 500μl of the top aqueous layer from each sample was transferred to a 
new 1.5ml microfuge tube. 1ml of ethanol was then added to the tubes to precipitate 
the DNA. The precipitated DNA was then pelleted by centrifugation at 15000 X g for 
2 minutes at room temperature. The precipitated DNA was then air dried for 
approximately 30 minutes before being resuspended in 200μl TE buffer (10mM Tris-
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HCl, 1mM EDTA, pH 8.0). All tubes were then incubated at 650C for 15 minutes in a 
heating block. DNA was then stored at 40C for use. 
 
Genotyping of COL3A1 rs1800255 and COL6A1 rs35796750 was performed using 
custom designed Fluorescence-based Taqman® polymerase chain reaction (PCR) 
assays (Applied Biosystems, Foster City, CA, USA). Allele specific probes and 
flanking primer sets (Appendix B) were used along with a pre-made PCR mastermix 
containing ampliTaq® DNA polymerase Gold (Applied Biosystems, Foster City, CA, 
USA) in a final reaction volume of 8 µl. The PCR consisted of a 10 min heat 
activation step (95 ºC) followed by 40 cycles of 15 s at 92 ºC and 1 min at 60 ºC. The 
PCR reactions were performed on the XP Thermal Cycler, Block model XP-G 
(BIOER Technology CO., LTD, Tokyo, Japan). Genotypes were determined by end-
point fluorescence using a 7900 HT Fast Real-Time PCR System, and SDS 
Software version 2.3 (Applied Biosystems, Foster City, CA, USA). Genotyping of 
COL5A1 rs12722 and COL12A1 rs970547 was performed using PCR and restriction 
fragment length polymorphism analysis as previously described (Appendix B) 
[29;131;153;154]. All genotyping was done at the UCT/MRC Research Unit for 
Exercise Science and Sports Medicine, University of Cape Town, Cape Town, South 
Africa.  
 
Investigators were blinded to the phenotypes of the participant samples while 
genotyping. Two investigators independently confirmed genotyping. Furthermore, a 
number of positive and negative controls were used to ensure genotyping accuracy. 
No discrepancies were observed. A total of 433/477 (90.8%), 455/477 (95.4%), 
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318/364 (87.4%) and 446/477 (93.5%) genotypes were identified for COL3A1 
rs1800255, COL5A1 rs12722, COL6A1 rs35796750 and COL12A1 rs970547. 
 
3.2.4 Statistical Analysis  
 
Continuous variables were compared between genotype groups using one-way 
analysis of variance (ANOVA) tests. Chi-squared tests or Fisher tests were used to 
compare categorical variables. Basic descriptive statistical analysis and frequencies 
were determined using STATISTICA 11 (StatSoft Inc, Tulsa, Oklahoma, USA). 
Inferred pseudo-haplotypes between gene variants were tested using Hapstat 
version 3.0 (Tammy Bailey, Danyu Lin and the University of North Carolina at Chapel 
Hill, Department of Biostatistics, 3101 McGavran-Greenberg CB #7420, Chapel Hill, 
North Carolina 27599-7420  USA) [111;112;215]. Hardy-Weinberg equilibrium was 
determined using the online program Genepop version 4.0.10 
(http://genepop.curtin.edu.au/). Significance was accepted when p<0.05. No 
adjustments were made for multiple testing in this study since no obvious 
appropriate method currently exists [135;146]. The Bonferroni adjustment was 
considered too conservative since the statistical tests are all on the same group of 
participants [135]. Adjustment for multiple testing was also considered inappropriate 
in this case since there is an a priori hypothesis that the gene variants investigated in 
this study are associated with the phenotype [146]. 
 
 




3.3.1 Participant characteristics 
 
There were significantly less males in the CON group when compared to the ACL 
group and NON sub-group (Table 3.1). Since gender-specific associations have 
previously been reported for ACL injuries [153;154], the characteristics of the male 
and female participants were also analyzed separately. The CON group, as well as 
the male CON sub-group, were significantly younger and weighed less (age and 
weight at recruitment) than both the ACL and NON groups or sub-groups (age and 
weight at time of first injury). The female sub-group were however similarly matched 
for age. Within the ACL group, the male and female participants’ age at recruitment 
were 4.2 ± 8.4 (n=174) and 5.1 ± 9.5 (n=65) years after the age of their first self-
reported ACL rupture, respectively. When appropriately co-varied, the CON group, 
as well as both the gender sub-groups, were similarly matched for height and BMI 
when compared to the ACL and NON groups or sub-groups. When co-varied for 
gender and age at recruitment the CON group weighed less than the ACL group and 
NON sub-group. Similarly when co-varied for age at recruitment the male CON sub-
groups weighed less than their respective ACL and NON sub-groups. The female 
sub-groups were however similarly matched for weight.  The average weight of the 
male ACL sub-group was 2.3 ± 13.6 kg (n = 171) greater at recruitment when 
compared the time of their first ACL rupture. Similarly, the average weight of the 
female ACL sub-group was 0.8 ± 3.5 kg (n = 65) greater at recruitment when 
compared the time of their first ACL rupture. With the exception of the female ACL 
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sub-group, which had significantly less South African-born participants, all the other 
groups and sub-groups were similarly match for country of birth.  
 
The CON group, as well as the male and female CON sub-groups, participated in 
contact sports and non-contact jumping sports for significantly less years than their 
respective ACL and NON groups and sub-groups (Table 3.2). There were no 
significant differences in years of participation in non-contact non-jumping sports 
between any of the CON groups or sub-groups and their respective ACL and NON 
groups or sub-groups (Table 3.2). The CON group, and male CON sub-group, 
participated in skiing for significantly less years than their respective ACL and NON 
groups and sub-groups (Table 3.2). There were no differences between the female 
CON and ACL or NON sub-groups and years of participation in skiing (Table 3.2). A 
list of reported contact and non-contact sports can be found in appendix C.3. 
 
There were no genotype effects on any of the participant characteristics for COL3A1 
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Table 3.1. General characteristics for the South African participants with anterior cruciate 
ligament rupture (ACL group), non-contact mechanism of injury (NON sub-group) and 
apparently healthy controls (CON group) recruited for this study. The male and female sub-
groups are also shown. 
All Participants CON (235) ACL (242) p-value
a
 NON (136) p-value
b
 
Gender (% male) 61.7 (145) 73.1 (177) 0.008 75.7 (103) 0.008 
Age (yrs) 29.3 ± 11.2 (229) 26.8 ± 11.0 (211) 0.018 26.2 ± 10.3 (129) 0.292 
Height (cm) 175.0 ± 9.4 (229) 177.4 ± 9.7 (221) 0.332c 178.2 ± 9.1 (129) 0.292c 
Weight (kg) 74.1 ± 14.8 (230) 80.3 ± 17.0 (221) 0.004d 80.4 ± 16.2 (133) 0.018d 
BMI 23.9 ± 4.1 (229)  24.7 ± 5.8 (221) 0.242d 24.7 ± 5.4 (129) 0.431d 
South African Born (%) 82.3 (195) 82.1 (183) 0.118 82.7 (110) 0.118 
Male Participants CON (145) ACL (177) p-value
a
 NON (103) p-value
b
 
Age (yrs) 29.5 ± 11.8 (142) 25.8 ± 10.0 (151) 0.003 25.3 ± 8.9 (96) 0.003 
Height (cm) 180.5 ± 6.4 (142) 181.3 ± 6.9 (163) 0.273 181.7 ± 6.7 (101) 0.165 
Weight (kg) 81.6 ± 13.0 (141) 86.5 ± 14.7 (163) 0.002e 86.2 ± 13.5 (100) 0.007e 
BMI 24.6 ± 4.6 (141) 25.6 ± 5.5 (163) 0.023e 25.4 ± 5.8 (101) 0.148e 
South African Born (%) 87.8 (122) 85.3 (139) 0.871 82.2 (83) 0.575 
Female Participants CON (90) ACL (65) p-value
a
 NON (33) p-value
b
 
Age (yrs) 28.9 ± 10.2 (87) 29.4 ± 12.8 (60) 0.812 29.1 ± 13.3 (33) 0.943 
Height (cm) 166.1 ± 5.9 (87) 166.3 ± 7.7 (58) 0.919 166.8 ± 6.1 (31) 0.877 
Weight (kg) 62.4 ± 8.5 (89) 63.0 ± 9.6 (58) 0.739e 62.6 ± 9.4 (33) 0.904e 
BMI 22.6 ± 2.7 (87) 22.1 ± 5.7 (58) 0.449e 22.5 ± 3.0 (31) 0.849e 
South African Born (%) 83.9 (73) 73.3 (44) 0.014 84.4 (27) 0.551 
      
Values are expressed as mean ± standard deviations or as percentages where appropriate. 
Number of participants is indicated in parentheses. Values in bold typeset are significant 
(p<0.05). For the ACL and NON groups and sub-groups age, height, weight and BMI are 
reported from time of injury. For the CON group and sub-groups the age, height and BMI are 
reported from time of recruitment. NON, non-contact mechanism of injury. 
a CON vs. ACL 
b CON vs. NON 
c Co-varied for gender 
d Co-varied for gender and age at recruitment 
e Co-varied for age 
 Table 3. 1. General characteristics for the South African participants recruited for this study. 
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Table 3.2. Years of participation in contact, non-contact non-jumping, non-contact jumping 
sports, as well as skiing, for the South African participants with anterior cruciate ligament 
rupture (ACL group), non-contact mechanism of injury (NON sub-group) and apparently 
healthy controls (CON group) recruited for this study. The male and female sub-groups are 
also shown. 
All Participants CON (235) ACL (242) p-valuea NON (136) p-valueb 
Contact Sports (yrs) 6.9 ± 8.2 (166) 12.3 ± 7.6 (152) <0.001 12.0 ± 7.3 (91) <0.001 
Non-contact  
Non-jumping Sports (yrs) 
27.2 ± 21.4 (216) 24.1 ± 20.3 (197) 0.126 25.5 ± 21.7 (117) 0.498 
Non-contact  
Jumping Sports (yrs) 
3.5 ± 6.6 (129) 10.0 ± 7.6 (62) <0.001 11.7 ± 8.4 (32) <0.001 
Skiing (yrs) 1.8 ± 7.5 (115) 8.1 ± 8.4 (17) 0.002 13.8 ± 11.1 (4) 0.002 
Male Participants CON (145) ACL (177) p-valuea NON (103) p-valueb 
Contact Sports (yrs) 9.2 ± 8.6 (115) 12.5 ± 7.6 (145) 0.001 12.1 ± 7.2 (88) 0.012 
Non-contact  
Non-jumping Sports (yrs) 
27.0 ± 21.4 (134) 23.2 ± 20.1 (146) 0.127 24.6 ± 21.2 (89) 0.411 
Non-contact  
Jumping Sports (yrs) 
1.2 ± 3.7 (68) 8.8 ± 9.2 (31) <0.001 11.6 ± 10.7 (16) <0.001 
Skiing (yrs) 1.7 ± 6.3 (70) 10.0 ± 9.7 (11) <0.001 16.7 ± 11.5 (3) <0.001 
Female Participants CON (90) ACL (65) p-valuea NON (33) p-valueb 
Contact Sports (yrs) 1.6 ± 3.1 (51) 7.4 ± 7.3 (7) <0.001 8.0 ± 8.9 (3) 0.003 
Non-contact  
Non-jumping Sports (yrs) 
27.6 ± 21.6 (82) 26.5 ± 20.9 (51) 0.779 28.5 ± 23.2 (28) 0.840 
Non-contact  
Jumping Sports (yrs) 
6.0 ± 8.0 (61) 11.2 ± 5.4 (31) 0.002 11.8 ± 5.6 (16) 0.009 






Values are expressed as mean ± standard deviations. Number of participants is indicated in 
parentheses. Values in bold typeset are significant (p<0.05).  
a CON vs. ACL 
b CON vs. NON 
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Table 3.3. Genotype effects of COL3A1 rs1800255, COL5A1 rs12722, COL6A1 rs35796750 
and COL12A1 rs970547 on physiological characteristics of participants. 
Polymorphism 
p-values 
Age Injured Height Weight Gender 
COL3A1 rs1800255 0.521 0.556 0.602 0.945 
COL5A1 rs12722 0.799 0.265 0.335 0.457 
COL6A1 rs35796750 0.585 0.823 0.820 0.993 
COL12A1 rs970547 0.624 0.918 0.950 0.992 
 
Table 3. 3. Genotype effects of COL3A1 rs1800255, COL5A1 rs12722, COL6A1 rs35796750 and COL12A1 rs970547 on 




3.3.2 Participant and Family History of Soft Tissue Injuries 
 
Family history, which includes any blood relative, of any ligament injury reported by 
the participant at the time of recruitment was significantly higher in the ACL group 
(odds ratio (OR) = 1.8, 95% confidence interval (CI) = 1.2 – 2.6, p=0.004) and NON 
sub-group (OR = 1.9, 95% CI = 1.2 – 3.0, p=0.004) when compared to the CON 
group (Table 3.4). A family history of ACL injuries was also similarly significantly 
higher in the ACL group (OR = 9.1, 95% CI = 3.5 – 23.5, p<0.001) and NON sub-
group (OR = 11.4, 95% CI = 4.3 – 30.4, p<0.001) when compared to the CON group 
(Table 3.4). There were no significant differences in the family history of any tendon 
injuries between the groups.  
 
Individually, significantly more participants in the ACL group and NON sub-group 
reported previous injuries of any ligament, as well as, previous posterior cruciate 
ligament (PCL), lateral collateral ligament (LCL) and/or the medial collateral ligament 
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(MCL) injuries in the knee (Table 3.4). There were significantly more self-reported 
participants with a history of lateral and/or medial ankle ligament injuries within the 
NON sub-group, but not within the ACL group. Finally the groups and sub-groups 
were similarly matched for a history of joint capsule disease and any tendon injury. 
Similar results were observed when male and female participants were analysed 





Table 3.4. Participant and family history of soft tissue injuries for the participants recruited 
for this study. 
 CON (235) ACL (242) p-value
a
 NON (136) p-value
b
 
Participant previous ligament injury 34.0 (80) 43.8 (106) 0.029 43.4 (59) 0.014 
Knee ligament injury
c
 3.0 (7) 11.6 (28) 0.003 11.0 (15) 0.007 
Ankle ligament strain
d
 21.7 (51) 28.9 (70) 0.070 31.6 (43) 0.039 
Participant previous tendon injury 20.0 (47) 21.5 (52) 0.689 25.7 (35) 0.640 
Participant history of joint capsule disease 9.8 (23) 10.3 (25) 0.322 13.2 (18) 0.111 
Family history ligament injury 26.8 (63) 39.3 (95) 0.004 41.2 (56) 0.003 
ACL injury 2.1 (5) 16.5 (40) <0.001 19.9 (27) <0.001 
Family history tendon injury 8.1 (19) 11.6 (28) 0.202 9.6 (13) 0.122 
 
Values are expressed as percentages with the number of participants (n) indicated in 
parentheses. Values in bold typeset are significant (p<0.05). CON, apparently healthy 
controls. ACL, anterior cruciate ligament. NON, non-contact mechanism of injury.  
a CON vs. ACL 
b CON vs. NON 
c includes the posterior cruciate ligament, the lateral collateral ligament and the medial 
collateral ligament.  
d includes the lateral and medial ankle ligaments.  
Table 3. 4. Participant and family history of soft tissue injuries for the participants recruited for this study. 
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3.3.3 COL3A1 and COL6A1 Genotype Frequency Distributions 
 
There were no significant differences in the COL3A1 rs1800255 and COL6A1 
rs35796750 genotype or allele frequency distributions between the ACL group and 
CON group or NON sub-group and CON group, or their respective gender sub-
groups (Tables 3.5 and 3.6). A tendency was however observed for the COL3A1 
rs1800255 minor A allele (p=0.071) and AA genotype (p=0.099) to be under-
represented in the male ACL sub-group when compared to the male CON sub-
group. Similar genotype frequency distributions were obtained when control 
participants with a self-reported history of any previous ligament injury were 
excluded from the analysis (Appendix C.2). Therefore these participants were 
included to increase the sample size and statistical power of the study.  All COL3A1 
(Table 3.5) and COL6A1 (Table 3.6) groups and sub-groups were all in Hardy-
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Table 3.5.  A comparison of the genotype frequency distributions for COL3A1 rs1800255 
(G/A), between control (CON group), anterior cruciate ligament rupture (ACL group) and 
non-contact mechanism of injury (NON sub-group) groups. Gender specific comparisons 
between the two groups are also reported. 









 GG GA AA 
All Participants        
CON 52.1 (111) 38.0 (81) 9.9 (21) 213  0.324 28.9 (123)  
ACL 55.9 (123) 39.1 (86) 5.0 (11) 220 0.151
a
 0.476 24.5 (108) 0.150
a
 
NON 57.4 (70) 36.9 (45) 5.7 (7) 122 0.368
b
 1.000 24.2 (59) 0.189
b
 
Male Participants        
CON 51.6 (65) 38.9 (49) 9.5 (12) 126  0.194 29.0 (73)  
ACL 58.9 (96) 37.4 (61) 3.7 (6) 163 0.099
 a
 0.500 22.3 (73) 0.071
a
 
NON 60.2 (56) 34.4 (32) 5.4 (5) 93 0.333
 b
 1.000 22.6 (42) 0.133
b 
Female Participants        
CON 52.9 (46) 36.8 (32) 10.3 (9) 87  0.431 28.7 (50)  
ACL 47.4 (27) 43.9 (25) 8.8 (5) 57 0.694
 a
 1.000 30.7 (35) 0.721
a
 
NON 48.3 (14) 44.8 (13) 6.9 (2) 29 nd nd 29.3 (17) nd
 
Table 3. 5. A comparison of the genotype frequency distributions for COL3A1 rs1800255 (G/A), between the South African (SA) anterior cruciate ligament (ACL) rupture 
(SA ACL) and control (SA CON) groups, as well as the Polish cohort groups (PL ACL and PL CON).  
Values are expressed as percentages with the number of participants indicated in 
parentheses. The total number (n) of participants genotyped in each individual or combined 
cohort is also indicated. Values in bold typeset are significant (p<0.05). All the ACL ruptures 
were diagnosed at surgery.  
HWE, Hardy-Weinberg Equilibrium. nd, not determined. 
a CON vs. ACL 
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Table 3.6.  A comparison of the genotype frequency distributions for COL6A1 rs35796750 
(T/C), between the control (CON group) participants, previously recruited anterior cruciate 
ligament rupture (ACL group subset 1) and previously recruited non-contact mechanism of 
injury (NON sub-group subset 1) groups. Gender specific comparisons between the two 
groups are also reported. 








p-value  TT TC CC 
All Participants        
CON 33.0 (65) 46.7 (94) 20.3 (40) 199  0.664 44.0 (174)  
ACL subset 1 32.1 (38) 53.6 (64) 14.3 (17) 119 0.345
a
 0.271  41.2 (98) 0.708
a
 
NON subset 1 32.8 (22) 55.2 (37) 11.9 (8) 67 0.287
b
 0.215 39.6 (53) 0.399
b
 
Male Participants        
CON 33.6 (42) 44.0 (55) 22.4 (28) 125  0.280  44.4 (111)  
ACL subset 1 30.4 (24) 57.0 (45) 12.7 (10) 79 0.118
a
 0.165 41.1 (65) 0.711
a
 
NON subset 1 29.2 (14) 58.3 (28) 12.5 (6) 48 0.196
b
 0.241 41.7 (40) 0.646
b
 
Female Participants        
CON 31.1 (23) 52.7 (39) 16.2 (12) 74  0.637  42.6 (63)  
ACL subset 1 35.0 (14) 47.5 (19) 17.5 (7) 40 0.867
a
 1.000 41.3 (33) 0.889
a
 
NON subset 1 42.1 (8) 47.4 (9) 10.5 (2) 19 nd nd 28.9 (11) nd 
Table 3. 6. A comparison of the genotype frequency distributions for COL6A1 rs35796750 (T/C), between the previously recruited South African (SA) anterior cruciate 
ligament (ACL) rupture (SA ACL 1) and control (SA CON) participants.  
Values are expressed as percentages with the number of participants indicated in 
parentheses. The total number (n) of participants genotyped in each individual or combined 
cohort is also indicated. All the ACL ruptures were diagnosed at surgery. The ACL and NON 
subset 1 participants were previously recruited by Posthumus et al. [153;154].  
HWE, Hardy-Weinberg Equilibrium. nd, not determined due to sample size. 
a CON vs. ACL 
b CON vs. NON 
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3.3.4 COL5A1 and COL12A1 Genotype Frequency Distributions 
 
Since both gender-specific associations have previously reported for the COL5A1 
and COL12A1 variants [153;154], the male and female sub-groups were analysed 
separately. When only the males were analysed, there were no significant 
differences in the COL5A1 rs12722 genotype frequency distributions between the 
ACL and CON or NON and CON sub-groups (Table 3.7). Similarly, no significant 
differences were identified in the COL12A1 rs970547 genotype distributions between 
the male ACL and CON or NON and CON sub-groups (Table 3.8). As expected, the 
COL5A1 rs12722 CC genotype was significantly (p=0.001 OR = 5.9, 95% CI 1.9 – 
17.9) under-represented in the larger female ACL (6.8%, n=4) sub-group when 
compared to the female CON (30.0%, n=27) sub-group (Table 3.7). Although not 
analysed because of the very small sample size, similar genotype distributions were 
identified within the NON sub-group (Table 3.7). No significant differences (p=0.393) 
were however identified in the COL12A1 rs970547 genotype frequency distributions 
between the female larger ACL and CON sub-groups (Table 3.8). Similar genotype 
distributions were identified within the NON sub-group (Table 3.8). Similar genotype 
frequency distributions were obtained when control participants with a self-reported 
history of any previous ligament injury were excluded from the analysis (Appendix 
C.2). All COL5A1 and COL12A1 sub-groups were all in HWE, except for the 
COL12A1 rs970547 NON male sub-group (Table 3.7 and 3.8). 
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Table 3.7. A gender specific comparison of the genotype frequency distributions for COL5A1 
rs12722 (T/C) between control (CON group), anterior cruciate ligament rupture (ACL group) 
and non-contact mechanism of injury (NON sub-group) groups within the larger South 
African cohort. 
 
COL5A1 rs12722 Genotype 
n p-value 
HWE 
p-value TT TC CC 
Male Participants      
CON 29.1 (41) 53.2 (75) 17.7 (25) 141  0.408 
ACL 27.9 (46) 55.8 (92) 16.4 (27) 165 0.899
a
 0.122 
NON 30.1 (28) 55.9 (52) 14.0 (13) 93 0.882
b
 0.204 
Female Participants      
CON 26.7 (24) 43.3 (39) 30.0 (27) 90  0.211 
ACL 44.1 (26) 49.2 (29) 6.8 (4) 59 0.001
c
 0.374 
NON 38.7 (12) 51.6 (16) 9.7 (3) 31 nd nd 
Table 3. 7. A gender specific comparison of the genotype frequency distributions for COL5A1 rs12722 (T/C) between anterior cruciate ligament rupture (ACL) and control 
(CON) groups within the larger South African cohort. 
Values are expressed as percentages with the number of participants indicated in 
parentheses. The total number (n) of participants genotyped in each individual or combined 
cohort is also indicated. Values in bold typeset are significant (p<0.05). All the ACL ruptures 
were diagnosed at surgery.  
HWE, Hardy-Weinberg Equilibrium; n.d., not determined due to small sample sizes 
a CON vs. ACL 
b CON vs. NON 
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Table 3.8. A gender specific comparison of the genotype frequency distributions for 
COL12A1 (A/G) between control (CON group), anterior cruciate ligament rupture (ACL 
group) and non-contact mechanism of injury (NON sub-group) groups within the larger SA 
cohort. 
 
COL12A1 rs970547 Genotype 
n p-value 
HWE 
p-value AA AG GG 
Male Participants      
CON 59.6 (84) 36.9 (52) 3.5 (5) 141  0.469
 
ACL 63.1 (101) 30.6 (49) 6.3 (10) 160 0.345
a
 0.158 
NON 64.0 (57) 28.1 (25) 7.9 (7) 89 0.184
b
 0.036 
Female Participants      
CON 57.6 (49) 41.2 (35) 1.2 (1) 85  0.104
 
ACL 65.0 (39) 26.7 (16) 8.3 (5) 60 0.393
c
 0.120 
NON 62.5 (20) 25.0 (8) 12.5 (4) 32 nd nd 
Table 3. 8. A gender specific comparison of the genotype frequency distributions for COL12A1 (A/G) between anterior cruciate 
ligament rupture (ACL) and control (CON) groups within the larger South African cohort. 
Values are expressed as percentages with the number of participants indicated in 
parentheses. The total number (n) of participants genotyped in each individual or combined 
cohort is also indicated. Values in bold typeset are significant (p<0.05). All the ACL ruptures 
were diagnosed at surgery. 
HWE, Hardy-Weinberg Equilibrium 
a CON vs. ACL 
b CON vs. NON 
c CON vs. ACL and AA vs AG + GG 
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3.3.5 Gene-Gene Interactions and ACL Rupture 
 
When only the males were analysed, no significant associations were identified 
between any of the four inferred pseudo-haplotypes, constructed from COL5A1 
rs12722 and COL12A1 rs970547, and risk of ACL rupture (Figure 3.6A). The major 
T+A inferred pseudo-haplotype was however significantly (p=0.022) over-
represented in the female ACL sub-group (50.5%, n=37) when compared to the 
female CON sub-group (38.1%, n=34) (Figure 3.6B). A similar tendency (p=0.052) 
was observed for the major T+A inferred pseudo-haplotype to be over-represented in 
the female NON sub-group (52.4%, n=17) when compared to the female CON sub-
group (38.1%, n=34) (Figure 3.6B). The COL3A1 rs1800255 gene variant was not 
independently associated with risk of ACL ruptures and only a trend was identified in 
the male sub-group, therefore analysis of gender-specific gene-gene interactions 
including COL3A1 rs180255, COL5A1 rs12722 and COL12A1 rs970547 were not 
determined in this study. 
 




























Figure 3.6. Inferred pseudo-haplotype frequency distributions for COL5A1 rs12722 and 
COL12A1 rs970547 in (A) male South African and (B) female South African participants.  
ACL, Anterior cruciate ligament rupture group. NON, non-contact mechanism of injury sub-
group. CON, control group.  




The first main finding of this study was that the COL3A1 rs1800255 gene variant was 
not independently associated with risk of ACL injuries. Although not significantly 
associated, a trend was observed for the rare COL3A1 A allele and AA genotype to 
be under-represented in the male ACL sub-group when compared to the male CON 
sub-group. Despite the lack of an independent association, this variant is proposed 
to be functional [94]. The alanine (rs1800255 G allele) to threonine (rs1800255 A 
allele) change at position 698 of the COL3A1 peptide is proposed to affect the tensile 
strength of type III collagen fibres [94]. The hydroxyl side chain of threonine is more 
hydrophilic than that of alanine and may result in distortion and unwinding of the 
collagen triple helix of type III collagen [94]. There was also no evidence from this 
study that this COL3A1 variant interacted with the COL5A1 rs12722 and/or 
COL12A1 rs970547 variants in modulating the risk of ACL ruptures. In contrast to 
this finding, a recent study showed that the COL3A1 rs1800255 AA genotype was 
associated with increased risk of ACL ruptures in Polish participants (both male and 
female) [137]. These results suggest that another variant within the COL3A1 gene or 
a neighbouring gene may be associated with risk of ACL ruptures. Further studies 
are required to investigate additional candidates in this region in the aetiology of ACL 
ruptures. 
 
The second main finding of this study was that COL6A1 rs35796750 did not 
associate with risk of ACL rupture in the self-reported Caucasian South African 
cohort, although it has been associated with a number of other soft-tissue 
phenotypes [101;138;191;197]. Therefore, this variant was not analysed in the newly 
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recruited South African subset. The genotype distributions of COL6A1 rs35796750 
were similar to previously reported values for Caucasian populations [197]. This 
finding does not discount the fact that additional variants within the COL6A1 gene, or 
other neighbouring genes, may still play a role in the aetiology of ACL injuries. 
Further work is required to test this hypothesis. 
 
Since, the COL5A1 rs12722 (T/C) and COL12A1 rs970547 (A/G) variants were 
previously associated with ACL rupture risk in Caucasian South African females 
[153;154], the gender-specific associations were repeated in a larger South African 
cohort. Similar to previously published results [153], the COL5A1 rs12722 CC 
genotype was significantly associated with reduced risk of ACL ruptures in the larger 
cohort of female participants. However COL12A1 rs970547 was not associated with 
risk of ACL rupture in the larger female cohort. As expected, no significant 
associations were identified between COL5A1 rs12722 and COL12A1 rs970547 and 
risk of ACL ruptures in the male participants investigated in this study [153;154].  
 
Since the independent analysis of COL5A1 rs12722 (T/C) and COL12A1 rs970547 
(A/G) within the larger South African cohort was not entirely repeatable, gene-gene 
interactions were investigated as a possible explanation of this discrepancy. As 
hypothesised, the major T+A inferred pseudo-haplotype constructed from these 
variants was associated with increased risk of ACL ruptures in the female 
participants. When data from an independent Polish cohort were analysed together 
with the South African cohort from this study the same major T+A inferred pseudo-
haplotype was similarly associated with an increased risk of ACL ruptures in the 
Polish female participants, as well as within the combined female cohorts [137]. 
Chapter 3   
86 
These findings are in agreement with the previously reported single association 
results for these variants [153;154], specifically the T and A alleles of COL5A1 and 
COL12A1, respectively, have been associated with increased risk of ACL rupture in 
females. As expected, no significant associations were identified between any of the 
four inferred COL5A1 and COL12A1 pseudo-haplotypes and risk of ACL rupture in 
the male participants.  
 
In a previous study it was shown that, although not independently associated with 
risk of ACL rupture, inferred pseudo-haplotypes constructed from variants within the 
COL5A1, COL11A1 and COL11A2 genes were associated with risk of Achilles 
tendinopathy in both a South African and an Australian cohort [71]. This finding, 
together with the results of this study, highlights the possibility that gene-gene 
interactions might mask independent single variant associations and that the 
multigenic nature of ACL ruptures needs to be considered in future research. 
 
As previously discussed (Chapter 2 Section 2.3.2) rs12722 is located within a 
functional region of the COL5A1  3’-UTR. In addition to rs12722, other variants within 
the 3’-UTR have been reported to be independently associated with chronic Achilles 
tendinopathy [2;71;107;131]. Future studies should investigate the association of 
these additional variants with ACL ruptures, especially in females. Although the 
COL12A1 rs970547 variant has been proposed to be functional (Chapter 2 Section 
2.6.2), it is possible that this variant is tightly linked to another functional variant. 
Future work is therefore required to examine the association of other COL12A1 
variants with ACL rupture. This work will assist in elucidating possible molecular 
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mechanisms through which variants within type XII collagen modulate the risk of 
ACL ruptures.  
 
Finally this study also showed, similarly to Posthumus et al. [152], that South African 
participants with a family history of any ligament injury were at a 1.8X greater risk of 
ACL rupture, while a family history of ACL injury increased this to a 9.1X greater risk 
of ACL rupture. Furthermore, an individual history of any previous ligament and any 
previous knee ligament injury were also risk factors for ACL rupture in the South 
African cohort. The ACL group and NON sub-group, and gender sub-groups, also 
reported playing contact sports for significantly more years than their respective 
CON groups and sub-groups, while the self-reported hours of non-contact sport were 
matched between the groups and sub-groups.  
 
In addition, it must be noted that the acute ACL rupture is a complex phenotype with 
numerous intrinsic and extrinsic risk factors [67]. Therefore, although this study has 
identified genetic and non-genetic intrinsic risk factors, it is important to acknowledge 
that they are not wholly responsible for the phenotype but rather contribute to the 
aetiology that may predispose an individual to risk of acute ACL rupture. This will be 
discussed in more detail in the final concluding chapter of this thesis (Chapter 10). 
 
The main limitation to this study was the reduced size of the South African sub-
groups after gender based analysis. This is not the first study to identify gender-
specific associations between gene variants and risk of ACL rupture [153;154], and 
the reasons for these gender-specific associations remain unknown. As mentioned 
above, a trend was observed for the rare COL3A1 rs1800255 A allele and AA 
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genotype to be under-represented in the male ACL sub-group when compared to the 
male CON sub-group. A larger cohort of male participants is therefore required to 
determine if a true independent association exists. In addition, a gene-gene 
interaction, between COL5A1 rs12722 and COL12A1 rs970547, was also 
significantly associated with risk of ACL ruptures in females only. It is tempting to 
speculate that these results may be due to direct or indirect interactions between sex 
hormones and the type V and XII collagen proteins. Interestingly, the expression of 
matrix metalloproteinase genes, MMP1 and MMP3, is higher in the ACL of women 
than in men [184]. Furthermore, a gene-gene interaction between MMP3 and 
COL5A1 rs12722 was shown to modulate risk of chronic Achilles tendinopathy [150]. 
This highlights an indirect mechanism through which these gender-specific 
associations may be explained, however further studies are required to determine 
the exact mechanisms involved. A second limitation to this study was that the 
exposure to extrinsic risk factors for the control participants could not be well 
documented. Therefore, although care was taken to recruit physically active 
individuals to match the ACL groups, the level of participation in high risk sports 
which involve cutting, pivoting and landing could not be accounted for in all control 
participants. The fact that the male sub-group was not matched for weight is a 
limitation to the study. It must however be noted that there were no genotype effects 
on weight and no significant genotype associations were observed for the male sub-
group in this study. 
 
In conclusion, the novel main findings of this study are that (i) the COL3A1 
rs1800255 and COL6A1 rs35796750 gene variants were not associated with risk of 
ACL injuries in South African participants and (ii) a significant interaction between 
  ACL Ruptures 
89 
 
the COL5A1 rs12722 T/C and COL12A1 rs970547 A/G variants is associated with 
risk of ACL rupture in females. Specifically the T+A inferred pseudo-haplotype was 
associated with increased risk of ACL ruptures in female participants. These results 
highlight the importance of investigating gene-gene interactions in the aetiology of 
ACL ruptures in multiple independent cohorts. Finally, the results of this chapter are 
summarised in table 3.9. 
 
Table 3.9. A continuing summary of the results of the chapters in this thesis. The results of 

























Haplotype nd T ♀3 nd A ♀3 
Achilles tendinopathy Chapter 4 
ROM Chapter 5 
Endurance Performance Chapter 6 
EAMC Chapter 7 
Rugby Union Chapter 8 
Table 3. 9. A continuing summary of the results of the chapters in this thesis. The results of chapter 3 are shown. 
Green shading indicates that the allele or genotype is associated with a reduced risk of 
injury. Red shading indicates that the allele or genotype is associated with an increased risk 
of injury. Grey shading indicates no independent association. Prev pub, previously 
published. ♀, associations identified only in females. ACL, anterior cruciate ligament; ROM, 
range of motion; EAMC, exercise-associated muscle cramps; nd, not determined.  
1 independent association previously reported by Posthumus et al. [153]. 
2 independent association previously reported by Posthumus et al. [154], but not 
idependently associated in this thesis. 
3 TA haplotype also associated with increased risk of female ACL ruptures when a Polish 
















Similarly to ligaments [59], the collagen fibril is also the major structural component 
of tendons (Chapter 2 Figure 2.12) [84]. Tendons subjected to large amounts of 
weight and force may become prone to injury and as a result the majority of tendon 
injuries affect the Achilles tendon followed by the, patellar, rotator cuff and forearm 
extensor tendons [162]. It is believed that approximately 30-50% of all sporting 
injuries occur to tendons and that 6-18% of these occur to the Achilles tendon [128]. 
Excluding injuries to the surrounding tissues, Achilles tendon injuries can mainly be 
divided into two separate categories; i) Achilles tendon ruptures and ii) Achilles 
tendinopathy. Ruptures of the Achilles tendon are acute and occur spontaneously 
[87], while Achilles tendinopathy is a chronic injury, degenerative in nature and 
caused by over-use and repetitive straining of the tendon [7], and is the focus of this 
chapter. 
 
A number of gene variants have been investigated in the aetiology of Achilles 
tendinopathy [2;50;71;131;155;170;171;179;181], including the candidate variants 
investigated in this thesis; COL3A1 rs1800255 (G/A) [170], COL5A1 rs12722 (C/T) 
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[131;179] and COL12A1 rs970547 (A/G) [181]. However, of these three, only 
COL5A1 rs12722 was found to be independently significantly associated with 
Achilles tendinopathy [131;179]. Specifically, the rs12722 CC genotype was 
significantly over-represented in physically active healthy control participants with no 
self-reported history of Achilles tendon injury when compared to participants with 
clinically diagnosed chronic Achilles tendinopathy in independent South African and 
Australian cohorts [131;179]. 
 
As mentioned in the previous chapter, type VI collagen is also present in the solid 
component of tendons [84], where it is known to interact directly with type V collagen 
[190]. Furthermore, like type III, V and XII collagen, type VI collagen also facilitates 
normal collagen fibrillogenesis [129]. The intronic COL6A1 rs35796750 (T/C) SNP 
(Chapter 3, Figure 3.4) is located near an intron branch site and is proposed to result 
in aberrant splicing of the COL6A1 mRNA [191], which may result in altered or 
aberrant type VI collagen fibrils. Although COL6A1 rs35796750 was not associated 
with ACL ruptures in a South African cohort (Chapter 3), the TT genotype of this 
variant has previously been associated with increased risk of ossification of the 
posterior longitudinal ligament [101;191] and the ligamentum flavum [101], as well as 
diffuse idiopathic skeletal hyperostosis [197].  
 
Since similarities and differences in the genetic associations between ACL and 
tendon injuries have been reported [131;152-155;179;181], the primary aim of this 
study was therefore to determine if COL6A1 rs35796750 is independently associated 
with risk of chronic Achilles tendinopathy in South African and Australian cohorts. 
Specifically, it was hypothesised that the COL6A1 rs35796750 TT genotype would 
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be associated with increased risk of chronic Achilles tendinopathy. In addition, 
collagen genes might interact with one another to modulate the risk of 
musculoskeletal soft tissue injuries (Chapter 3) [71]. The secondary aim was 
therefore to investigate gene-gene interactions between COL6A1 rs35796750 and 
the COL3A1 rs1800255 and COL5A1 rs12722 variants, which were previously 
genotyped in both cohorts, and risk of chronic Achilles tendinopathy in South African 
and Australian cohorts. It was hypothesised that the COL5A1 rs12722 T, COL6A1 
rs35796750 T and either of the COL3A1 rs1800255 alleles may be implicated in 
gene-gene interactions associated with increased risk of chronic Achilles 
tendinopathy. The COL12A1 rs970547 variant was not included in the analysis since 
it had only been previously genotyped in the South African cohort [181]. 
 




Five hundred and seventy-eight unrelated physically active participants, 283 South 
African (SA) self-reported Caucasian participants and 295 Australian (AUS) self-
reported Caucasian participants were recruited and included in this study. The SA 
cohort included 116 participants with clinically diagnosed chronic Achilles 
tendinopathy (SA TEN Group) and 167 apparently healthy controls (SA CON Group). 
The AUS cohort was made up of 85 participants with clinically diagnosed chronic 
Achilles tendinopathy (AUS TEN Group) and 210 apparently healthy controls (AUS 
CON Group). 
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The SA TEN participants were recruited from medical practices within Cape Town in 
South Africa and were all physically active prior to the onset of the condition. The 
clinically diagnosis, which was performed as described in Mokone et al (2006) [131], 
was made and reviewed by experienced sports clinicians. The stringent clinical 
diagnostic criteria for TEN was a gradual progressive pain over the posterior lower 
limb in the Achilles tendon area for greater than 6 months. The following six criteria 
were also used in the diagnosis: (1) early morning pain over the Achilles tendon 
area, (2) early morning stiffness over the Achilles tendon area, (3) a history of 
swelling over the Achilles tendon area, (4) tenderness to palpation over the Achilles 
tendon, (5) palpable nodular thickening over the affected Achilles, or (6) movement 
of the painful area in the Achilles tendon with plantar-dorsi-flexion (positive ‘‘shift’’ 
test) [131]. In addition to these criteria, soft-tissue ultrasound examination was 
performed in a sub-group of subjects to confirm the above diagnosis.   
 
The AUS TEN participants were recruited at the Musculoskeletal Research Centre of 
La Trobe University, Melbourne, Australia. The clinical diagnosis for the AUS TEN 
participants was performed as described for the South African participants above 
and confirmed by soft tissue ultrasound examination   
 
The SA and AUS control subjects were recruited from various recreational sporting 
clubs.  Exclusion criteria included history of current or past fluoroquinolone antibiotic 
use or previous local corticosteroids injection in the Achilles tendon or the area 
surrounding the Achilles tendon prior to the onset of symptoms. Furthermore, 
participants with diagnosed connective tissue disorders or any other systemic 
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diseases believed to be associated with chronic Achilles tendinopathy, such as, but 
not limited to, EDS, benign hypermobility joint syndrome, rheumatoid arthritis, 
systemic lupus erythematosus, hyperparathyroidism, renal insufficiency, diabetes 
mellitus and familial hypercholesterolemia were also excluded from the study.  
 
Prior to participation in this study, all the participants gave informed written consent 
(Appendix A.3). In addition, each participant completed personal details, medical 
history, as well as a sports participation questionnaire (Appendix A.4). This study 
was approved by the Human Research Ethics Committee of the Faculty of Health 
Sciences within the University of Cape Town, South Africa and the Human Ethics 
Committee of La Trobe University, Melbourne, Australia, respectively (Appendix 
A.1).  
 
4.2.2 Variant Selection 
 
The COL6A1 rs35796750 variant was chosen for the same reasons as listed in 
chapter 3 section 3.2.2. 
 
4.2.3 DNA Extraction and Genotyping Methods 
 
For the South African cohort, approximately 4.5ml of venous blood was collected, at 
the registration of each event, from all participants by venipuncture of a forearm vein 
into an EDTA vacutainer tube. Blood samples were stored at 4˚C until DNA was 
extracted, as previously described [108], with minor modifications [131]. An outline of 
this methodology was described in chapter 3, section 3.2.3. For the Australian cohort 
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DNA was extracted from approximately 4.5 ml of venous blood using a sequenced 
extraction technique (FlexiGene DNA Kit, Qiagen P/L, Valencia, California, USA) as 
per the manufacturer’s recommendations. The DNA samples were genotyped at the 
UCT/MRC Research Unit for Exercise Science and Sports Medicine, University of 
Cape Town, South Africa for COL6A1 rs35796750 was performed using custom 
designed Fluorescence-based Taqman® polymerase chain reaction (PCR) assays 
(Applied Biosystems, Foster City, CA, USA) as described in chapter 3 section 3.2.3.  
Investigators were blinded to the phenotypes of the participant samples while 
genotyping. Two investigators independently confirmed genotyping. Furthermore, a 
number of positive and negative controls were used to ensure genotyping accuracy. 
No discrepancies were observed. A total of 404/578 (69.8%) genotypes (200/283 
(70.7%) SA genotypes and 204/295 (69.2%) AUS genotypes) were identified for 
COL6A1 rs35796750. This low genotyping call rate may be due to degraded DNA 
samples since recruitment of participants and DNA isolation for these samples was 
conducted in 2004-2005. In order to avoid genotyping errors, samples that failed 
twice to amplify during PCR were considered as unsuccessfully genotyped and no 
further attempts were made to genotype them. 
 
Genotypes, for COL3A1 rs1800255, COL5A1 rs12722 and COL12A1 rs970547, 
used in the analysis of collagen gene-gene interactions was obtained from previous 
studies [131;170;179;181]. Genotype and allele frequency distributions and 
independent association results can be found in appendix C.3-5. 
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4.2.4 Statistical Analysis 
 
The same statistical tests and haplotype analysis methods were performed as 
described in chapter 3 section 3.2.4. Significance was accepted when p<0.05. No 
adjustments were made for multiple testing in this study for the same reasons as 




4.3.1 Participant Characteristics 
 
Table 4.1 shows the general characteristics for the South African and Australian 
participants in this study. The SA TEN group was significantly older at age of injury 
than the SA CON group at age of recruitment. The SA TEN group was significantly 
heavier than the SA CON group. The AUS TEN had significantly more male 
participants when compared to the AUS CON group. All other general characteristics 
were matched between the SA and AUS TEN and CON groups (Table 4.1). The SA 
and AUS TEN groups were 6.9 ± 8.1 yrs and 8.9 ± 9.8 yrs older at the time of 
recruitment than when they were first diagnosed with Achilles tendinopathy. There 
were no COL6A1 rs35796750 genotype effects on age (p=0.969), height (p=0.925), 
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Table 4.1. General characteristics for the South African (SA) and Australian (AUS) 
participants with chronic Achilles tendinopathy (TEN) and apparently healthy controls (CON) 
recruited for this study. 
SA Participants TEN (116) CON (167) p-value 
Age (yrs) 41.1 ± 14.1 (99) 36.3 ± 10.9 (160) 0.001 
Height (cm) 176.4 ± 8.8 (100) 174.8 ± 9.1 (160) 0.540
a
 





) 24.8 ± 3.3 (84) 23.5 ± 2.8 (156) 0.087
b
 
Gender (% male) 69.3 (79) 62.7 (104) 0.135 
AUS Participants TEN (85) CON (210) p-value 
Age (yrs) 40.4 ± 14.2 (84) 38.5 ± 12.4 (205) 0.268 
Height (cm) 174.0 ± 9.9 (82) 171.5 ± 9.2 (207) 0.057
a
 





) 26.5 ± 3.8 (82) 24.6 ± 3.9 (207) 0.235
b
 
Gender (% male) 72.9 (62) 40.2 (84) <0.001 
Table 4. 1. General characteristics for the South African (SA) and Australian (AUS) participants recruited for this study. 
Values are expressed as mean ± standard deviations or as percentages where appropriate. 
Number of participants is indicated in parentheses. For the TEN groups age, height, weight 
and BMI are reported from time of injury. For the CON groups age, height, weight and BMI 
are reported from time of recruitment. Values in bold typeset are significant (p<0.05). BMI, 
body mass index. 
a Co-varied for gender  
b Co-varied for age and gender 
 
As mentioned above in section 4.2.1, stringent clinical diagnostic criteria were used 
during the recruitment of participants by an experienced medical practitioner [131]. 
The frequency of SA TEN participants clinically diagnosed with tenderness to 
palpation, early morning stiffness, a history of swelling, early morning pain, palpable 
thickening, and a positive ‘‘shift’’ test are displayed in table 4.2. In addition, twenty 
(17.2%) of the SA TEN participants were diagnosed by ultrasound examination of 
the affected Achilles tendon. Approximately 12.9% (n=15) had a confirmed bilateral 
Achilles tendinopathy while 8.6% (n=10) reported multiple injuries to the tendon. 
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Table 4.2. The frequency of the clinical diagnostic criteria within the South African 
participants with diagnosed chronic Achilles tendinopathy (SA TEN). 
Clinical Diagnosis SA TEN (116) 
Tenderness to palpation 21.6 (25) 
Early morning stiffness 16.4 (19) 
History of swelling 12.9 (15) 
Early morning pain 10.3 (12) 
Palpable thickening 7.8 (9) 
Positive ‘‘shift’’ test 7.8 (9) 
At least one of the above 38.8 (45) 
All of the above  5.2 (6) 
Table 4. 2. The frequency of the clinical diagnostic criteria within the South African participants with diagnosed chronic Achilles tendinopathy (SA TEN). 




All participants in the AUS TEN group were examined using ultrasound examination 
of the affected Achilles tendon to confirm pathology in addition to their clinical 
diagnosis [179]. Furthermore 51.8% (n=44) of the AUS TEN participants were 
diagnosed with bilateral chronic Achilles tendinopathy while 27.1% (n=23) reported 
multiple injuries to the tendon.  
 
Running was found to be the predominant sporting activity resulting in injury (19.0%, 
n=22) in the SA cohort. The SA cohort was matched for the mean number of years 
participating in running (SA CON 8.7 ± 9.5 yrs, n=57, SA TEN 8.3 ± 10.7 yrs, n=41, 
p=0.821). However, the SA CON group (3.4 ± 3.1 hrs, n=57) reported significantly 
(p=0.017) more hours of running training when compared to the SA TEN group (1.9 
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± 2.4 hrs, n=36). Although all AUS participants were physically active individuals, the 
type of sporting activities performed, the hours of training and the frequency of 
activity were not recorded.  
 
4.3.2 COL6A1 rs35796750 and Achilles Tendinopathy 
 
The individual genotype frequency distributions for COL6A1 rs35796750 within the 
South African and Australian cohorts, as well as in all participants, are provided in 
table 4.3. There were no significant differences in the COL6A1 rs35796750 genotype 
or allele frequency distributions between either cohort, or when they were combined 
(Tables 4.3). Since no previous studies have shown a gender-specific association 
with the COL6A1 rs35796750 variant, gender-specific analysis of risk of Achilles 
tendinopathy was not investigated. The SA TEN (p=0.806) and CON (p=0.565) 
groups and the AUS TEN (p=0.188) group were in HWE (Table 4.3). The AUS CON 
group was out of HWE (p=0.011) (Table 4.3). In addition, when the cohorts were 
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Table 4.3. A comparison of the genotype and allele frequency distributions for COL6A1 
rs35796750 (T/C) between the South African and Australian Achilles tendinopathy groups 
and their respective control groups. Genotype and allele frequency distributions after 
combining the cohorts are also reported. 








p-value  TT TC CC 
SA TEN 40.0 (32) 48.8 (39) 11.3 (9) 80  0.806 35.6 (57)  
SA CON 37.5 (45) 50.0 (60) 12.5 (15) 120 0.925 0.565 37.5 (90) 0.703 
AUS TEN 27.9 (17) 59.0 (36) 13.1 (8) 61  0.188 42.6 (52)  
AUS CON 26.6 (38) 60.1 (86) 13.3 (19) 143 0.982 0.011 43.4 (124) 0.913 
All TEN 34.8 (49) 53.2 (75) 12.1 (17) 141  0.043 38.7 (109)  
All CON 31.6 (83) 55.5 (146) 12.9 (34) 263 0.806 0.023 40.7 (214) 0.574 
 
Values are expressed as percentages with the number of participants indicated in 
parentheses. The total number (n) of participants genotyped in each individual or combined 
cohort is also indicated. Significant p-values are indicated in bold.  
HWE, Hardy-Weinberg Equilibrium; n.d., not determined due to small sample sizes; SA, 
South African; AUS, Australia; All, South Africa and Australia; TEN, participants with 
diagnosed Achilles tendinopathy; CON, apparently healthy control participants. 
Table 4. 3. A comparison of the genotype and allele frequency distributions for COL6A1 rs35796750 (T/C) between the South 





4.3.3 Gene-gene Interactions and Achilles Tendinopathy 
 
Gene-gene interactions between COL6A1 rs35796750 and the previously genotyped 
COL3A1 rs1800255 (G/A) [170] and COL5A1 rs12722 (T/C) [131;179] were 
investigated. The South African and Australian cohorts were combined to increase 
the sample size for the analysis, since the genotype frequency distributions were 
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similar between the TEN and CON groups for all three variants. The COL12A1 
rs970547 variant was therefore not included in these gene-gene interaction analyses 
since it has not been genotyped in the Australian cohort (Appendix C.6) [181]. The 
A+C+C inferred pseudo-haplotype, constructed from COL3A1 rs1800255, COL5A1 
rs12722 and COL6A1 rs35796750, was significantly (p=0.005) under-represented in 
the TEN group (0.0%, n=0) when compared to the CON group (7.6%, n=28) (Figure 
4.1). Interestingly, the A+C inferred pseudo-haplotype, constructed from COL3A1 
rs1800255 and COL6A1 rs35796750, was also significantly (p=0.038) under-
represented in the TEN group (5.0%, n=10) when compared to the CON group 
(11.5%, n=43) (Appendix C.7). All the two-gene inferred pseudo-haplotypes are 













Figure 4. 1. Inferred pseudo-haplotype frequencies, constructed from COL3A1 rs1800255, COL5A1 rs12722 and COL6A1 
rs37596750, in South African and Australian participants with clinically diagnosed Achilles tendinopathy (TEN group) and 
apparently healthy controls (CON group). 
 
 
Figure 4.1. Inferred pseudo-haplotype frequencies, constructed from COL3A1 rs1800255, 
COL5A1 rs12722 and COL6A1 rs37596750, in South African and Australian participants 
with clinically diagnosed Achilles tendinopathy (TEN group) and apparently healthy controls 
(CON group). Numbers of participants are listed above each column. 





The COL6A1 rs35796750 variant was not independently associated with risk of 
chronic Achilles tendinopathy in a South African or Australian cohort. As mentioned 
previously this variant was selected because of proposed functionality [191], 
previous association studies with other connective tissue phenotypes [101;191;197], 
as well as the role of type VI collagen in fibrillogenesis [129] and its interaction with 
type V collagen [190]. Therefore, although COL6A1 rs35796750 was not associated 
with risk of Achilles tendinopathy in this study it does not exclude the fact that 
additional COL6A1 variants may still play a role in in the aetiology of Achilles 
tendinopathy.  
 
Gene-gene interactions between COL6A1 rs35796750 and the previously 
investigated COL3A1 rs1800255 [170] and COL5A1 rs12722 [131;179] variants were 
also explored. A significant two-gene inferred pseudo-haplotype constructed from 
COL3A1 rs1800255 and COL6A1 rs35796750 was associated with risk of Achilles 
tendinopathy. Consistent with the hypothesis, the A+C inferred pseudo-haplotype 
was associated with reduced risk of Achilles tendinopathy. Similarly, the A+C+C 
inferred pseudo-haplotype, constructed from COL3A1 rs1800255, COL5A1 rs12722 
and COL6A1 rs35796750, was also associated with reduced risk of ACL ruptures. 
These results implicate, for the first time, the COL3A1 rs1800255 and COL6A1 
rs35796750 gene variants as risk factors for Achilles tendinopathy.  Further studies 
are required to investigate how these, and other, collagen types may interact to 
modulate risk of Achilles tendinopathy.  
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In addition, it must be noted that chronic Achilles tendinopathy is a complex 
phenotype with numerous intrinsic and extrinsic risk factors [128]. Therefore, 
although this study has identified novel genetic risk factors, it is important to 
acknowledge that they are not wholly responsible for the phenotype but rather 
contribute to the aetiology that may predispose an individual to risk of chronic 
Achilles tendinopathy. This will be discussed in more detail in the final concluding 
chapter of this thesis (Chapter 10). 
 
The main limitation to this study was low genotyping call rate for the COL6A1 
rs35796750 variant. A possible reason for this is described in the genotyping section 
4.2.3. These low call rates may also be responsible for the AUS CON group being 
out of HWE. The differences in participant characteristics between the SA TEN and 
CON and AUS TEN and CON groups are a further limitation to this study. Both the 
SA and AUS TEN groups weighed more than their corresponding SA and AUS CON 
groups however participants were not recruited at the time of the injury and this data 
was self-reported. The TEN participants from both cohorts anecdotally reported an 
increase in weight after injury however this cannot be confirmed. Finally, the lack of 
physical activity data, including the type of sporting activities performed, the hours of 
training and the frequency of activity, for the Australian cohort is also a limitation to 
this study. 
 
In conclusion, the COL6A1 rs35796750 variant is not independently associated with 
risk of Achilles tendinopathy. However, the novel finding of this study was that the 
COL3A1 rs1800255 and COL6A1 rs35796750 variants interact to modulate risk of 
Achilles tendinopathy in the combined South African and Australian cohorts. In 
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addition, the COL3A1 rs1800255, COL5A1 rs12722 and COL6A1 rs35796750 
further modulate the risk of Achilles tendinopathy. Future studies are required to 
investigate how these, and other, collagen types may interact to modulate risk of 
chronic Achilles tendinopathy. The results of this chapter are summarised in table 4. 
 
 
Table 4.4. A continuing summary of the results of the chapters in this thesis. The results of 























AA ♀  
prev pub2 













Haplotype A C C nd 
ROM Chapter 5 
Endurance Performance Chapter 6 
EAMC Chapter 7 
Rugby Union Chapter 8 
Table 4. 4. A continuing summary of the results of the chapters in this thesis. The results of chapter 4, and all preceding chapters, are shown. 
Green shading indicates that the allele or genotype is associated with a reduced risk of 
injury. Red shading indicates that the allele or genotype is associated with an increased risk 
of injury. Grey shading indicates no independent association. Prev pub, previously 
published. ♀, associations identified only in females. ACL, anterior cruciate ligament; ROM, 
range of motion; EAMC, exercise-associated muscle cramps; nd, not determined.  
1 independent association previously reported by Posthumus et al. [153]. 
2 independent association previously reported by Posthumus et al. [154], but not independently 
associated in this thesis. 
3 T+A pseudo-haplotype also associated with increased risk of female ACL ruptures when a Polish 
cohort was analysed [137]. 
4 no independent association previously reported by Saunders [170] 
5 independent association previously reported by Mokone et al. [131] and repeated by September et 
al. [179]. 














The causes of anterior cruciate ligament (ACL) ruptures, chronic Achilles 
tendinopathy, as well as, other musculoskeletal soft tissue injuries are poorly 
understood and complex [67;128]. As reported in the previous chapters multiple 
extrinsic and intrinsic risk factors, including a genetic component, have been 
associated with these injuries [71;131;137;150;152-155;160;171;179-181]. Joint 
range of motion (ROM) or flexibility has also been proposed as one of the intrinsic 
risk factors for ACL ruptures and chronic Achilles tendinopathy [95;96;103].  
 
Joint range of motion may be defined as the range of motion available to a joint or 
group of joints, that does not result in injury, and is influenced by the muscles, 
tendons, ligaments and bones associated with that joint [6]. Like musculoskeletal soft 
tissue injuries, joint ROM is also a complex multifactorial phenotype 
[6;11;70;119;204]. A number of intrinsic factors, which includes a heritable 
component [11;119], and extrinsic factors are known to influence inter-individual 
The data presented in this chapter has been published in a condensed form in 
the peer-reviewed article: O'Connell K, Posthumus M, Collins M. No association 
between COL3A1, COL6A1 or COL12A1 gene variants and range of motion. Journal 
of Sports Sciences. 2013;31(2):181-7. 
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range of motion [6;70;204]. It has been estimated, in classical twin studies, that 
approximately 64-70% of the variability in normal (non-pathological) joint range of 
motion may be heritable [11;119]. COL5A1 rs12722 (C/T), which is a focus of this 
thesis, was the first variant reported to be associated with normal joint range of 
motion in independent cohorts [1;28;29;40]. Specifically, the CC genotype has been 
reported to be associated with an age-dependent increase in sit-and-reach ROM in 
apparently healthy physically active individuals [29]. In addition, analysis of ultra-
endurance athletes, who participated in a 56km road race, showed that the C and T 
alleles were over-represented in the “flexible-fast” and “inflexible-slow” groups 
respectively [28]. In contrast to these findings, the CT genotype was also shown to 
be associated with both increased knee hyperextension and general joint laxity in 
females only [13] and with increased sit-and-reach and straight leg raise ROM in 
uninjured participants as well as those with Achilles tendon injuries [40], while the CT 
genotype was also significantly over-represented in a cohort of Italian high-level 
international rhythmic gymnasts when compared to an active control group [196]. As 
expected, athletes with a -/- COL5A1 rs71746744 (-/AGGG) genotype also had on 
average a significantly higher pre-race sit-and-reach ROM [1]. As previously 
mentioned (Chapter 2 Figure 2.7) both rs12722 and rs71746744 are located within 
the function 3’-untranslated region (UTR) of the COL5A1 gene [107].  
 
A genetic continuum is proposed for collagen genes, such as COL5A1 (Chapter 2 
Section 2.2), in which rare mutations result in severe disorders. Extreme joint 
hypermobility, which is one of the clinical features of the inherited connective tissue 
disorders such as classical (types 1 and 2) and hypermobility (type 3) types of 
Ehlers-Danlos Syndrome (EDS), are caused by rare mutations within collagen genes 
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[19;33;122-124;186;218]. Approximately a half of the classical type of EDS is caused 
by mutations within COL5A1 [19;123]. These mutations within the COL5A1 gene 
result in a 50% reduction in type V collagen production, aberrant fibrillogenesis and 
altered mechanical properties of connective tissues [19;123]. COL3A1 mutations 
cause the vascular type of EDS (type 4), which has been reported to cause aberrant 
fibrillogenesis [186]. As previously discussed (Chapter 2 Section 2.6), in addition to 
types V and III collagen, types VI and XII collagen, as well as other non-collagen 
proteins, are all implicated in fibrillogenesis [56;115;129;141;213]. Recently 
mutations within the COL12A1 gene have also been shown to cause a novel EDS 
[218], while the COL12A1 rs970547 AA genotype was also associated with 
increased knee hyperextension in females [13]. Mutations within the COL6A1 gene 
do not result in any of the EDS types, however patients with EDS resulting from 
tenascin-X deficiency show reduced COL6A1 expression [31]. Furthermore, 
mutations in COL6A1 do cause Bethlem myopathy [17;109] and Ullrich congenital 
muscular dystrophy [17;109;140], of which a symptom is joint hypermobility. 
 
In summary (1) Rare mutations within the four collagen genes investigated in this 
thesis (COL3A1, COL5A1, COL6A1 and COL12A1) cause joint hypermobility, (2) 
joint ROM is an intrinsic risk factors for ACL ruptures and chronic Achilles 
tendinopathy, (3) the collagens encoded by these candidate genes are all involved in 
fibrillogenesis, (4) all four collagen gene common variants investigated in this study 
are either independently associated or form part of inferred pseudo-haplotypes 
associated with modifying the risk ACL ruptures and/or chronic Achilles 
tendinopathy. Since these observations are in agreement with the genetic continuum 
hypothesis presented in chapter 2, the primary aim of this study in the thesis was to 
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investigate the independent association of the COL3A1 rs1800255 (G/A), COL6A1 
rs35796750 (T/C) and COL12A1 rs970547 (A/G) variants with three measures of 
range of motion, namely sit-and-reach, straight leg raise (SLR) and total shoulder 
rotation (ShTR) range of motion. The secondary aim of this study was to determine if 
any gene-gene interactions between these collagen genes were associated with the 
sit-and-reach ROM. 
 




Three hundred and fifty apparently healthy, injury free and physically active 
Caucasian participants were recruited from fitness centers/clubs and two road 
running events within the greater Cape Town area of South Africa. The inclusion 
criteria have been previously described [28;29]. Briefly, only participants that (1) 
were non-obese (Body mass index (BMI) less than 30 kg.m-2), (2) were over the age 
of 18 years and (3) reported no serious injuries in the last 12 months were recruited. 
 
All participants gave written informed consent (Appendix A.3) and completed a 
physical activity, medical history and flexibility training questionnaire (Appendix A.4).  
Ethical approval for the study was obtained from the Human Research Ethics 
Committee of the University of Cape Town (Appendix A.1). In addition, permission to 
conduct this study was also granted by the organising committee(s) of the respective 
running races, where applicable.  
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5.2.2 Anthropometric and Range of Motion Measurements 
 
Anthropometric measurements and range of motion assessments were measured as 
previously described [28;29]. Briefly, three clinically validated ROM assessments 
were performed on the subjects at two separate testing sessions. Two lower body 
assessments, the sit-and-reach test [212] and straight leg raise (SLR) test [63], were 
performed at separate visits to prevent one influencing the other. Participants were 
requested to return for their second testing session between one and ten days after 
their initial session. The third assessment, an upper body assessment, was the 
shoulder internal (IR) and external rotation (ER) in 90° abduction [10;24]. This 
assessment was always performed on the same day as the SLR test. 
 
Both the sit-and-reach and straight leg raise (SLR) range of motion tests are indirect 
measures of lumbar and hamstring musculotendinous unit range of motion [63;212]. 
Total shoulder rotation (ShTR) was calculated by combining measures of internal 
and external rotation at 90o of abduction [10;24]. Measurements of straight leg raise 
and total shoulder rotation range of motion were determined for dominant and non-
dominant limbs. Measures of sit-and-reach, straight leg raise and total shoulder 
rotation range of motion were recorded in triplicate and the best score used. 
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5.2.3 Variant Selection 
 
Three independent sequence variants were investigated in this study. Namely 
COL3A1 rs1800255, COL6A1 rs35796750 and COL12A1 rs970547. The reasons for 
their selection have been stated in chapter 3, section 3.2.2. Furthermore, these 
variants have been independently associated with, or interact to modulate, the risk of 
musculoskeletal soft tissue injuries (Chapter 3 and 4). 
 
5.2.4 DNA Extraction and Genotyping Methods 
 
Approximately 4.5ml of venous blood was collected from all participants by 
venipuncture of a forearm vein into an EDTA vacutainer tube. These samples were 
stored at 4˚C until DNA extraction, as previously described [108], with minor 
modifications [131]. An outline of this methodology was described in chapter 3, 
section 3.2.3. 
 
Participants were genotyped for COL3A1 rs1800255, COL6A1 rs35796750 and 
COL12A1 rs970547. Investigators were blinded to the performance results of the 
participant samples while genotyping. Two investigators independently confirmed 
genotyping.  A number of positive and negative controls were used to ensure quality 
and accuracy of genotyping. No discrepancies were observed. Of the 350 
participants recruited only 314 (89.7%), 313 (89.4%) and 315 (90.0%) genotypes 
were obtained for COL3A1 rs1800255, COL6A1 rs35796750 and COL12A1 
rs970547 respectively.  
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Genotyping of COL3A1 rs1800255 and COL6A1 rs35796750 was performed using 
custom designed Fluorescence-based Taqman® polymerase chain reaction (PCR) 
assays (Applied Biosystems, Foster City, CA, USA) as described in chapter 3. 
Additional genotyping information is available in appendix B. 
 
COL12A1 rs970547 was genotyped as previously described [39;42]. Briefly, 
fragments containing the COL12A1 AluI RFLP were amplified by polymerase chain 
reaction (PCR). The polymerase chain reaction products were then digested with 
AluI to produce 599bp and 16bp fragments for the G allele; 460, 139 and 16bp 
fragments for the A allele. The digest fragments were separated, together with a 
100bp DNA ladder, on 6% non-denaturing polyacrylamide electrophoresis gels and 
visualized by SYBER Gold staining (Invitrogen Molecular ProbesTM, Oregon, USA).  
The gels were photographed under UV light using a Uvitec photodocumentation 
system (Uvitec Limited, Cambridge, UK) and the sizes of the DNA fragments 
determined. Additional genotyping information is available in appendix B. All 
genotyping was done at the UCT/MRC Research Unit for Exercise Science and 
Sports Medicine, University of Cape Town, Cape Town, South Africa. 
 
5.2.5 Statistical Analysis 
 
The same statistical tests and haplotype analysis methods were performed as 
described in chapter 3 section 3.2.4. Although not significantly different, large 
differences (≥10%) were identified between the frequencies of male participants in 
the SNP genotype groups. In addition, gender is a known factor in the aetiology of 
ROM [6;73]. Therefore, all of the analyses presented in this study are presented for 
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males and females separately or, when the whole cohort was analysed, were co-
varied for gender. Furthermore, analysis of COL6A1 rs35796750 was also co-varied 
for weight due to the significant inter-genotype differences identified. Bivariate 
correlations were used to investigate the relationship between participant 
characteristics and measures of range of motion. Significance was accepted when 
p<0.05. No adjustments were made for multiple testing in this study for the same 




5.3.1 Participant Characteristics 
 
Average age, height, weight, BMI and ROM measurements of all participants, as well 
as the male and female participants, are presented in table 5.1. There were no 
significant differences in the average ages of the male and female participants. As 
expected the males were significantly taller and heavier than their female 
counterparts. On average the female participants had significantly higher (p<0.001) 
measures of range of motion than male participants for all measurements (Table 
5.1), except for non-dominant shoulder total rotation which only showed a tendency 
to be higher in females after adjusting for height, weight and self-reported flexibility 
training. Mean time spent on flexibility training was 1.3 ± 2.7 minutes/week (n=112).  
 
Correlations between participant age, weight, height, BMI and flexibility training and 
all measures of range of motion are presented in table 5.2. A significant negative 
correlation was identified between age and dominant SLR ROM in males only, while 
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a significant positive correlation was identified between BMI and non-dominant ShTR 
ROM in females only (Table 5.2). No other significant correlations were identified.  
 
 
Table 5.1. General characteristics, as well as upper and lower body range of motion (ROM) 
measurements for all participants. A comparison between male and female participants is 





a p value b 
 Male (216) Female (134) 
Age (yrs) 32.8 ± 11.8 (350) 33.2 ± 12.3 (216) 32.4 ± 10.8 (134) 0.570 nd 
Height (cm) 174.4 ± 9.4 (310) 180.0 ± 6.7 (187) 166.1 ± 6.4 (122) <0.001 nd 
Weight (kg) 72.6 ± 13.0 (310) 79.3 ± 10.9 (187) 62.5 ± 8.6 (122) <0.001 nd 
BMI (kg.m
-2
) 23.8 ± 3.9 (308) 24.4 ± 2.8 (187) 23.0 ± 5.0 (122) 0.001 nd 
SR ROM (mm) 270.1 ± 110.2 (344) 245.8 ± 106.9 (213) 309.8 ± 104.1 (131) <0.001 0.009 
Non-Dom SLR (°) 87.8 ± 20.4 (162) 81.1 ± 17.8 (95) 97.4 ± 20.1 (67) <0.001 <0.001 
Dom SLR (°) 92.5 ± 20.4 (162) 84.8 ± 17.6 (95) 103.4 ± 19.1 (67) <0.001 0.001 
Non-Dom ShTR (°) 204.2 ± 28.6 (157) 196.7 ± 25.0 (93) 215.2 ± 30.2 (64) <0.001 0.056 
Dom ShTR (°) 198.7 ± 26.6 (159) 190.5 ± 23.3 (94) 210.4 ± 26.7 (65) <0.001 <0.001 
Table 5. 1.General characteristics, as well as upper and lower body range of motion (ROM) measurements for all participants. A comparison between male and female 
participants is also presented. 
Values are expressed as mean ± standard deviation. Number of participants with non-
missing data is indicated in parentheses. Values in bold typeset are significant (p<0.05). 
BMI, body mass index; SR, sit-and-reach; mm, millimetres; Non-Dom, non-dominant; SLR, 
straight leg raise; Dom, dominant; ShTR, shoulder total rotation; nd, not determined. 
a male vs female 
b co-varied for height, weight and flexibility training 
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Table 5.2. Correlations between Participant General Characteristics and Measures of Range 
of Motion (ROM) in males and females. 
Male Participants 
 SR ROM (mm) Non-Dom SLR (°) Dom SLR (°) Non-Dom ShTR (°) Dom ShTR (°) 





(95) r=-0.087 p=0.408 (93) 
r=0.182 
p=0.862 (94) 
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Table 5. 2.Correlations between Participant General Characteristics and Measures of Range of Motion (ROM) in males and females. 
Number of participants with non-missing data is indicated in parentheses. Values in bold 
typeset are significant (p<0.05). 
a There were also no significant correlations of flexibility training with any of the ROM 
measurements when only those participants with a self-reported history of flexibility training 
were included in the analysis.   
SR, sit-and-reach; mm, millimetres; Non-Dom, non-dominant; SLR, straight leg raise; Dom, 
dominant; ShTR, shoulder total rotation; BMI, body mass index; yrs, years, kg, kilogram; m, 
metres; min, minutes; wk, week 
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Participants with a self-reported history of flexibility training (47.7%, n=112) had 
significantly higher (p=0.007) measures for sit-and-reach range of motion 
measurements than the 123 participants with no self-reported history of flexibility 
training (Table 5.3). No significant differences in the other measures of range of 
motion were identified when participants with a self-reported history of flexibility 
training were compared to those with no history of flexibility training (Table 5.3).   
 
No significant genotype interactions were identified between COL3A1 rs1800255, 
COL6A1 rs35796750 or COL12A1 rs970547 and participant age, gender, height, 
BMI, minutes of flexibility training per week or hours of exercise per week (Table 
5.4). A significant genotype effect was determined between only COL6A1 
rs35796750 and participant weight (TT: 73.9 kg, TC: 70.7 kg, CC: 75.7 kg, p=0.035). 
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Table 5.3. Differences in range of motion (ROM) measurements between participants with a 









 No (123) 
SR ROM (mm) 288.4 ± 113.7 (107) 239.7 ± 108.0 (121) 0.007 
Non-Dom SLR (°) 91.7 ± 21.4 (70) 83.6 ± 18.8 (85) 0.066 
Dom SLR (°) 96.5 ± 20.7 (70) 88.1 ± 19.2 (85) 0.066 
Non-Dom ShTR (°) 204.9 ± 28.2 (68) c 202.8 ± 29.3 (82) 0.781 
Dom ShTR (°) 200.3 ± 27.3 (68) c 196.1 ± 26.0 (84) 0.871 
Table 5. 3.Differences in range of motion (ROM) measurements between participants with a self-reported history (Yes) and no history (No) of weekly flexibility training. 
Values are expressed as mean ± standard deviation. Number of participants is indicated in 
parentheses. Values in bold typeset are significant (p<0.05). 
SR, sit-and-reach; mm, millimetres; Non-Dom, non-dominant; SLR, straight leg raise; Dom, 
dominant; ShTR, shoulder total rotation 
a All 112 participants reported doing lower body flexibility (111 hamstrings, 106 quadriceps,  
80 soleus, 95 gastrocnemius, 74 groin) training. 
b p values adjusted for gender.  
c Non-Dom ShTR and Dom ShTR for participants who reported Upper body Flexibility 
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Table 5.4. Genotype effects of COL3A1 rs1800255, COL6A1 rs35796750 and COL12A1 
rs970547 on physiological characteristics of participants. 
Polymorphism 
p-values 





COL3A1 rs1800255 0.126 0.725 0.668 0.274 0.513 0.130 0.413 
COL6A1 rs35796750 0.108 0.066 0.035 0.743 0.136 0.359 0.684 
COL12A1 rs970547 0.977 0.232 0.788 0.596 0.197 0.863 0.108 
Table 5. 4.Genotype effects of COL3A1 rs1800255, COL6A1 rs35796750 and COL12A1 rs970547 on physiological characteristics of participants. 




5.3.2 Collagen Genes and Range of Motion 
 
The COL3A1 rs1800255 (p=0.180), COL6A1 rs35796750 (p=0.219) and COL12A1 
rs970547 (p=0.988) variants were not significantly associated with sit-and-reach 
range of motion (Table 5.5). In addition, no significant associations were identified 
between dominant straight leg raise, non-dominant straight leg raise, dominant total 
shoulder rotation or non-dominant total shoulder rotation range of motion and 
COL3A1 rs1800255, COL6A1 rs35796750 or COL12A1 rs970547 (Table 5.5). In 
addition, no significant genotype interactions were identified for any of the measures 
of range of motion after further adjusting for self-reported history of flexibility training 
(Table 5.5).  
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Since the COL5A1 rs12722 gene variant was previously shown to be associated with 
sit-and-reach ROM in older participants (≥35yrs old) [29], associations between 
COL3A1 rs1800255, COL6A1 rs35796750 and COL12A1 rs970547 were 
investigated in an older group (≥35yrs old) (Table 5.6). The COL3A1 rs1800255, 
COL6A1 rs35796750 and COL12A1 rs970547 were not significantly associated with 
sit-and-reach range of motion in this older group (Table 5.6). Analysis of the other 
measures of ROM could not be investigated due to small sample sizes in the older 
group (Table 5.6). Furthermore, no significant age-genotype interaction effects were 
identified between any of the range of motion measurements and COL3A1 
rs1800255 (p≥0.143), COL6A1 rs35796750 (p≥0.104) or COL12A1 rs970547 
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Table 5.5. Differences in range of motion (ROM) measurements between the COL3A1 
rs1800255, COL6A1 rs35796750 and COL12A1 rs970547 genotype groups. 
 COL3A1 rs1800255 Genotypes 
p value 
a p value c 
 GG (160) GA (124) AA (25) 
SR ROM (mm) 279 ± 110 (160) 268 ± 106 (124) 243 ± 122 (25) 0.180 0.090 
Non-Dom SLR (°) 90 ± 21 (75) 87 ± 20 (57) 83 ± 20 (8) 0.423 0.335 
Dom SLR (°) 94 ± 21 (75) 91 ± 19 (57) 89 ± 21 (8) 0.389 0.265 
Non-Dom ShTR (°) 207 ± 32 (72) 205 ± 25 (55) 185 ± 32 (8) 0.120 0.114 
Dom ShTR (°) 200 ± 30 (73) 200 ± 24 (56) 193 ± 24 (8) 0.773 0.715 
 COL6A1 rs35796750 Genotypes 
p value 
b p value d 
 TT (115) TC (139) CC (54) 
SR ROM (mm) 272 ± 103 (115) 262 ± 118 (139) 284 ± 111 (54) 0.219 0.426 
Non-Dom SLR (°) 89 ± 21 (48) 84 ± 22 (67) 93 ± 18 (24) 0.128 0.178 
Dom SLR (°) 94 ± 24 (48) 89 ± 19 (67) 97 ± 16 (24) 0.051 0.078 
Non-Dom ShTR (°) 204 ± 28 (46) 200 ± 30 (64) 206 ± 34 (24) 0.687 0.686 
Dom ShTR (°) 197 ± 25 (47) 195 ± 28 (65) 206 ± 32 (24) 0.293 0.209 
 COL12A1 rs970547 Genotypes 
p value 
a p value c 
 AA (187) AG (112) GG (11) 
SR ROM (mm) 271 ± 107 (187) 265 ± 119 (112) 266 ± 102 (11) 0.988 0.877 
Non-Dom SLR (°) 91 ± 20 (95) 85 ± 21 (57) 74 ± 12 (5) 0.059 0.077 
Dom SLR (°) 96 ± 22 (95) 89 ± 118 (57) 84 ± 8 (5) 0.093 0.125 
Non-Dom ShTR (°) 209 ± 30 (93) 197 ± 25 (54) 206 ± 32 (5) 0.144 0.208 
Dom ShTR (°) 202 ± 29 (93) 193 ± 23 (56) 202 ± 20 (5) 0.214 0.241 
Table 5. 5.Differences in range of motion (ROM) measurements between the COL3A1 rs1800255, COL6A1 rs35796750 and COL12A1 rs970547 genotype groups. 
Values are expressed as mean ± standard deviation. Number of participants is indicated in 
parentheses. SR, sit-and-reach; mm, millimetres; Non-Dom, non-dominant; SLR, straight leg 
raise; Dom, dominant; ShTR, shoulder total rotation. 
a p values adjusted for gender.  
b p values adjusted for gender and weight. 
c p values adjusted for gender and self-reported history of flexibility training. 
d p values adjusted for gender, weight and self-reported history of flexibility training. 
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Table 5.6. Differences in range of motion (ROM) measurements between the COL3A1 
rs1800255, COL6A1 rs35796750 and COL12A1 rs970547 genotype groups for participants 
≥35yrs old. 
 COL3A1 rs1800255 Genotypes 
p value 
a p value c 
 GG (49) GA (53) AA (11) 
SR ROM (mm) 277.5 ± 126.3 (49) 244.8 ± 91.8 (53) 206.1 ± 104.6 (11) 0.109 0.137 
Non-Dom SLR (°) 87.9 ± 24.7 (8) 73.7 ± 19.8 (7) 0.0 ± 0.0 (0) nd nd 
Dom SLR (°) 92.9 ± 23.9 (8) 81.6 ± 30.7 (7) 0.0 ± 0.0 (0) nd nd 
Non-Dom ShTR (°) 221.4 ± 21.1 (6) 184.6 ± 28.9 (6) 0.0 ± 0.0 (0) nd nd 
Dom ShTR (°) 209.1 ± 12.5 (6) 192.3 ± 90.7 (7) 0.0 ± 0.0 (0) nd nd 
 COL6A1 rs35796750 Genotypes 
p value 
b p value d 
 TT (44) TC (55) CC (13) 
SR ROM (mm) 253.0 ± 97.7 (44) 260.2 ± 117.2 (55) 277.2 ± 105.9 (13) 0.679 0.258 
Non-Dom SLR (°) 92.9 ± 18.6 (8) 76.7 ± 25.7 (9) 0.0 ± 0.0 (0) nd nd 
Dom SLR (°) 96.6 ± 22.7 (8) 86.6 ± 28.6 (9) 0.0 ± 0.0 (0) nd nd 
Non-Dom ShTR (°) 203.4 ± 23.7 (7) 199.4 ± 36.5 (7) 0.0 ± 0.0 (0) nd nd 
Dom ShTR (°) 206.7 ± 23.5 (7) 194.2 ± 24.1 (8) 0.0 ± 0.0 (0) nd nd 
 COL12A1 rs970547 Genotypes 
p value 
a p value c 
 AA (57) AG (39) GG (4) 
SR ROM (mm) 261.3 ± 112.1 (57) 246.7 ± 107.7 (39) 302.5 ± 128.4 (4) 0.547 0.658 
Non-Dom SLR (°) 95.9 ± 22.3 (9) 72.7 ± 20.9 (6) 64.0 ± 0.0 (1) nd nd 
Dom SLR (°) 104.7 ± 24.7 (9) 77.3 ± 17.7 (6) 84.0 ± 0.0 (1) nd nd 
Non-Dom ShTR (°) 215.6 ± 29.2 (8) 192.5 ± 21.5 (4) 183.0 ± 0.0 (1) nd nd 
Dom ShTR (°) 210.2 ± 26.9 (8) 191.4 ± 15.5 (5) 210.0 ± 0.0 (1) nd nd 
Table 5. 6. Differences in range of motion (ROM) measurements between the COL3A1 rs1800255, COL6A1 rs35796750 and COL12A1 rs970547 genotype groups for participants ≥35yrs old. 
Values are expressed as mean ± standard deviation. Number of participants is indicated in 
parentheses. SR, sit-and-reach; mm, millimetres; Non-Dom, non-dominant; SLR, straight leg raise; 
Dom, dominant; ShTR, shoulder total rotation; nd, not determined. 
a p values adjusted for gender.  
b p values adjusted for gender and weight. 
c p values adjusted for gender and self-reported history of flexibility training. 
d p values adjusted for gender, weight and self-reported history of flexibility training. 
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Table 5.7. Age-genotype interaction effects for the range of motion measurements and 




SR ROM (mm) Non-Dom SLR (°) Dom SLR (°) Non-Dom ShTR (°) Dom ShTR (°) 
COL3A1 rs1800255 0.143 0.643 0.500 0.191 0.741 
COL6A1 rs35796750 0.476 0.263 0.365 0.147 0.104 
COL12A1 rs970547 0.573 0.100 0.133 0.279 0.451 
Table 5. 7. Age-genotype interaction effects for the range of motion measurements and COL3A1 rs1800255, COL6A1 rs35796750 and COL12A1 rs970547 variants. 
SR, sit-and-reach; mm, millimetres; Non-Dom, non-dominant; SLR, straight leg raise; Dom, 




5.3.3 Gene-Gene Interactions and Range of Motion 
 
Gene-gene interactions between COL3A1 rs1800255, COL6A1 rs35796750, 
COL12A1 rs970547, and the previously genotyped COL5A1 rs12722 [28;29;40], and 
sit-and-reach ROM (SR-ROM) measurements were investigated. Gene-gene 
interaction analysis between these variants and the other ROM measures (Non-Dom 
SLR, Dom SLR, Non-Dom ShTR and Dom ShTR) could not be calculated due to 
small group sizes. Participants were divided into a High (participants in the upper 
half of SR-ROM scores) and a Low (participants in the lower half of SR-ROM scores) 
group based on their SR-ROM scores. No significant gene-gene interactions were 
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identified when all four gene variants were used to construct pseudo-haplotypes 
(Figure 5.1), or when any three variants were used (Appendix C.9) 
 
Significant gene-gene interactions were identified when two-gene pseudo-haplotypes 
were constructed (Appendix C.8). A summary of these significant interactions is 
presented in table 5.8. The G+C inferred pseudo-haplotype, constructed from 
COL3A1 rs1800255 and COL6A1 rs35796750, was significantly (p=0.017) over-
represented in the High SR-ROM group (30.4%, n=52) when compared to the Low 
SR-ROM group (25.8%, n=44) (Table 5.8). Significant interactions were also 
identified when COL5A1 rs12722 and COL6A1 rs35796750 were analysed. 
Specifically, the C+T inferred pseudo-haplotype was significantly (p=0.020) over-
represented in the High SR-ROM group (27.9%, n=48) when compared to the Low 
SR-ROM group (23%, n=40), while the T+T inferred pseudo-haplotype was 
significantly (p=0.028) under-represented in the High SR-ROM group (31.5%, n=54) 
when compared to the Low SR-ROM group (37.3%, n=64) (Table 5.8). No other 
significant interactions were identified between any of the variant combinations and 
SR-ROM groups (Appendix C.8). Gene-gene interactions between these variants 
and SR-ROM groups in the older group (≥35yrs old) could not be determined due to 
small sample sizes.  
 












Figure 5. 1.Inferred pseudo-haplotype frequencies, constructed from COL3A1 rs1800255, COL5A1 rs12722, COL6A1 





Figure 5.1. Inferred pseudo-haplotype frequencies, constructed from COL3A1 rs1800255, 
COL5A1 rs12722, COL6A1 rs37596750 and COL12A1 rs970547, and their interaction 
between High and Low Sit-and-Reach Range of Motion (SR-ROM) Measurements. Numbers 






Table 5.8. A summary of the two-gene inferred pseudo-haplotypes significantly associated 





















    
COL12A1 
rs970547 (A/G) 
    
Table 5. 8. A summary of the two-gene pseudo-haplotypes significantly associated with Sit-and-Reach Range of Motion Measurements. 
The gene variant on the left contributes the first allele listed in each combination. Green 
shading indicates that the inferred pseudo-haplotype is associated with an increased ROM. 
Red shading indicates that the inferred pseudo-haplotype is associated with a reduced 
ROM. 
 





The COL3A1 rs1800255, COL6A1 rs35796750 and COL12A1 rs970547 variants are 
not independently associated with specific upper and lower body joint range of 
motion (ROM) measurements. Furthermore, no age-genotype effects were identified 
between these gene variants and any of the measures of ROM investigated in this 
study. Despite a lack of independent associations, a number of gene-gene 
interactions were identified. Specifically, two-gene interactions between COL3A1 
rs1800255 and COL6A1 rs35796750 and COL5A1 rs12722 and COL6A1 
rs35796750 were associated with sit-and-reach ROM. The G+C inferred pseudo-
haplotype, constructed from COL3A1 rs1800255 and COL6A1 rs35796750, was 
associated with increased sit-and-reach ROM and implicates these genes in the 
aetiology of ROM for the first time. Future studies are therefore required to determine 
how types III and VI collagen might interact in the collagen fibril and how these 
interactions would modulate the aetiology of ROM. 
 
Interestingly, the inferred pseudo-haplotypes constructed from COL5A1 rs12722 and 
COL6A1 rs35796750 appeared to be dominated by the rs12722 allele. Specifically 
within the inferred pseudo-haplotypes, the rs12722 T and C alleles were associated 
with decreased and increased sit-and-reach ROM respectively, regardless of which 
COL6A1 rs35796750 allele was present. Furthermore, these results for COL5A1 
rs12722 are consistent with previously reported findings [28;29]. Interactions 
between types V and VI have been described [190], however further studies are 
required to determine the how these interactions might modulate ROM.  
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Mutations within the four genes investigated in this study result in musculoskeletal 
soft tissue abnormalities with symptoms of joint hypermobility [17;31;33;109;122-
124;186;218]. Future studies are therefore required to investigate additional variants 
within these genes, especially COL12A1 which was not implicated in this study, as 
markers for joint ROM.  
 
As stated above, the results for COL5A1 rs12722 in this study are consistent with 
previously reported findings [28;29], however three additional studies have shown 
contrasting results [13;40;196]. Specifically, the CT genotype was shown to be 
associated with increased sit-and-reach and straight leg raise ROM in uninjured 
participants as well as those with Achilles tendon injuries [40], with both increased 
knee hyperextension and general joint laxity in females only [13], and was over-
represented in a cohort of female Italian high-level international rhythmic gymnasts 
[196]. The average age (±43yrs old) of participants recruited by Collins et al. [40] 
was considerably higher than that described in this thesis (±32yrs old). Furthermore, 
approximately 70% (85/119) of the cohort recruited by Collins et al. [40] reported a 
history of chronic Achilles tendinopathy or Achilles tendon rupture. Therefore, the 
difference in average ages and injury profiles between these cohorts may explain the 
inconsistent findings [28;29;40], since it cannot be excluded that the injured 
participants had an altered ROM at the time of measurement that may not represent 
their pre-injury values [40]. There are two key differences in methodology between 
the more recent studies [13;196] and those described in this thesis. (i) Both identified 
associations between COL5A1 rs12722 and ROM in younger participants (±22yrs 
old [13], ±12yrs old [196]), when compared to this study (±32yrs old). (ii) Both 
identified associations between COL5A1 rs12722 and ROM in females only [13;196], 
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whereas this study did not report gender-specific associations. Therefore, one 
possible explanation for these differences is the change in collagen integrity with 
increasing age which results in substantial loss of tendon flexibility and reduced 
ROM [148]. It may therefore be proposed that the difference in type V collagen 
regulation and accumulation, as a result of rs12722, would become more apparent 
with increasing age. Future work is required to explore the reasons for these 
differences. All the studies however agree that variants within the 3’-untranslated 
region of the COL5A1 gene are associated with several measures of ROM.     
 
Joint range of motion is an important risk factor for soft tissue injuries [208] and, as 
will be discussed in the next chapter, is also strongly associated with running 
economy [77]. Therefore, it is important to identify the intrinsic and extrinsic factors 
that may determine range of motion, including the genetic component. This would 
allow for better understanding of the aetiologies of both injury risk and performance. 
As such additional research is required to further identify factors associated with joint 
range of motion. This will be discussed in more detail in the final concluding chapter 
of this thesis (Chapter 10). 
 
As expected, female participants had higher measurements for all measures of 
range of motion than male participants [6;73]. Participant age did not correlate with 
range of motion measurements. This is in contradiction to previously published 
findings [44;90]. A possible explanation for this is that 150 participants (43%) were 
below the age of 25 yrs. Furthermore, in agreement with previous studies [46;193], 
sit-and-reach range of motion measurements were significantly different between 
participants with a self-reported history of flexibility training when compared to those 
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with no history of flexibility training, and both dominant and non-dominant leg straight 
leg raise range of motion measurements were also higher in participants with self-
reported flexibility training. No significant differences in dominant or non-dominant 
total shoulder rotation range of motion measurements were identified between 
participants with a self-reported history of flexibility training when compared to those 
with no history of flexibility training. This may be due to the low number (12.3%, 
n=43) of participants that reported doing upper body flexibility training. In addition, 
the type of sporting or other physical activities performed by these participants may 
also be responsible for a lack of difference between dominant or non-dominant total 
shoulder rotation range of motion measurements. 
 
One limitation to this study was that the state of menstrual cycle at the time of 
recruitment and ROM testing was not recorded for the female participants. 
Furthermore, the number of peri- and/or postmenopausal women was also not 
recorded. The effects of menstrual cycle on ROM, measured by knee joint laxity, 
have previously produced equivocal results [214]. 
 
In conclusion, a novel gene-gene interaction between COL3A1 rs1800255 and 
COL6A1 rs35796750 was significantly associated with sit-and-reach ROM. In 
addition, significant interactions were also identified between COL5A1 rs12722 and 
COL6A1 rs35796750. No independent associations or age-genotype effects were 
determined between COL3A1 rs1800255, COL6A1 rs35796750 or COL12A1 
rs970547 and measures of upper and lower body range of motion. Additional 
variants within these genes, as well as additional genes, should be investigated for 
their contribution to inter-individual differences in joint range of motion. This would 
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add to the current understanding of range of motion as well as other phenotypes 
which are known to be heavily modulated by changes in range of motion, such as 
soft tissue injury [208] and athletic performance [77]. A summary of the results of this 
chapter are presented in table 5.9. 
 
Table 5.9. A continuing summary of the results of the chapters in this thesis. The results of 






































Haplotype A C C nd 
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Haplotype not associated C T 
not 
associated 
Endurance Performance Chapter 6 
EAMC Chapter 7 
Rugby Union Chapter 8 
Table 5. 9. A continuing summary of the results of the chapters in this thesis. The results of chapter 6, and all preceding chapters, are shown. 
Green shading indicates that the allele or genotype is associated with a reduced risk of 
injury, except for ROM where it represents an increased ROM when compared to other 
genotypes. Red shading indicates that the allele or genotype is associated with an increased 
risk of injury. Grey shading indicates no independent association. Prev pub, previously 
published. ♀, associations identified only in females. ACL, anterior cruciate ligament; ROM, 
range of motion; EAMC, exercise-associated muscle cramps; nd, not determined.  
1 independent association previously reported by Posthumus et al. [153]. 
2 independent association previously reported by Posthumus et al. [154], but not independently associated in this 
thesis. 
3 T+A pseudo-haplotype also associated with increased risk of female ACL ruptures when a Polish cohort was 
analysed [137]. 
4 no independent association previously reported by Saunders [170] 
5 independent association previously reported by Mokone et al. [131] and repeated by September et al. [179]. 
6 no independent association previously reported by September et al. [181]. 
7 independent association previously reported by Brown et al. [28;29]. 









It is widely accepted that multiple extrinsic factors, such as  training and nutrition, 
play a role in determining athletic ability [118]. However, studies have also shown 
that athletic ability is also modulated by numerous intrinsic factors. Inter-individual 
genetic variation [26] and joint range of motion (ROM) [45;77] are two intrinsic 
factors associated with athletic ability. Reduced ROM, specifically sit-and-reach 
ROM, has also been associated with improved endurance running economy and 
performance [45;77;82]. As described previously in chapter 2 section 2.3.2 and in 
chapter 5 section 5.1, the COL5A1 rs12722 variant was associated with lower limb 
ROM measurements, including sit-and-reach ROM in numerous studies [29;40;196]. 
Furthermore, the COL5A1 rs12722 TT genotype was associated with improved 
The data presented in this chapter has been published in a condensed form in 
the peer-reviewed articles:  
O'Connell K, Posthumus M, Collins M. COL6A1 gene and Ironman triathlon 
performance. International Journal of Sports Medicine. 2011;32(11):896-901. 
O'Connell K, Posthumus M and Collins M. Collagen gene interactions and 
endurance running performance. South African Journal of Sports Medicine. 
2014;26(1):9-14 
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endurance running performance during the South African Ironman triathlon [151]. 
The association between the COL5A1 rs12722 TT and rs71746744 (-/AGGG) 
AGGG/AGGG genotypes and improved endurance running performance was later 
replicated in a road running event [1;28]. In addition, as described in chapter 2 
section 2.2, these functional COL5A1 variants regulate type V collagen production 
[107], which may lead to increased type V collagen production [107], thereby 
affecting normal collagen fibrillogenesis and altering the mechanical properties of the 
tissue, leading to improved endurance performance [41].  
 
Similarly to types V collagen, types III, VI and XII collagen also regulate 
fibrillogenesis [56;115;129;141;213], and by implication the mechanical properties of 
connective tissue, resulting in inter-individual variations in endurance performance. 
Therefore, like the COL5A1 rs12722 gene variant, it may be proposed that common 
potentially functional variants within the COL3A1, COL6A1 and COL12A1 genes, 
such as the COL3A1 rs1800255, COL6A1 rs35796750 and COL12A1 rs970547 
variants investigated in the previous chapters of this thesis, may also be associated 
with athletic endurance performance. 
 
Furthermore, as mentioned in chapter 2 section 2.6.4, mutations within the COL6A1 
gene cause severe skeletal muscle disorders such as Bethlem myopathy [17;109] 
and Ullrich congenital muscular dystrophy [17;109;140], characterized by muscle 
weakness and connective tissue abnormalities. A murine Col6a1 knockout model, 
that simulates these myopathies, revealed that the average weekly distance run by 
these myopathic Col6a1 -/- mice was consistently less than the wildtype mice [21], 
  Endurance Performance 
133 
 
strengthening the hypothesis that common variants within COL6A1 are associated 
with athletic performance. 
 
Since COL5A1 rs12722 was previously associated with endurance running 
performance, the primary aim of this study was to determine if COL3A1 rs1800255, 
COL6A1 rs35796750 and COL12A1 rs970547 are associated with athletic 
endurance performance in participants of four South African Ironman triathlon 
events.  Specifically, it may be hypothesised that, due to the proposed functional 
effects of these variants, the COL6A1 rs35796750 TT and COL12A1 rs970547 AA 
genotypes, and either COL3A1 rs1800255 genotype, would be associated with 
improved endurance performance. The secondary aim of this study was to 
investigate gene-gene interactions between COL3A1 rs1800255, COL6A1 
rs35796750 and COL12A1 rs970547, and COL5A1 rs12722 where appropriate, and 
endurance performance. Specifically, that the COL5A1 rs12722 T, COL6A1 
rs35796750 T, COL12A1 rs970547 A and either of the COL3A1 rs1800255 alleles 
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A total of six hundred and sixty one male Caucasian participants were recruited from 
four South African Ironman triathlon events, consisting of a 3.8 km sea swim, 180 km 
cycle and 42.2 km run, for this genetic case-control association study. Specifically, 
participants were recruited at the registration of either the 2000 (n=96) and 2001 
(n=294) events held in Gordon’s Bay (approximately 50km outside of Cape Town) or 
the 2006 (n=219) and 2007 (n=52) Port Elizabeth events (approximately 750km east 
of Cape Town). Only male participants were recruited since gender is a known factor 
in determining athletic performance [26;198]. 
 
Race results were obtained from the race organisers and participants were divided 
into three equal tertiles, for the 3.8 km swim, the 180 km bike and the 42.2 km run 
components, based on their finishing times. The fastest triathletes were placed into 
the Fast tertile. Those that finished in the mid-field were placed in the Middle tertile 
and the slowest triathletes were placed into the Slow tertile.  
 
All participants completed informed consent forms (Appendix A.3) and a physical 
activity questionnaire (Appendix A.4). In addition, participants of the Port Elizabeth 
sub-group completed training history questionnaires (Appendix A.4). Training history 
was not documented at the events held in Gordon’s Bay. Approval for the study was 
obtained from the Human Research Ethics Committee of the Faculty of Health 
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Sciences within the University of Cape Town and the race organisers of each event 
(Appendix A.1). 
 
For participants that entered more than one event only data from one race year was 
used. Since training data was obtained during the Port Elizabeth events, the event 
priority for the participants who had completed more than one event was 2006, then 
2007 and finally 2001, which had a more complete and larger dataset than the 2000 
event. 
 
6.2.2 Variant Selection 
 
Three independent sequence variants were investigated in this study. Namely 
COL3A1 rs1800255, COL6A1 rs35796750 and COL12A1 rs970547. The reasons for 
their selection have been stated in chapter 3, section 3.2.2. Furthermore, these 
variants have been independently associated with or interact to (i) modulate the risk 
of musculoskeletal soft tissue injuries (Chapter 3 and 4) and/or (ii) modulate joint 
range of motion (Chapter 5).  
 
6.2.3 DNA Extraction and Genotyping Methods 
 
Approximately 4.5ml of venous blood was collected, at the registration of each event, 
from all participants by venipuncture of a forearm vein into an EDTA vacutainer tube. 
Blood samples were stored at 4˚C until DNA was extracted, as previously described 
[108], with minor modifications [131]. An outline of this methodology was described 
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in chapter 3, section 3.2.3. All analyses were performed at the UCT/MRC Research 
Unit for Exercise Science and Sports Medicine, University of Cape Town, South 
Africa. 
 
Genotyping of COL3A1 rs1800255 and COL6A1 rs35796750 was performed using 
custom designed Fluorescence-based Taqman® polymerase chain reaction (PCR) 
assays (Applied Biosystems, Foster City, CA, USA) as described in chapter 3. 
COL12A1 rs970547 was genotyped using the AluI restrinction fragment length 
polymorphism (RFLP) method as previously described in chapter 5 [154;181]. 
Additional genotyping information is available in appendix B. All genotyping was 
done at the UCT/MRC Research Unit for Exercise Science and Sports Medicine, 
University of Cape Town, Cape Town, South Africa. 
 
Investigators were blinded to the performance results of the participant samples 
while genotyping. Two investigators independently confirmed genotyping. 
Furthermore, a number of positive and negative controls were used to ensure 
genotyping accuracy. No discrepancies were observed. A total of 642/661 (97.1%), 
661/661 (100.0%) and 629/661 (95.2%) participants were genotyped for COL3A1 
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6.2.4 Statistical Analysis  
 
The same statistical tests and haplotype analysis methods were performed as 
described in chapter 3 section 3.2.4. In addition the magnitude of changes in 
performance variables were determined on a scale of effect sizes (ES) where: <0.2 = 
trivial, 0.21-0.6 = small, 0.61-1.2 = moderate, 1.21-2.0 = large, 2.1-4.0 = very large 
and >4.0 = nearly perfect [76]. Bivariate correlations were used to determine the 
relationship between overall race time and participant physiological characteristics. 
Multivariate analyses were performed by forward stepwise regression. Significance 
was accepted when p<0.05. No adjustments were made for multiple testing in this 




6.3.1 Participant Characteristics 
 
The general characteristics of the six hundred and sixty one male participants 
included in this study are presented in table 6.1. Participants from the Gordon’s Bay 
events (2000 and 2001; 34.7 ± 7.9 years, n=390) were significantly younger 
(p<0.001) than those recruited from the Port Elizabeth events (2006 and 2007; 38.2 
± 8.4 years, n=269) (Table 6.1). Significantly less (p=0.002 and p=0.037) South 
African born participants competed in the 2000 (53.2%, n=50) and 2001 (63.6%, 
n=185) events when compared to the 2006 event (73.3%, n=118) (Table 6.1). 
Significantly less (p=0.002) participants residing in South Africa competed in the 
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2001 event (75.7%, n=215) when compared to the 2006 event (86.8%, n=190) 
(Table 6.1).  
 
Participant age (r=0.220, p<0.001), weight (r=0.318, p<0.001) and BMI (r=0.394, 
p<0.001) were all significantly correlated with the overall race time (Figure 6.1). 
Participants height was not significantly correlated with overall race time (r=0.007, 
p=0.865) (Figure 6.1C) In addition mean overall race time was significantly different 
between the race years (p<0.001) (Table 6.1). 
 
No genotype effects were identified between any of the participant characteristics 
and the COL3A1 rs1800255, COL6A1 rs35796750 or COL12A1 rs970547 variants 
(Table 6.2). The COL3A1 rs1800255 (p=0.428), COL6A1 rs35796750 (p=0.178) and 
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Table 6.1. General characteristics for the South African Ironman triathlon participants that 
were recruited at the registration of either the 2000 and 2001 events held in Gordon’s Bay or 
the 2006 and 2007 Port Elizabeth events. 
 
All (661) 2000 event  
(96) 
2001 event  
(294) 
2006 event  
(219) 
2007 event  
(52) p-value 
Age (yrs) 36.1 ± 8.3 
(659) 
34.5 ± 7.2  
(96) 
34.7 ± 8.1  
(294) 
38.2 ± 8.6  
(219) 
38.4 ± 7.1  
(50) 
<0.001 
Height (cm) 180.5 ± 6.6 
(559) 
180.5 ± 7.4  
(85) 
180.5 ± 6.5  
(267) 
180.3 ± 6.4  
(158) 
181.4 ± 6.8  
(49) 0.794 
Weight (kg) 78.6 ± 9.4 
(586) 
77.5 ± 10.2  
(94) 
78.8 ± 8.7  
(274) 
78.2 ± 9.3  
(166) 




) 24.0 ± 2.3 
(555) 
23.7 ± 2.4  
(85) 
24.0 ± 2.1  
(264) 
24.0 ± 2.2  
(157) 
24.7 ± 3.2  
(49) 0.084 
CoB (% SA) 65.0 (388) 53.2 (50) 63.6 (185) 73.3 (118) 68.6 (35) 0.011 
CoR (%SA) 81.2 (468) 85.7 (12) 75.7 (215) 86.8 (190) 86.3 (44) 0.011 
Overall (min) 768.6 ± 96.0 
(661) 
750.3 ± 94.3  
(96) 
755.9 ± 93.9  
(294) 
787.6 ± 94.8  
(219) 
794.5 ± 100.0  
(52) 
<0.001 
Table 6. 1. General characteristics for the South African Ironman triathlon participants that were recruited at the registration of either the 2000 and 2001 events held in 
Gordon’s Bay or the 2006 and 2007 Port Elizabeth events. 
Values are expressed as mean ± standard deviations or as percentages where appropriate. 
Number of participants is indicated in parentheses. Values in bold typeset are significant 
(p<0.05). BMI, body mass index. CoB, country of birth. CoR, country of residence. SA, South 
Africa. Overall, overall race time. 
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Table 6.2. Genotype effects of COL3A1 rs1800255, COL6A1 rs35796750 and COL12A1 
rs970547 on physiological characteristics of participants. 
Polymorphism 
p-values 
Age Height Weight BMI CoB  CoR  
COL3A1 rs1800255 0.852 0.293 0.347 0.402 0.630 0.859 
COL6A1 rs35796750 0.341 0.627 0.948 0.332 0.164 0.681 
COL12A1 rs970547 0.463 0.319 0.903 0.438 0.866 0.829 
Table 6. 2. Genotype effects of COL3A1 rs1800255, COL6A1 rs35796750 and COL12A1 rs970547 on physiological characteristics of participants. 
















Figure 6.1. Correlations between overall race time and participant (A) age, (B) weight, (C) 
height and (D) body mass index (BMI). 
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6.3.2 Participant Training History 
 
Participant self-reported training history data, characterising the 15 weeks prior to 
each event, collected at the 2006 and 2007 Port Elizabeth South African Ironman 
triathlon events is presented in table 5.3. The distance (km/wk) and duration (hrs/wk) 
trained, for the swim, bike and run, and combined, were similar for each COL6A1 
rs35796750 genotype group. Interestingly, although not significant, linear trends 
were observed in the self-reported bike training duration (p=0.059) and run training 
duration (p=0.050) between genotype groups (Table 6.3). Specifically, for bike 
training duration, triathletes with the COL6A1 rs35796750 TT genotype trained for 
the least number of hours per week (7.7 ± 2.6 hrs/wk) followed by those with a TC 
genotype (8.1 ± 2.8 hrs/wk), while triathletes with a CC genotype (9.1 ± 3.6 hrs/wk) 
trained the most hours per week. The magnitude of these changes in genotype 
specific duration cycled were considered “small” (ES=0.24). Similarly, for run training 
duration, triathletes with the COL6A1 rs35796750 TT genotype trained for the least 
number of hours per week (4.5 ± 1.5 hrs/wk) followed by those with a TC genotype 
(4.6 ± 1.7 hrs/wk), while triathletes with a CC genotype (5.9 ± 5.9 hrs/wk) trained the 
most hours per week. The magnitude of these changes in genotype specific duration 
run were also considered “small” (ES=0.16). 
 
Although probably not biologically relevant, the COL3A1 rs1800255 variant was 
significantly (p=0.002) associated with swim training duration (hrs/wk). Specifically, 
participants with a COL3A1 rs1800255 GA genotype (3.4 ± 1.6 hrs/wk) trained 
significantly (p=0.001) more hours than those participants with a COL3A1 rs1800255 
GG (2.8 ± 1.0 hrs/wk) or AA (2.3 ± 0.9 hrs/wk) genotype. The magnitude of these 
changes in genotype specific swimming duration were considered “small” (ES=0.48). 
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The distance (km/wk) and duration (hrs/wk) trained, for the bike, run and combined, 
were not significantly associated with COL3A1 rs1800255 (Table 6.3). Furthermore, 
no significant associations were identified between COL12A1 rs970547 and distance 
or duration trained, for the swim, bike, run or combined (Table 6.3).  
 
 
Table 6.3. Participant self-reported training history for the COL3A1 rs1800255, COL6A1 
rs35796750 and COL12A1 rs970547 genotype groups of the Port Elizabeth sub-group. 
 
All (187) 
COL3A1 rs1800255 Genotype 
p value 
 GG (97) GA (73) AA (17) 
Training (km/wk)      
Swim 6.4 ± 3.0 (185) 6.4 ± 2.8 (95) 6.5 ± 3.2 (73) 6.1 ± 3.1 (17) 0.857 
Bike 224.3 ± 84.9 (170) 218.2 ± 92.9 (85) 232.0 ± 76.5 (69) 223.8 ± 76.2 (16) 0.606 
Run 45.7 ± 18.0 (182) 47.0 ± 20.4 (92) 44.8 ± 13.3 (73) 42.4 ± 21.6 (17) 0.535 
Combined 
a
 236.9 ± 85.8 (155) 230.2 ± 95.6 (76) 245.3 ± 75.2 (63) 235.3 ± 77.3 (16) 0.588 
Training (hrs/wk)      
Swim 3.0 ± 1.3 (184) 2.8 ± 1.0 (97) 3.4 ± 1.6 (70) 2.3 ± 0.9 (17) 0.002 
Bike 8.1 ± 2.9 (171) 8.1 ± 3.2 (89) 8.2 ± 2.5 (66) 7.8 ± 2.9 (16) 0.875 
Run 4.5 ± 1.7 (174) 4.6 ± 1.9 (92) 4.5 ± 1.4 (65) 4.1 ± 1.8 (17) 0.575 
Combined 
a
 15.4 ± 4.8 (162) 15.5 ± 4.8 (85) 15.6 ± 3.7 (61) 14.3 ± 4.5 (16) 0.568 
 
All (271) 
COL6A1 rs35796750 Genotype 
p value 
 TT (76) TC (139) CC (56) 
Training (km/wk)      
Swim 6.4 ± 3.0 (215) 6.6 ± 3.0 (58) 6.4 ± 3.1 (110) 6.3 ± 2.8 (47) 0.820 
Bike 224.7 ± 82.6 (199) 224.0 ± 78.6 (54) 221.1 ± 81.9 (102) 234.1 ± 89.9 (43) 0.689 
Run 47.0 ± 18.1 (212) 46.4 ± 14.0 (58) 45.5 ± 17.1 (108) 51.5 ± 23.9 (46) 0.162 
Combined 
a
 238.0 ± 82.5 (183) 233.8 ± 77.0 (49) 237.5 ± 83.3 (93) 244.1 ± 88.5 (41) 0.840 
Training (hrs/wk)      
Swim 3.1 ± 1.7 (214) 3.2 ± 1.8 (59) 2.9 ± 1.2 (112) 3.3 ± 3.4 (43) 0.340 
Bike 9.0 ± 12.5 (198) 7.7 ± 2.6 (55) 8.1 ± 2.8 (103) 13.2 ± 27.2 (40) 0.059 
Run 4.9 ± 3.1 (201) 4.5 ± 1.5 (54) 4.6 ± 1.7 (106) 5.9 ± 5.9 (41) 0.050 
Combined 
a
 15.6 ± 4.4 (188) 14.9 ± 3.9 (53) 15.5 ± 4.3 (99) 16.8 ± 5.2 (36) 0.148 
 
All (207) 
COL12A1 rs970547 Genotype 
p value 
 AA (120) AG (82) GG (5) 
Training (km/wk)      
Swim 6.4 ± 3.0 (207) 6.3 ± 2.8 (120) 6.7 ± 3.2 (82) 5.6 ± 1.5 (5) 0.531 
Bike 222.7 ± 83.3 (190) 216.9 ± 83.6 (110) 231.6 ± 82.8 (75) 218.7 ± 90.4 (5) 0.499 
Run 46.3 ± 17.8 (203) 44.9 ± 16.6 (117) 48.5 ± 19.6 (81) 44.0 ± 9.6 (5) 0.371 
Combined 
a
 236.5 ± 83.6 (174) 229.8 ± 82.6 (97) 246.1 ± 84.8 (72) 229.5 ± 89.9 (5) 0.449 
Training (hrs/wk)      
Swim 3.0 ± 1.5 (206) 3.0 ± 1.7 (119) 3.1 ± 1.4 (82) 2.3 ± 0.7 (5) 0.513 
Bike 8.9 ± 12.8 (190) 9.5 ± 16.6 (110) 8.2 ± 2.9 (75) 7.6 ± 2.1 (5) 0.752 
Run 4.9 ± 3.1 (194) 4.9 ± 3.7 (113) 4.8 ± 2.0 (76) 4.3 ± 0.4 (5) 0.896 
Combined 
a
 15.5 ± 4.4 (180) 15.3 ± 4.3 (103) 15.8 ± 4.7 (72) 14.2 ± 2.3 (5) 0.607 
Table 6. 3. Participant self-reported training history for the COL3A1 rs1800255, COL6A1 rs35796750 and COL12A1 rs970547 genotype groups of the Port Elizabeth sub-
group. 
Values are expressed as mean ± standard deviations. Number of participants is indicated in 
parentheses. Values in bold typeset are significant (p<0.05). 
a Combined = Swim + Bike + Run 




6.3.4 Collagen Genes and Performance in the South African Ironman triathlon 
 
The finishing times for the swim, bike and run components of the Ironman triathlon 
were independently compared between the COL3A1 rs1800255, COL6A1 
rs35796750 and COL12A1 rs970547 genotype groups. Overall finishing time was 
not analysed since any identified associations would merely be due to component 
specific associations. Significant COL6A1 rs35796750 genotype differences were 
observed in the times to complete the bike (p=0.033) component when all 
participants were analysed (Table 6.4). Specifically, participants with the COL6A1 
rs35796750 TT genotype completed the bike component significantly (p=0.014) 
faster than those with a CC or TC genotype. The magnitude of the change in bike 
performance between triathletes with the COL6A1 rs35796750 TT genotype 
compared to those with a TC or CC genotype was considered “small” (ES=0.21). No 
significant genotype effects were identified for the swim or run finishing times.  The 
COL3A1 rs1800255 and COL12A1 rs970547 variants were not significantly 
associated with time to complete any of the individual components (3.8 km swim, 
180 km bike or  42.2 km run) of the 226 km Ironman triathlon (Table 6.4). 
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Table 6.4. Finishing times for the COL3A1 rs1800255, COL6A1 rs35796750 and COL12A1 




COL3A1 rs1800255 Genotype 
p value 
 GG (333) GA (265) AA (44) 
3.8 km Swim (min) 77.2 ± 17.4 (629) 77.4 ± 17.3 (326) 76.6 ± 17.6 (259) 79.7 ± 17.2 (44) 0.535 
180 km Bike (min) 393.7 ± 42.0 (615) 394.0 ± 42.7 (317) 392.2 ± 41.6 (254) 399.4 ± 39.9 (44) 0.565 
42.2 km Run (min) 288.4 ± 49.1 (620) 285.9 ± 50.2 (324) 289.9 ± 47.4 (253) 297.8 ± 51.1 (43) 0.264 
 
All (661) 
COL6A1 rs35796750 Genotype 
p value 
 TT (196) TC (344) CC (121) 
3.8 km Swim (min) 77.9 ± 17.4 (644) 76.0 ± 16.4 (192) 78.5 ± 17.7 (337) 79.1 ± 18.0 (115) 0.191 
180 km Bike (min) 394.6 ± 42.1 (630) 388.3 ± 40.6 (186) 398.3 ± 42.4 (331) 394.4 ± 42.8 (113) 0.033 
42.2 km Run (min) 288.2 ± 50.1 (640) 284.9 ± 51.1 (193) 291.0 ± 49.7 (331) 285.8 ± 49.4 (116) 0.348 
 
All (629) 
COL12A1 rs970547 Genotype 
p value 
 AA (344) AG (255) GG (30) 
3.8 km Swim (min) 78.5 ± 17.6 (614) 78.8 ± 17.1 (334) 78.2 ± 17.9 (251) 76.9 ± 20.4 (29) 0.800 
180 km Bike (min) 395.2 ± 41.5 (600) 393.8 ± 39.8 (330) 397.6 ± 43.2 (243) 391.6 ± 47.3 (27) 0.504 
42.2 km Run (min) 290.1 ± 49.7 (609) 289.0 ± 50.7 (331) 290.8 ± 49.3 (249) 297.0 ± 40.7 (29) 0.681 
Table 6. 4. Finishing times for the COL3A1 rs1800255, COL6A1 rs35796750 and COL12A1 rs970547 genotype groups in the 3.8km swim, 180km bike and 42.2km run 
components. 
Values are expressed as mean ± standard deviations. Number of participants is indicated in 
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Participants were grouped into Fast, Middle and Slow performance tertiles of equal 
number. Significant (p=0.009) differences in COL6A1 rs35796750 genotype 
frequency distribution were identified between the bike component tertiles (Table 
6.6). When the COL6A1 rs35796750 TT genotype was compared to the C allele 
(TC+CC genotypes), a significant linear trend (p=0.008) was identified in the bike 
performance tertiles. Specifically, the COL6A1 rs35796750 TT genotype had the 
highest representation in the Fast tertile (TT genotype 35.7%), followed by the 
Middle tertile (TT genotype 29.0%) and the Slow tertile (TT genotype 23.8%) (Figure 
6.2). No significant linear trends were identified between COL6A1 rs35796750 and 
the swim (p=0.463) or run (p=0.741) performance tertiles (Table 6.6).  
 
No significant differences were identified for COL3A1 rs1800255 (Table 6.5) or 
COL12A1 rs970547 (Table 6.7) between the tertiles for time to complete any of the 
individual components of the Ironman triathlon. 
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Table 6.5. Performance tertiles for the COL3A1 rs1800255 genotype groups in the 3.8km 
swim, 180km bike and 42.2km run components of the triathlon. 
 COL3A1 rs1800255 Genotype 
p value 
3.8 km Swim GG (333) GA (265) AA (44) 
Fast 52.7 (119) 40.7 (92) 6.6 (15) 
0.803 Middle 50.7 (104) 43.4 (89) 5.9 (12) 
Slow 52.0 (103) 39.4 (78) 8.6 (17) 
 COL3A1 rs1800255 Genotype 
 
180 km Bike GG (333) GA (265) AA (44) 
Fast 53.0 (115) 41.9 (91) 5.1 (11) 
0.506 Middle 48.4 (103) 42.7 (91) 8.9 (19) 
Slow 53.5 (99) 38.9 (72) 7.6 (14) 
 COL3A1 rs1800255 Genotype 
 
42.2 km Run GG (333) GA (265) AA (44) 
Fast 56.4 (119) 38.4 (104) 5.2 (11) 
0.565 Middle 50.0 (104) 41.8 (87) 8.2 (17) 
Slow 50.3 (101) 42.3 (85) 7.5 (15) 
Table 6. 5. Performance tertiles for the COL3A1 rs1800255 genotype groups in the 3.8km swim, 180km bike and 42.2km run components of the triathlon. 
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Table 6.6. Performance tertiles for the COL6A1 rs35796750 genotype groups in the 3.8km 
swim, 180km bike and 42.2km run components of the triathlon. 
 COL6A1 rs35796750 Genotype 
p value 
3.8 km Swim TT (196) TC (344) CC (121) 
Fast 32.0 (73) 51.8 (118) 16.2 (37) 
0.463 Middle 30.0 (63) 49.1 (103) 21.0 (44) 
Slow 27.2 (56) 56.3 (116) 16.5 (34) 
 COL6A1 rs35796750 Genotype 
 
180 km Bike TT (196) TC (344) CC (121) 
Fast 35.7 (75) 42.9 (90)  21.4 (450 
0.009 Middle 28.6 (60) 57.1 (120) 14.3 (30) 
Slow 24.3 (51) 58.1 (122) 17.6 (37) 
 COL6A1 rs35796750 Genotype 
 
42.2 km Run TT (196) TC (344) CC (121) 
Fast 29.7 (66) 50.0 (111) 20.3 (45) 
0.741 Middle 31.3 (67) 50.5 (108) 18.2 (39) 
Slow 29.4 (60) 54.9 (112) 15.7 (32) 
Table 6. 6. Performance tertiles for the COL6A1 rs35796750 genotype groups in the 3.8km swim, 180km bike and 42.2km run components of the triathlon. 
Values are expressed as percentages. Number of participants is indicated in parentheses. 
Values in bold typeset are significant (p<0.05). 
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Table 6.7. Performance tertiles for the COL12A1 rs970547 genotype groups in the 3.8km 
swim, 180km bike and 42.2km run components of the triathlon. 
 COL12A1 rs970547 Genotype 
p value 
3.8 km Swim AA (344) AG (255) GG (30) 
Fast 54.8 (115) 41.0 (86) 4.2 (9) 
0.704 Middle 50.8 (102) 44.2 (89) 5.0 (10) 
Slow 57.6 (117) 37.4 (76) 5.0 (10) 
 COL12A1 rs970547 Genotype 
 
180 km Bike AA (344) AG (255) GG (30) 
Fast 55.9 (114) 39.2 (80) 4.9 (10) 
0.796 Middle 56.7 (118) 39.9 (83) 3.4 (7) 
Slow 52.4 (98) 42.3 (80) 5.3 (10) 
 COL12A1 rs970547 Genotype 
 
42.2 km Run AA (344) AG (255) GG (30) 
Fast 56.4 (114) 40.1 (81) 3.5 (7) 
0.461 Middle 56.5 (117) 39.1 (81) 4.4 (9) 
Slow 50.0 (100) 43.5 (87) 6.5 (13) 
Table 6. 7.Performance tertiles for the COL3A1 rs1800255 and COL12A1 rs970547 genotype groups in the 3.8km swim, 180km bike and 42.2km run components of the 
triathlon. 
Values are expressed as percentages. Number of participants is indicated in parentheses. 
  











Figure 6. 2. Genotype frequency distributions (TT vs. TC+CC) for the COL6A1 rs35796750 T/C variant in the Fast, Middle and 







Figure 6.2. Genotype frequency distributions (TT vs. TC+CC) for the COL6A1 rs35796750 
T/C variant in the Fast, Middle and Slow tertiles of the bike component of the triathlon. 
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6.3.4 Gene-Gene Interactions and Performance in the South African Ironman 
triathlon 
 
Inferred pseudo-haplotypes between COL3A1 rs1800255 G/A, COL6A1 rs35796750 
C/T and COL12A1 rs970547 A/G were constructed for the swim, cycle and run times 
(Figure 6.3). When the swim component of the triathlon was analysed, the A+C+A 
inferred pseudo-haplotype was significantly (p=0.047) under-represented in the Fast 
swim tertile (5.4%, n=14) when compared to the Slow swim tertile (12.6%, n=29) 
(Figure 6.3A). No significant gene-gene interactions were identified when the cycling 
component of the triathlon was identified (Figure 6.3B). Analysis of the run 
component showed that the G+C+A inferred pseudo-haplotype was significantly 
(p=0.049) over-represented in the Fast run tertile (26.1%, n=65) when compared to 
the Slow run tertile (20.1%, n=46) (Figure 6.3C).  
  



























Figure 6. 3. Frequency distributions of inferred pseudo-haplotypes constructed from COL3A1 rs1800255, COL6A1 rs35796750 






Figure 6.3. Frequency distributions of inferred pseudo-haplotypes constructed from COL3A1 
rs1800255, COL6A1 rs35796750 and COL12A1 rs970547 between the Fast, Middle and 
Slow tertiles in the time to complete (A) the swim component of the triathlon, (B) the cycling 
component of the triathlon and (C) the run component of the triathlon. Number of 
participants is indicated above each column.  
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Since COL5A1 rs12722 was previously associated with endurance running 
performance in this cohort [151], inferred pseudo-haplotypes were constructed from 
COL3A1 rs1800255 G/A, COL5A1 rs12722 C/T, COL6A1 rs35796750 C/T and 
COL12A1 rs970547 A/G for the three disciplines of the Ironman triathlon (Figure 
6.4). When the swim component of the triathlon was analysed, the G+C+T+A 
inferred pseudo-haplotype was significantly (p=0.020) over-represented in the Fast 
swim tertile (15.1%, n=39) when compared to the Slow swim tertile (8.2%, n=19), 
while the A+T+C+A inferred pseudo-haplotype was significantly (p=0.028) under-
represented in the Fast swim tertile (2.5%, n=6) when compared to the Slow swim 
tertile (8.8%, n=20) (Figure 6.4A). No significant gene-gene interactions were 
identified when the cycling component of the triathlon was identified (Figure 6.4B). 
Analysis of the run component showed that the G+T+C+A inferred pseudo-haplotype 
was significantly (p=0.043 and p=0.025) over-represented in both the Fast (15.7%, 
n=39) and Middle (17.6%, n=43) run tertiles when compared to the Slow run tertile 
(11.5%, n=27) respectively (Figure 6.4C). 
 
  






















Figure 6. 4. Frequency distributions of inferred pseudo-haplotypes constructed from COL3A1 rs1800255, 




Figure 6.4. Frequency distributions of inferred pseudo-haplotypes constructed from COL3A1 
rs1800255, COL5A1 rs12722, COL6A1 rs35796750 and COL12A1 rs970547 between the Fast, 
Middle and Slow tertiles in the time to complete (A) the swim component of the triathlon, (B) the 
cycling component of the triathlon and (C) the run component of the triathlon. Number of participants 
is indicated above each column. 
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Closer inspection of the inferred pseudo-haplotypes associated with the swim 
component of the triathlon show that the COL12A1 variant does not contribute to the 
interaction. Therefore, inferred pseudo-haplotypes were constructed from COL3A1 
rs1800255, COL5A1 rs12722 and COL6A1 rs35796750 and investigated for 
associations with the swim component. As expected, the G+C+T inferred pseudo-
haplotype was significantly (p=0.038 and p=0.027) over-represented in both the Fast 
(19.2%, n=49) and Middle (17.8%, n=44) tertiles when compared to the Slow tertile 
(12.5%, n=29). 
 
6.5.5 Multivariate Analysis for the Determination of Performance 
 
A multivariate analysis was used to describe the relationship between participant 
characteristics and variant genotypes and the swim, bike and run components of the 
triathlon. Weight, and not BMI, was included in these analyses since height was not 
significantly correlated with overall race time. Therefore age, weight, race year and 
the independently associated variants were included in models to determine 
performance for the swim, bike and run components of the triathlon (Table 6.8). The 
variables race year and age predicted 37% of the variance (p<0.001, standard error 
of the estimate (SEE)=13.3) in the time to complete the swim component. Age, 
weight and the COL6A1 rs35796750 genotype (TT vs. TC+CC) predicted 8% of the 
variance (p<0.001, SEE=39.7) in the bike component. For the run component, only 
weight predicted 15% of the variance (p<0.001, SEE=45.8). 
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Table 6.8. Multivariate analysis for time to complete the swim, bike and run components of 
the South African Ironman triathlon. 
Multivariate analysis β B p value 
3.8km Swim time (min) 
   
  Race Year 0.487 3.03 <0.001 
  Age (yrs) 0.276 0.57 <0.001 
  Weight (kg) 0.056 0.10 0.096 
180km Bike time (min) 
   
  Race Year 0.040 0.614 0.337 
  Age (yrs) 0.185 0.947 <0.001 
  Weight (kg) 0.160 0.708 <0.001 
 COL6A1 rs35796750 Genotype (TT vs TC+CC) -0.093 -8.352 0.024 
42.2km Run time (min) 
   
  Race Year 0.045 0.83 0.259 
  Age (yrs) 0.067 0.42 0.095 
  Weight (kg) 0.376 2.01 <0.001 
  COL5A1 rs12722 Genotype (TT vs TC+CC) 0.054 5.58 0.171 
Table 6. 8.Multivariate analysis for time to complete the swim, bike and run components of the South African Ironman triathlon. 
For the 3.8km Swim time: R=0.611, adjusted R2=0.370, SEE=13.3, p<0.0001. For the 
180km Bike time: R=0.285, adjusted R2=0.075, SEE=39.7, p<0.0001. For the 42.2km Run 
time: R=0.398, adjusted R2=0.152, SEE=45.8, p<0.0001. p values in bold typeset are 
significant (p<0.05). 
  





The first novel main finding of this study was the identification of a variant within the 
COL6A1 gene as a performance marker for the bike component of the South African 
Ironman triathlon. The COL6A1 rs35796750 C/T SNP was associated with 
performance during the 180km bike component of the 226km South African Ironman 
triathlon. In this study male triathletes with a TT genotype completed the bike of the 
triathlon significantly faster than those triathletes with a TC or CC genotype. In 
addition, a significant linear trend was found in the COL6A1 rs35796750 TT 
genotype frequencies of the bike performance tertiles. Specifically the TT genotype 
was over-represented in the fastest bike performance tertile. Furthermore, the 
COL6A1 rs35796750 genotype (TT vs TC+CC), age and weight contributed to 8% of 
the variance in the time to complete the bike of the South African Ironman triathlon. 
These results are in agreement with the hypothesis that the TT genotype would be 
beneficial in athletic performance, since the C allele is associated with negative 
outcomes in other multifactorial conditions. No significant independent associations 
were identified between this variant and time to complete the 3.8 km swim or 42.2 
km run components of the events. 
 
Interestingly, although not significant, there was a trend for triathletes with the 
COL6A1 rs35796750 TT genotype to train for fewer hours when compared to those 
with TC or CC genotypes. Despite this, it may be concluded that this variant did not 
have a training effect since the TT genotype was associated with increased cycling 
performance. Further research is however required to test this hypothesis. 
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The second novel main finding of this study is that inferred pseudo-haplotypes 
constructed from the COL3A1 rs1800255 (G/A), COL6A1 rs35796750 (C/T) and 
COL12A1 rs970547 (A/G) variants interact to modulate endurance running 
performance in four South African Ironman triathlons. The G+C+A inferred pseudo-
haplotype, constructed from COL3A1 rs1800255, COL6A1 rs35796750 and 
COL12A1 rs970547, was over-represented in the Fast tertile when compared to the 
Slow tertile for the running component of the South African Ironman triathlon. 
Furthermore, since the COL5A1 rs12722 variant was previously associated with 
endurance running [151], additional gene-gene interactions between COL3A1 
rs1800255, COL5A1 rs12722, COL6A1 rs35796750 and COL12A1 rs970547 and 
endurance performance were investigated. Again, participants with the major 
G+T+C+A pseudo-haplotype were significantly over-represented in the Fast and 
Middle tertiles when compared to those in the Slow tertile when the running 
component of the triathlon was analysed. These findings implicate the COL3A1, 
COL6A1 and COL12A1 genes as novel potential markers for endurance running 
performance. Additional studies should investigate these genes in true endurance 
running events, such as marathons, in order to confirm the findings of this study. 
Furthermore, since no single variant independent associations were identified for 
COL3A1 rs1800255, COL6A1 rs35796750 and COL12A1 rs970547 and endurance 
running performance, these findings highlight the importance of gene-gene 
interactions when investigating multi-genic complex phenotypes such as endurance 
performance. 
 
Interestingly, gene-gene interactions were identified in this study, between COL3A1 
rs1800255, COL5A1 rs12722 and COL6A1 rs35796750, for time to complete the 
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swim component of the triathlon. A significant association was also identified 
between COL3A1 rs1800255 and swimming training duration only. Specifically, 
participants with a GA genotype self-reported significantly more hours per week of 
swimming training, in the 15 weeks prior to the event, than their GG and AA 
counterparts. Mechanical loading is known to alter collagen gene expression 
however [92;93], since swimming is a non-load-bearing activity the reasons for these 
associations remain unknown and further research is needed to explain a possible 
mechanism.  
 
Athletic performance is a multifactorial and polygenic phenotype [26;198]. Although 
this will be discussed in more detail in the final concluding chapter of this thesis 
(Chapter 10), it is important to note that a number of previous studies have 
associated genetic variants with athletic performance, specifically in the South 
African Ironman triathlon [43;151;172]. It must be stated that numerous extrinsic 
factors contribute to athletic performance as well [118]. It is therefore important that 
there were no differences in total distance (km/wk) or duration (hrs/wk) trained, or 
differences in distance (km/wk) or duration (hrs/wk) trained for each component of 
the triathlon, between the COL6A1 rs35796750 or COL12A1 rs970547 genotype 
groups among the participants with complete self-reported training history data. A 
significant association was identified between COL3A1 rs1800255 and swimming 
training duration only. Specifically, participants with a GA genotype self-reported 
significantly more hours per week of swimming training, in the 15 weeks prior to the 
event, than their GG and AA counterparts. Mechanical loading is known to alter 
collagen gene expression however [92;93], since swimming is a non-load-bearing 
activity the reasons for this association remain unknown. No addition associations 
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were identified between COL3A1 rs1800255 and self-reported training duration or 
training distance.  
 
The lack of self-reported training history for the participants recruited during the 2000 
and 2001 South African Ironman triathlon events is a limitation to this study. Training 
data for the 2000 and 2001 events would have allowed for the addition of self-
reported training history to the multivariate analysis for times to complete each 
component of the triathlon. The inclusion of training history as well as other intrinsic 
and extrinsic factors may help explain more of the variance in each component than 
that explained by the current models. A second limitation to this study was that more 
South African born participants participated in the 2006 and 2007 events when 
compared to the 2000 and 2001 events. Therefore, although there may be effects 
due to population stratification, all participants were of self-reported Caucasian 
descent and there were no differences in weight, height or BMI between the four 
events. Furthermore, there were no genotype effects on country of birth. Finally, this 
study only investigated male triathletes. Gender is a known factor in the aetiology of 
athletic performance [26], and therefore additional studies are required to investigate 
these gene variants in female cohorts to determine if the associations identified in 
this study may be gender-specific, as shown when some of these variants were 
investigated in other exercise-associated phenotypes [137;153;154] (Chapter 3). 
 
In conclusion this study identified, for the first time, an association between 
endurance cycling performance in the South African Ironman triathlon and a variant 
within the COL6A1 gene. Specifically the COL6A1 rs35796750 TT genotype is 
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associated with increased performance during the bike of the South African Ironman 
triathlon. In addition, a second novel finding of this study is that the COL3A1 
rs1800255, COL6A1 rs35796750 and COL12A1 rs970547 variants interact to 
modulate endurance running performance in four South African Ironman triathlons. 
Furthermore, these variants also interact with COL5A1 rs12722 to modulate 
endurance running performance. These findings implicate collagen gene variants as 
novel potential markers of endurance running and cycling performance. Finally, a 
summary of the results of this chapter can be found in table 6.8. 
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Table 6.8. A continuing summary of the results of the chapters in this thesis. The results of 

















Genotype not associated CC ♀ prev pub1 not associated 
AA ♀ 
prev pub2 






prev pub5 not associated 
not associated 
prev pub6 
Haplotype A C C nd 
ROM 
Genotype not associated CC prev pub7 not associated not associated 





Genotype not associated not associated not associated not associated 





Genotype not associated not associated TT not associated 





Genotype not associated TT prev pub8 not associated not associated 
Haplotype G T C A 
EAMC Chapter 7 
Rugby Union Chapter 8 
Table 6. 9.A continuing summary of the results of chapters in this thesis. The results of chapter 5, and all preceding chapters, are shown.  
Green shading indicates that the allele or genotype is associated with a reduced risk of injury, except for ROM 
and endurance performance where it represents an increased ROM or endurance performance. Red shading 
indicates that the allele or genotype is associated with an increased risk of injury. Grey shading indicates no 
independent association. Prev pub, previously published. ♀, associations identified only in females. ACL, anterior 
cruciate ligament; ROM, range of motion; EAMC, exercise-associated muscle cramps; nd, not determined.  
1 independent association previously reported by Posthumus et al. [153]. 
2 independent association previously reported by Posthumus et al. [154], but not independently associated in this 
thesis. 
3 T+A pseudo-haplotype also associated with increased risk of female ACL ruptures when a Polish cohort was 
analysed [137]. 
4 no independent association previously reported by Saunders [170] 
5 independent association previously reported by Mokone et al. [131] and repeated by September et al. [179]. 
6 no independent association previously reported by September et al. [181] 
7 independent association previously reported by Brown et al. [28;29]. 
8 independent association previously reported by Posthumus et al. [151]  and repeated by Abrahams et al. [1]. 
9 only male participants were included in this study. 













Exercise Associated Muscle Cramping (EAMC) is defined as “painful, spasmodic 
and involuntary contraction of skeletal muscle that occurs during or immediately after 
exercise” [176].  It is a common medical condition among participants of endurance 
events such as ultra-marathons and triathlons. EAMC has a reported lifetime 
prevalence of 26%, 30-50% and 67% in physical education students [134], marathon 
runners [125] and triathletes [88], respectively. Despite its high prevalence the 
aetiology of EAMC remains unknown [174]. A number of hypotheses to explain the 
primary factors contributing to EAMC have however been proposed. These include 
the electrolyte depletion, dehydration and the more recent altered neuromuscular 
control hypotheses [174].  
 
As mentioned in chapter 2 section 2.5.4, the altered neuromuscular control 
hypothesis implicates the following primary factors in the development of EAMC i) an 
increased exercise intensity or duration [174;175;183], ii) the development of muscle 
The data presented in this chapter has been published in a condensed form in 
the peer-reviewed article: O'Connell K, Posthumus M, Schwellnus MP, Collins M. 
Collagen genes and exercise-associated muscle cramping. Clinical Journal of Sport 
Medicine. 2013;23(1):64-9. 
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fatigue [174], iii) contraction of the muscle in a shortened position [174], and iv) 
possible tissue damage [174]. Pre-race serum creatine kinase activity showed a 
tendency to be higher in participants who developed EAMC during the 2009 56 km 
Two Oceans ultra-marathon when compared to 29 non-crampers [175]. Furthermore, 
cross-sectional studies have reported an association between a positive family 
history of EAMC and increased risk of EAMC [125;183]. A survey study showed an 
association between a family history of EAMC and a past history of EAMC in 1300 
marathon runners [125]. This association was later confirmed in a case-control study 
of 433 Ironman triathletes where the frequency of a positive family history of EAMC 
was significantly more common in triathletes with a past history of EAMC when 
compared to those with no history of EAMC [183]. However, in two subsequent 
prospective cohort studies, a positive family history of EAMC was not associated 
with the risk of developing EAMC during an event in Ironman triathletes [178] and 
distance runners [175]. 
 
As established in chapter 2 and shown in previous experimental chapters within this 
thesis there is a genetic predisposition, specifically with collagen genes, to 
musculoskeletal soft tissue injuries (Chapters 3 and 4) [131;153;179] and athletic 
endurance performance (Chapter 6) [1;28;138;151]. Therefore, since muscle 
damage, increased exercise intensity and duration, and a familial predisposition may 
play a role in the aetiology of EAMC, it may be proposed that variants within collagen 
genes that code for components of the musculoskeletal system increase 
susceptibility to EAMC. 
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Mutations within the COL3A1, COL5A1 and COL12A1 genes are known to cause 
Ehlers-Danlos Syndrome (EDS) [33;217;218]. Although not a common symptom, 
muscle cramps have been reported as a clinical feature of EDS [168]. Bethlem 
myopathy [17;109;140] and Ullrich congenital muscular dystrophy [17;109;140] are 
caused by mutations within the COL6A1 gene, highlighting its importance in muscle 
function. Since mutations in the COL5A1, COL3A1, COL6A1 and COL12A1 genes 
are known to result in connective tissue pathologies, it may be proposed that 
variants within these genes may modulate the risk of developing EAMC.  
 
The aim of this study was therefore to determine if an association exists between 
past history of EAMC and COL3A1 rs1800255 (G/A), COL5A1 rs12722 (C/T), 
COL6A1 rs35796750 (C/T) and COL12A1 rs970547 (A/G) in participants of the 
South African Ironman triathlon and the Two Oceans ultra-marathon. Specifically, it 
was hypothesised that the COL5A1 rs12722 TT, COL6A1 rs35796750 TT and 
COL12A1 rs970547 AA genotypes, and either COL3A1 rs1800255 genotype, would 
be associated with increased risk of EAMC. Since the collagen genes might interact 
with one another to modulate the risk of musculoskeletal soft tissue injuries 
(Chapters 3 and 4) [71], the secondary aim was to investigate gene-gene 
interactions between the COL3A1 rs1800255, COL5A1 rs12722, COL6A1 
rs35796750 and/or COL12A1 rs970547 variants and risk of EAMC. It was also 
hypothesised that the COL5A1 rs12722 T, COL6A1 rs35796750 T, COL12A1 
rs970547 A and either of the COL3A1 rs1800255 alleles may be implicated in gene-
gene interactions associated with increased risk of EAMC. 
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Four hundred and forty-one male Caucasian participants were recruited at the 
registration of either the 2006 and 2007 226 km South African Ironman triathlon 
(n=271) or the 2009 and 2011 56 km Two Oceans ultra-marathon (n=170) for this 
genetic case-control association study (Figure 7.1). These events were chosen due 
to the high reported lifetime prevalence of EAMC in marathon runners and triathletes 
as described above. In addition only males were included in this study because 
previous studies have reported that males are more likely to experience EAMC 
[174;177]. Furthermore, as stated previously, athletic performance is associated with 
EAMC [174;177] and is also gender specific [26;198]. One hundred and eighteen 
participants reported a history of EAMC within the last 12 months prior to the event 
(EAMC group), while 150 reported no history of a previous (lifelong) EAMC (NON 
group). The participants included in this study therefore are not representative of all 
ultra-marathon runners or triathletes, but rather a selectively defined subset from 
these sports. Training data were only obtained during the Ironman events. 
Participants included in this study did not participate in both the Ironman and ultra-
marathon events. Only the 2006 or 2009 data was analysed for those participants 
that were recruited at both Ironman or Two-Oceans events, respectively. This 
preference was due to the completeness of the respective data sets, as well as the 
specific data collected at each event.  
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All participants completed written informed consent forms (Appendix A.3) and a 
physical activity, medical history and cramping history questionnaire (Appendix A.4). 
Specifically, EAMC was defined as “painful, spontaneous, sustained spasm of a 
muscle during or immediately (within 6 hours) after exercise (in training or 
competition).” Approval for the study was obtained from the Human Research Ethics 
Committee of the University of Cape Town (Appendix A.1) and the organisers of the 














Figure 7. 1. Flow diagram showing the total number of participants recruited at the South African Ironman triathlon and Two 




Figure 7.1. Flow diagram showing the total number of participants recruited at the South 
African Ironman triathlon and Two Oceans ultra-marathon events. In addition, the 
breakdown of included participants into those that reported a history of EAMC within 12 
months prior to the event (EAMC group) and those with no self-reported history of previous 
(lifelong) EAMC (NON group), as well as the number of participants in each sub-group, are 
shown. EAMC, Exercise Associated Muscle Cramps. SA, South African. TO, Two Oceans. 
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7.2.2 Variant Selection 
 
Four independent sequence variants were investigated in this study. Namely 
COL3A1 rs1800255, COL5A1 rs12722, COL6A1 rs35796750 and COL12A1 
rs970547. The reasons for their selection have been stated in chapter 3, section 
3.2.2. Furthermore, these variants have been independently associated with, or 
interact to modulate, the risk of musculoskeletal soft tissue injuries (Chapter 3 and 4) 
and/or endurance performance (Chapter 6). 
 
7.2.3 DNA Extraction and Genotyping Methods 
 
Approximately 4.5ml of venous blood was collected from all participants by 
venipuncture of a forearm vein into an EDTA vacutainer tube. These samples were 
stored at 4˚C until DNA extraction, as previously described [108], with minor 
modifications [131]. An outline of this methodology was described in chapter 3, 
section 3.2.3. 
 
All participants were genotyped for COL5A1 rs12722, COL3A1 rs1800255, COL6A1 
rs35796750 and COL12A1 rs970547. Genotyping of COL3A1 rs1800255 and 
COL6A1 rs35796750 was performed using custom designed Fluorescence-based 
Taqman® polymerase chain reaction (PCR) assays (Applied Biosystems, Foster 
City, CA, USA) as described in chapter 3. Genotyping of COL5A1 rs12722 and 
COL12A1 rs970547 was performed using PCR and restriction fragment length 
polymorphism analysis as previously described (Appendix B) [29;131;153;154] 
(Chapter 5). All genotyping was done at the UCT/MRC Research Unit for Exercise 
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Science and Sports Medicine, University of Cape Town, Cape Town, South Africa. 
All genotyping was done at the UCT/MRC Research Unit for Exercise Science and 
Sports Medicine, University of Cape Town, Cape Town, South Africa. 
 
Investigators were blinded to the phenotypes of the participant samples while 
genotyping. Furthermore, a number of positive and negative controls were used to 
ensure genotyping accuracy. No discrepancies were observed. Of the 268 included 
participants, genotypes for COL5A1 rs12722, COL3A1 rs1800255, COL6A1 
rs35796750 and COL12A1 rs970547 were obtained for 264 (98.5%), 228 (85.1%), 
209 (78.0%) and 225 (84.0%) participants respectively. A number of positive and 
negative controls were used to ensure quality and accuracy of genotyping. No 
discrepancies were observed.  
 
7.2.4 Statistical Analysis  
 
The same statistical tests and haplotype analysis methods were performed as 
described in chapter 3 section 3.2.4. Age, weight, height, overall performance (where 
appropriate) and participant genotype data were used in a multivariate logistic 
regression analysis to determine their contribution to risk of past history of EAMC. 
Significance was accepted when p<0.05. No adjustments were made for multiple 
testing in this study for the same reasons as outlined in chapter 3 section 3.2.4. 
  





7.3.1 Participant characteristics 
 
Descriptive participant characteristics of the EAMC and NON groups are presented 
in Table 7.1. Age, height, weight, body mass index (BMI) and country of birth (% 
South African born) were similar between the EAMC and NON groups. Overall 
participant performance in the 2006 and 2007 Ironman triathlon and 2009 and 2011 
Two Oceans ultra-marathon sub-groups are also presented in Table 7.1. The EAMC 
group (766.8 ± 94.0, n=95) was significantly faster (min) overall than the NON group 
(799.1 ± 95.8, n=116) in the 2006 and 2007 Ironman triathlon sub-group (p=0.015). 
There was no significant difference between the EAMC (295.0 ± 102.9, n=46) and 
NON (299.2 ± 106.8, n=25) groups for overall finishing time (min) in the 2009 and 
2011 Two Oceans ultra-marathon sub-group (p=0.894). The distance (km/week) and 
duration (hrs/week) of training 15 weeks prior to the triathlon were not significantly 
different between the EAMC and NON groups (Table 7.2). Training data was not 
obtained from participants recruited at the 2009 and 2011 Two Oceans ultra-
marathon events. There were no significant genotype effects on participant age, 
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Table 7.1. General characteristics and finishing times of the participants that reported a 
history of EAMC within the last 12 months prior to the event (EAMC group) and the 
participants with a reported history of never suffering from EAMC (NON group). 
 All (n=268) EAMC (n=118) NON (n=150) p-value 
Age
 
(y) 38.4 ± 8.9 (266) 38.4 ± 8.9 (116) 38.4 ± 8.9 (150) 0.976 
Height (cm) 179.4 ± 7.5 (245) 180.2 ± 7.3 (110) 178.7 ± 7.5 (135) 0.122 
Weight (kg) 77.2 ± 10.7 (260) 77.9 ± 10.3 (115) 76.7 ± 11.0 (145) 0.360 
BMI (kg/m
2
) 23.9 ± 2.6 (244) 24.0 ± 2.4 (110) 23.9 ± 2.7 (134) 0.911 
Country of Birth 
(% SA Born) 
73.0 (143) 72.5 (66) 73.3 (77) 1.000 
2006 and 2007 sub-
groups Overall (min) 
784.6 ± 96.1 (211) 766.8 ± 94.0 (95) 799.1 ± 95.8 (116) 0.015 
2009 and 2011 sub-
groups Overall (min) 
297.3 ± 103.9 (46) 295.0 ± 102.9 (21) 299.2 ± 106.8 (25) 0.894 
Table 7. 1.General characteristics and finishing times of the participants that reported a history of EAMC within the last 12 months prior to the event (EAMC group) and the participants with a reported history of never suffering from EAMC (NON group). 
Values are expressed as means ± standard deviations, or percentages where appropriate. 
The number of participants is in parentheses. Numbers in bold typeset are significant 
(p<0.05) (EAMC vs. NON). BMI, Body Mass Index. SA, South Africa. 
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Table 7.2. Training history for the 2006 and 2007 Ironman triathlon sub-groups, during the 
15 weeks prior to the triathlon, for the participants that reported a history of EAMC within the 
last 12 months prior to the event (EAMC group), and the participants with a reported history 
of never suffering from EAMC (NON group). 
 
All Participants a 
(n=211) EAMC (n=95) NON (n=116) p value 
Training duration (hrs/wk)    
3.8km Swim 3.1 ± 1.7 (203) 3.1 ± 1.9 (91) 3.1 ± 1.5 (112) 0.874 
180km Bike 9.2 ± 12.8 (188) 10.3 ± 18.9 (84) 8.4 ± 2.8 (104) 0.328 
42.2km Run 4.9 ± 3.1 (192) 5.3 ± 4.1 (86) 4.6 ± 1.8 (106) 0.122 
226km Overall  15.9 ± 4.2 (177) 15.9 ± 4.0 (79) 15.8 ± 4.3 (98) 0.800 
Training distance (km/wk)    
3.8km Swim 6.5 ± 3.0 (206) 6.8 ± 3.2 (93) 6.2 ± 2.8 (113) 0.164 
180km Bike 226.3 ± 78.1 (188) 228.0 ± 74.9 (85) 224.9 ± 81.0 
(103) 
0.790 
42.2km Run 47.6 ± 18.3 (200) 47.2 ± 14.6 (89) 48.0 ± 20.9 (111) 0.769 
226km Overall  238.8 ± 77.9 (175) 243.8 ± 76.9 (81) 234.5 ± 78.9 (94) 0.430 
Table 7. 2.Training history for the 2006 and 2007 Ironman triathlon sub-groups, during the 15 weeks prior to the triathlon, for the participants that reported a history of EAMC within the last 12 months prior to the event (EAMC group), and the participants 
with a reported history of never suffering from EAMC (NON group). 
Values are expressed as means ± standard deviations, or percentages where appropriate. 
The number of participants is in parentheses.  
a Training history was not obtained from participants recruited at the 2009 and 2011 Two 
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Table 7.3. Genotype effects of COL3A1 rs1800255, COL5A1 rs12722, COL6A1 rs35796750 
and COL12A1 rs970547 on physiological characteristics of participants. 
Polymorphism 
p-values 
Age Height Weight BMI Country of 
Birth 
COL3A1 rs1800255 0.923 0.430 0.643 0.641 0.916 
COL5A1 rs12722 0.285 0.495 0.743 0.827 0.471 
COL6A1 rs35796750 0.433 0.695 0.447 0.458 0.398 
COL12A1 rs970547 0.596 0.253 0.486 0.307 0.806 
Table 7. 3.Genotype effects of COL3A1 rs1800255, COL5A1 rs12722, COL6A1 rs35796750 and COL12A1 rs970547 on physiological characteristics of participants. 
p-values in bold typeset indicate significant differences (p<0.05). BMI, body mass index. 
 
 
7.3.2 Nature of the self-reported past history of EAMC 
 
A trend was observed for the frequency of self-reported previous (life-long) tendon or 
ligament injury to be higher in participants with a past history of EAMC (p=0.050). 
Specifically, the frequency of self-reported injuries was lower in the NON group 
(33.8%) when compared to the EAMC group (46.4%).  
 
7.3.3 Independent Collagen Gene Associations and History of Exercise 
Associated Muscle Cramping 
 
COL5A1 rs12722 genotype frequency was significantly associated with past history 
of EAMC (p=0.034) (Figure 7.2B). Specifically the COL5A1 rs12722 CC genotype 
was significantly under-represented (p=0.031, OR=2.2, 95% CI 1.1–4.5) in the 
EAMC group (CC genotype 11.1%) when compared to the NON group (CC genotype 
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21.8%). There were no significant differences in the COL3A1 rs1800255 (Figure 
7.2A; p=0.828), COL6A1 rs35796750 (Figure 7.2C; p=0.300) or COL12A1 rs970547 
(Figure 7.2D; p=0.120) genotype frequencies between the EAMC and NON groups. 
The COL12A1 rs970547 EAMC group was out of Hardy Weinberg equilibrium 
(p=0.011). The EAMC and NON groups for COL3A1 rs1800255 (EAMC p=0.627, 
NON p=1.000), COL5A1 rs12722 (EAMC p=1.000, NON p=0.324) and COL6A1 
rs35796750 (EAMC p=1.000, NON p=0.723), as well as, the COL12A1 rs970547 
NON group (p=0.309) were in Hardy Weinberg equilibrium. 
 
Participants in the EAMC group were divided in three sub-groups based on their 
number of self-reported cramps suffered in the last ten races. Participants reported 
suffering from no cramps, 1 cramp or 2+ cramps in the last ten races. No genotype 
effect was determined for COL5A1 rs12722 (p=0.480), COL3A1 rs1800255 
(p=0.112), COL6A1 rs35796750 (p=0.181) or COL12A1 rs970547 (p=0.759) and 
number of self-reported cramps in the last ten races. 












Figure 7. 2. Genotype frequencies for the participants that reported a history of EAMC within 12 months prior to the event 
(EAMC group) and those with no self-reported history of previous (lifelong) EAMC (NON group) for the (A) COL5A1 rs12722, 




Figure 7.2. Genotype frequencies for the participants that reported a history of EAMC within 
12 months prior to the event (EAMC group) and those with no self-reported history of 
previous (lifelong) EAMC (NON group) for the (A) COL3A1 rs1800255, (B) COL5A1 
rs12722, (C) COL6A1 rs35796750 and (D) COL12A1 rs970547 polymorphisms. Numbers of 
participants (n) are indicated above each specific column. Values above the figures refer to 
the overall p-value. p-values above a genotype group refer to the pairwise post-hoc analysis. 
 
 
7.3.4 Gene-Gene Interactions and History of Exercise Associated Muscle 
Cramping 
 
Gene-gene interactions between COL3A1 rs1800255, COL5A1 rs12722, COL6A1 
rs35796750 and COL12A1 rs970547 were investigated (Figure 7.3). The major 
G+T+C+A inferred pseudo-haplotype was significantly (p=0.028) over-represented in 
the EAMC group (22.7%, n=27) when compared to the NON group (14.2, n=21). 
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Furthermore, the G+C+T+A inferred pseudo-haplotype was significantly (p=0.021) 
under-represented in the EAMC group (11.1%, n=13) when compared to the NON 











Figure 7. 3. Frequency distributions of the inferred pseudo-haplotypes constructed from COL3A1 rs1800255, COL5A1 rs12722, 
COL6A1 rs35796750 and COL12A1 rs970547 between participants that reported a history of EAMC within 12 months prior to 
the event (EAMC group) and those with no self-reported history of previous (lifelong) EAMC (NON group). 
 
Figure 7.3. Frequency distributions of the inferred pseudo-haplotypes constructed from 
COL3A1 rs1800255, COL5A1 rs12722, COL6A1 rs35796750 and COL12A1 rs970547 
between participants that reported a history of EAMC within 12 months prior to the event 




Among the two significantly identified inferred pseudo-haplotypes the direction of 
association for the COL5A1 rs12722 and COL6A1 rs35796750 variants was 
consistent, while COL3A1 rs1800255 and COL12A1 rs970547 showed no evidence 
of contributing to the inferred pseudo-haplotypes (Figure 7.3). Therefore additional 
inferred pseudo-haplotypes were constructed from only COL5A1 rs12722 T/C and 
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COL6A1 rs35796750 T/C. The T+C inferred pseudo-haplotype was significantly 
(p=0.011) over-represented in the EAMC group (33.1%, n=39) when compared to 
the NON group (23.9%, n=35) (Figure 7.4). Furthermore, the C+T pseudo-haplotype 
was significantly (p=0.007) under-represented in the EAMC group (16.0 %, n=19) 







Figure 7. 4. Frequency distributions of the inferred pseudo-haplotypes constructed from COL5A1 rs12722 and COL6A1 
rs35796750 between participants that reported a history of EAMC within 12 months prior to the event (EAMC group) and those 
with no self-reported history of previous (lifelong) EAMC (NON group). 
 
 
Figure 7.4. Frequency distributions of the inferred pseudo-haplotypes constructed from 
COL5A1 rs12722 and COL6A1 rs35796750 between participants that reported a history of 
EAMC within 12 months prior to the event (EAMC group) and those with no self-reported 
history of previous (lifelong) EAMC (NON group). 
 
 
7.3.5 Logistic Regression Analysis for Risk of Past History of EAMC 
 
Participant weight and height have previously been identified as risk factors for past 
history of EAMC [29]. Furthermore, the COL5A1 rs12722 CC genotype is 
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independently associated with past history of EAMC (Figure 7.2A) and self-reported 
history of tendon or ligament injury showed a strong trend with risk of past history of 
EAMC. Therefore, participant weight (kg), height (cm), self-reported history of tendon 
or ligament injury (Yes vs. No) and COL5A1 rs12722 genotype (CC vs. TC+TT) were 
incorporated into a logistic regression model to determine risk of past history of 
EAMC in all participants (Table 7.4). The COL5A1 rs12722 genotype (CC vs. 
TC+TT) (OR=3.09, 95% CI = 2.64-3.54, p=0.013) and self-reported history of tendon 
or ligament injury (Yes vs. No) (OR=2.03, 95% CI = 1.72-2.34, p=0.024) significantly 
contributed to past history of EAMC. 
 
 
Table 7.4. Regression analysis for the determination of risk of past history of EAMC. 
 Level of effect OR (95% CI) Wald 
Statistic p value 
Weight (kg) - 1.00 (0.96-1.04) -0.036 0.998 
Height (cm) - 1.05 (0.99-1.10) 2.772 0.096 
Tendon/Ligament Injury  
(Yes vs. No) Yes 2.03 (1.72-2.34) 5.094 0.024 
COL5A1 rs12722 genotype 
(CC vs. TC+TT) TC+TT 3.09 (2.64-3.54) 6.113 0.013 
Table 7. 4. Regression analysis for the determination of risk of past history of EAMC. 
Numbers in bold typeset are significant contributors to the model for past history of EAMC 
(p<0.05). OR, odds ratio. CI, confidence interval. 
 
 
Furthermore, in order to determine the effect of overall performance on a past history 
of EAMC, a separate logistic regression was also determined analysing only the 
participants from the 2006 and 2007 Ironman triathlon sub-groups (Table 7.5). As 
before, participant weight (kg), height (cm), self-reported history of tendon or 
ligament injury (Yes vs. No) and COL5A1 rs12722 genotype (CC vs. TC+TT) were 
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incorporated. Furthermore, overall finishing time for the Ironman triathlon was also 
included in the model since the EAMC group was shown to be significantly faster 
than the NON group (Table 7.1). Training history was not included in the model since 
no significant interactions were observed (Table 7.2). The COL5A1 rs12722 
genotype (CC vs. TC+TT) (OR=2.85, 95% CI = 2.40-3.30, p=0.022), self-reported 
history of tendon or ligament injury (Yes vs. No) (OR=1.98, 95% CI = 1.67-2.29, 
p=0.031) and overall finishing time for the Ironman triathlon (OR=1.00, 95% CI = 






Table 7.5. Regression analysis for the determination of risk of past history of EAMC in 
participants of the 2006 and 2007 South African Ironman triathlons. 
 Level of effect OR (95% CI) Wald 
Statistic p value 
Weight (kg) - 1.02 (0.98-1.06) 0.859 0.354 
Height (cm) - 1.03 (0.97-1.09) 1.085 0.298 
Overall performance (min) - 1.00 (1.00-1.00) 3.955 0.047 
Tendon/Ligament Injury (Yes vs. 
No) Yes 1.98 (1.67-2.29) 4.651 0.031 
COL5A1 rs12722 genotype (CC 
vs. TC+TT) TC+TT 2.85 (2.40-3.30) 5.207 0.022 
Table 7. 5. Regression analysis for the determination of risk of past history of EAMC in participants of the 2006 and 2007 South African Ironman triathlons. 
Numbers in bold typeset are significant contributors to the model for past history of EAMC 
(p<0.05). SE, standard error of the estimate. 





This is the first study to identify a genetic variant as a potential marker for a past 
history of exercise-associated muscle cramps. The COL5A1 3’-UTR rs12722 (C/T) 
polymorphism was associated with self-reported EAMC during the 12 months prior to 
participating in either the 2006 and 2007 South African Ironman triathlons or the 
2009 and 2011 Two Oceans ultra-marathons. Specifically, the CC genotype was 
significantly over-represented in participants with no self-reported history of previous 
(lifelong) EAMC when compared to participants that reported a past history of EAMC 
within 12 months prior to the event. In addition, a significant interaction between 
COL5A1 rs12722 and COL6A1 rs35796750 was identified. Specifically, the T+C 
pseudo-haplotype, constructed from COL5A1 rs12722 T/C and COL6A1 rs35796750 
T/C, was associated with increased risk of a past history of EAMC, while the C+T 
pseudo-haplotype was significantly associated with reduced risk. Multivariate 
regression analysis of all participants revealed the COL5A1 rs12722 genotype 
(TC+TT) and previous tendon/ligament injury as positive contributors to risk of past 
history of EAMC. Furthermore, when only participants of the 2006 and 2007 Ironman 
triathlons sub-group were analysed, the COL5A1 rs12722 genotype (TC+TT), 
previous tendon/ligament injury and faster overall finishing time were all positive 
contributors to risk of past history of EAMC. No independent associations were 
identified between COL3A1 rs1800255, COL6A1 rs35796750 or COL12A1 rs970547 
and risk of past history of EAMC. 
 
This novel study shows that structural components (types V and VI collagen) of the 
extracellular matrix of musculoskeletal soft tissue are associated with a past history 
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of EAMC. Prospective cohort studies are required to establish a cause-effect 
relationship however, the COL5A1 genetic continuum discussed in chapter 2 section 
2.2 suggests a possible molecular mechanism [107]. Specifically, the COL5A1 3’-
UTR functional form containing the rs12722 T allele may contribute to increase 
mRNA stability [107]. These changes in COL5A1 expression may alter the structural 
and mechanical properties of collagen fibrils [41]. It has been proposed that the 
increased type V collagen production associated with the TT genotype of rs12722 
results in increased stiffness and/or creep inhibition, and reduced tensile strength 
[41]. These changes increase the risk of musculoskeletal soft tissue injuries. In 
contrast, the CC genotype is proposed to have reduced stiffness and greater tensile 
strength [41]. The changes in these mechanical properties may explain the reduced 
risk of EAMC within individuals with a CC genotype. Further work is required to test 
this hypothesis. The function of type VI collagen is still largely unknown [201], 
however type V and type VI collagen are known to interact [190]. Therefore, although 
a function for COL6A1 rs35796750 has been proposed [191], additional studies are 
required to determine the functional effects of this variant to add to the 
understanding of how the COL5A1 and COL6A1 genes may interact to modulate the 
risk of EAMC.   
 
In addition to the association identified with COL5A1 rs12722, and the interaction 
with COL6A1 rs35796750, a faster overall finishing time was also associated with a 
past history of EAMC in the 2006 and 2007 Ironman triathlon events. This result was 
expected since increased exercise performance has previously been associated with 
risk of EAMC in larger prospective cohorts from the 2006 and 2007 South African 
Ironman triathlons [183] and the 2009 Two Oceans ultra-marathon [175]. The 
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COL5A1 rs12722 TT genotype is also associated with increased endurance running 
performance [151]. Interestingly, multivariate logistic analysis revealed that both the 
COL5A1 rs12722 T allele and a faster overall finishing time contribute to an 
increased risk of past history of EAMC. Future studies are required to further 
investigate this relationship between exercise performance, EAMC and COL5A1 
rs12722. In addition, the complex multifactorial aetiology of EAMC will be discussed 
in more detail in the final concluding chapter of this thesis (Chapter 10). 
 
EAMC is a multifactorial phenotype [174] and therefore, although this will be 
discussed in more detail in the final concluding chapter of this thesis (Chapter 10), 
one of the main limitations of this study is that the regression analyses only identified 
overall finishing time, history of tendon or ligament injuries (Yes vs. No) and COL5A1 
rs12722 genotype (CC vs. TC+TT) as significant contributors to risk of past history of 
EAMC. Logistic estimates revealed the COL5A1 rs12722 TT and TC genotypes, a 
history of tendon or ligament injuries and a faster overall finishing time as positive 
contributors to risk of past history of EAMC, however other previously described risk 
factors [183] such as weight and height an did not contribute to the model. This 
highlights the need for replication and validation of these associations in other larger 
and independent cohorts. In addition, these results demonstrate the importance of 
identifying new risk factors that may help to further explain the aetiology of EAMC. A 
second major limitation to this study is that muscle damage is only proposed to alter 
risk of EAMC [174] and that creatine kinase activity is weakly associated with risk of 
EAMC [175]. In order to add weight to the hypothesis that alterations to the collagen 
fibril mechanical properties as a result of COL5A1 rs12722, or other collagen gene 
variants, modulate the risk of EAMC, further studies are required to investigate the 
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relationship between risk of EAMC and muscle damage. Additional limitations to this 
study include a small sample size and the use of self-reported data, such as past 
history of EAMC. In order to strengthen these findings additional studies are required 
in larger independent cohorts containing individuals diagnosed with EAMC. Finally, 
only males were included in this study because previous studies have reported that 
males are more likely to experience EAMC [174;177]. Furthermore, as stated 
previously, athletic performance is associated with EAMC [174;177] and is also 
gender specific [26;198]. Additional studies are therefore required to investigate 
these gene variants in female cohorts to determine if the associations identified in 
this study may be gender-specific, as shown when some of these variants were 
investigated in other exercise-associated phenotypes [137;153;154] (Chapter 3). 
 
In conclusion, the main finding of this study was the novel identification of COL5A1 
rs12722 as a potential marker for a past history of EAMC. Specifically the COL5A1 
rs12722 CC genotype was significantly over-represented in participants that reported 
never suffering from EAMC, when compared to participants that reported suffering 
from EAMC within 12 months prior to the events. A significant interaction was also 
identified between the COL5A1 and COL6A1 genes and risk of past history of 
EAMC. These results suggest that changes to collagen containing connective tissue 
may directly and/or indirectly modulate the risk of a past history of EAMC, however 
further investigation is required. A summary of the results of this chapter are 
presented in table 7.6. 
Chapter 7   
184 
 
Table 7.6. A continuing summary of the results of the chapters in this thesis. The results of 
















Genotype not associated CC ♀ prev pub1 not associated 
AA ♀ 
prev pub2 






prev pub5 not associated 
not associated 
prev pub6 
Haplotype A C C nd 
ROM 
Genotype not associated CC prev pub7 not associated not associated 





Genotype not associated not associated not associated not associated 





Genotype not associated not associated TT not associated 





Genotype not associated TT prev pub8 not associated not associated 




Genotype not associated CC not associated not associated 
Haplotype not associated C T not associated 
Rugby Union Chapter 8 
Table 7. 6. A continuing summary of the results of the chapters in this thesis. The results of chapter 7, and all preceding chapters, are shown. 
Green shading indicates that the allele or genotype is associated with a reduced risk of injury, except for ROM 
and endurance performance where it represents an increased ROM or endurance performance. Red shading 
indicates that the allele or genotype is associated with an increased risk of injury. Grey shading indicates no 
independent association. Prev pub, previously published. ♀, associations identified only in females. ACL, anterior 
cruciate ligament; ROM, range of motion; EAMC, exercise-associated muscle cramps; nd, not determined.  
1
 independent association previously reported by Posthumus et al. [153]. 
2
 independent association previously reported by Posthumus et al. [154], but not independently associated in this thesis. 
3
 T+A pseudo-haplotype also associated with increased risk of female ACL ruptures when a Polish cohort was analysed 
[137]. 
4
 no independent association previously reported by Saunders [170] 
5
 independent association previously reported by Mokone et al. [131] and repeated by September et al. [179]. 
6
 no independent association previously reported by September et al. [181] 
7
 independent association previously reported by Brown et al. [28;29]. 
8
 independent association previously reported by Posthumus et al. [151]  and repeated by Abrahams et al. [1]. 
9 
only male participants were included in this study. 










Rugby union football, hereafter referred to as rugby, is a global recreational and 
professional team sport which involves both high (examples: tackling, scrummaging 
and sprinting) and low (examples: standing, walking and jogging) intensity activities 
[167]. Teams are comprised of 15 players and can be divided into two discrete sub-
groups; forwards (playing positions 1-8) and backs (playing positions 9-15) [167]. 
Although it is expected that all 15 players, irrespective of their position or sub-group, 
are competent at all aspects of the game, a high level of specialisation still remains 
within and between these sub-groups [167]. Within a single game of rugby, backs 
have been shown to cover a greater total distance than forwards [167]. Furthermore, 
within the backs sub-group, outside backs (playing positions 11, 14 and 15) sprinted 
greater distances and covered less distance at medium-intensity running or while 
jogging when compared to inside backs (playing positions 9, 10, 12 and 13) [167]. 
 
A number of studies have reported differences in player characteristics between 
playing positions and playing level [157;158;185]. However, these descriptive studies 
do not help to determine the underlying factors which may be over-represented in 
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individuals within particular playing positions or playing levels. Only two studies have 
investigated genetic markers for determining individual playing position [14;15] and 
playing level [14]. The first of these studies showed that there were differences in 
measures of leg power between forwards and backs when the players were grouped 
according to their ACE rs5186 (I/D) genotypes [15]. A second study by the same 
group investigated the functional ACTN3 rs1815739 (R/X) gene variant as a marker 
of playing position and level [14]. No associations were identified between ACTN3 
rs1815739 and playing position or playing level [14].  
 
To date, a number of collagen gene variants have been implicated in the aetiology of 
exercise-related phenotypes [28;29;40;71;131;138;139;151;153-155;171;179]. As 
previously discussed COL5A1 rs12722 has been associated with range of motion 
[28;29;40] and endurance running performance [28;151]. Furthermore the functional 
COL5A1 3’-UTR region [107] , containing rs12722, may affect levels of the type V 
collagen α1 chain synthesis and thereby modulate fibrillogenesis and the mechanical 
properties of connective tissues [41]. Therefore, it was hypothesised that the 
COL5A1 gene may be a good candidate for associations with other endurance or 
power based sports in which musculoskeletal soft tissue mechanical properties may 
be regarded as an important feature, such as rugby union [41]. Fibrillogenesis is also 
regulated by, amongst other proteins, the three other collagens, namely types III, VI 
and XII, which are the focus of this thesis [56;78;190;213]. Interestingly, types VI and 
XII collagen are also known to interact with type V collagen within the fibril 
[78;190;213]. The COL6A1 rs35796750 variant is independently implicated in 
endurance cycling performance (Chapter 6) [138]. In addition, inferred pseudo-
haplotypes constructed from COL3A1 rs1800255, COL5A1 rs12722, COL6A1 
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rs35796750 and COL12A1 rs970547 were implicated in endurance running 
performance (Chapter 6).  
 
Therefore the primary aim of this study was to determine if COL3A1 rs1800255, 
COL5A1 rs12722, COL6A1 rs35796750 and COL12A1 rs970547 are associated with 
playing level in rugby union. The secondary aim was to investigate these variants for 
associations within and between the forwards and backs playing position sub-
groups. The third aim was to investigate gene-gene interactions between COL3A1 
rs1800255, COL5A1 rs12722, COL6A1 rs35796750 and/or COL12A1 rs970547 for 
associations with playing level in rugby union and within and between the forwards 
and backs playing positions sub-groups. 
 




Three hundred and fifty-three self-reportedly Caucasian unrelated participants were 
recruited for this case-control genetic association study. One hundred and seventy 
professional rugby union players were recruited from South African teams competing 
the in the Super 15 rugby tournament (rugby group). The rugby group was further 
sub-divided into two sub-groups; forwards (playing positions 1-8, n=103) and backs 
(playing positions 9-15, n=67). An additional 183 participants, made up of 85 
participants that had never played rugby and 98 recreational rugby players, were 
recruited as controls (control group). Rugby union is played predominantly by males 
and so this study included only male participants. 
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Prior to participation in this study, all the participants gave informed written consent 
(Appendix A.3). In addition, each participant completed a sports participation 
questionnaire (Appendix A.4). This study was approved by the Human Research 
Ethics Committee of the Faculty of Health Sciences within the University of Cape 
Town, South Africa (Appendix A.1). 
 
8.2.2 Variant Selection 
 
Four independent sequence variants were investigated in this study. Namely 
COL3A1 rs1800255, COL5A1 rs12722, COL6A1 rs35796750 and COL12A1 
rs970547. The reasons for their selection have been stated in chapter 3, section 
3.2.2. Furthermore, these variants have been independently associated with, or 
interact to modulate, the risk of musculoskeletal soft tissue injuries (Chapter 3, 4 and 
7) and/or endurance performance (Chapter 6). 
 
8.2.3 DNA Extraction and Genotyping Methods 
 
Approximately 4.5ml of venous blood was collected from all participants by 
venipuncture of a forearm vein into an EDTA vacutainer tube. These samples were 
stored at 4˚C until DNA extraction, as previously described [108], with minor 
modifications [131]. An outline of this methodology was described in chapter 3, 
section 3.2.3. 
 
All participants were genotyped for COL3A1 rs1800255, COL5A1 rs12722, COL6A1 
rs35796750 and COL12A1 rs970547. Genotyping of COL3A1 rs1800255 and 
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COL6A1 rs35796750 was performed using custom designed Fluorescence-based 
Taqman® polymerase chain reaction (PCR) assays (Applied Biosystems, Foster 
City, CA, USA) as described in chapter 3. Genotyping of COL5A1 rs12722 and 
COL12A1 rs970547 was performed using PCR and restriction fragment length 
polymorphism analysis as previously described (Appendix B) [29;131;153;154] 
(Chapter 5). All genotyping was done at the UCT/MRC Research Unit for Exercise 
Science and Sports Medicine, University of Cape Town, Cape Town, South Africa. 
All genotyping was done at the UCT/MRC Research Unit for Exercise Science and 
Sports Medicine, University of Cape Town, Cape Town, South Africa. 
 
Investigators were blinded to the phenotypes of the participant samples while 
genotyping. Furthermore, a number of positive and negative controls were used to 
ensure genotyping accuracy. No discrepancies were observed. Of the 353 included 
participants, a total of 301 (85.3%), 312 (88.4%), 310 (87.8%) and 317 (89.8%) 
participants were genotyped for COL3A1 rs1800255, COL5A1 rs12722, COL6A1 
rs35796750 and COL12A1 rs970547 respectively. All laboratory work was 
conducted at the MRC/UCT Research Unit for Exercise Science & Sports Medicine, 
University of Cape Town, Cape Town, South Africa. 
 
8.2.4 Statistical Analysis 
 
The same statistical tests and haplotype analysis methods were performed as 
described in chapter 3 section 3.2.4. Significance was accepted when p<0.05. No 
adjustments were made for multiple testing in this study for the same reasons as 
outlined in chapter 3 section 3.2.4. 





8.3.1 Participant Characteristics 
 
The genotype frequency distributions between the participants that had never played 
rugby and the recreational rugby players were similar for COL3A1 rs1800255 
(p=0.988), COL5A1 rs12722 (p=0.152), COL6A1 rs35796750 (p=0.469) and 
COL12A1 rs970547 (p=0.211), and were therefore these participants were combined 
for all further analysis as a single CON group (Appendix C.10). The general physical 
characteristics for all participants are presented in table 8.1. The control group was 
significantly older than the rugby group. The rugby group was significantly taller and 
when compared to the control group. Similar results were identified for the forwards 
and backs sub-groups, except that the backs and control group were matched for 
height (Table 8.1). The forwards sub-group was significantly taller (p<0.001), heavier 
(p<0.001), with a corresponding higher BMI (p<0.001) than the backs sub-group. 
Furthermore, approximately 28% (n=48) of the rugby group played Rugby Union at 
an international level. 
 
Although probably not biologically relevant, participants with the COL3A1 rs1800255 
GA genotype (186.1 ± 7.9 cm, n=130) were significantly (p<0.001) taller than those 
with the GG (182.5 ± 6.6 cm, n=143) or AA (183.0 ± 8.1 cm, n=20) genotypes. There 
were no additional genotype effects on any of the participant characteristics for 
COL3A1 rs1800255, COL5A1 rs12722, COL6A1 rs35796750 and COL12A1 
rs970547 (Table 8.2).  
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Table 8.1. Physical characteristics for the professional rugby union players (rugby group) 
and participants that had never played rugby or played recreational rugby (control group), as 


















30.7 ± 9.5  
(178) 
28.1 ± 5.3  
(166) 
28.1 ± 5.5  
(99) 
28.0 ± 5.0  
(67) 0.002 0.016 <0.001 
Height (cm) 
181.5 ± 6.7  
(175) 
186.6 ± 7.6  
(168) 
190.0 ± 6.7 
(101) 
181.4 ± 5.7  
(67) <0.001 <0.001 0.970 
Weight (kg) 
82.8 ± 11.2  
(178) 
102.5 ± 12.9  
(170) 
110.8 ± 8.6  
(103) 









24.9 ± 4.0  
(173) 
29.4 ± 3.0  
(168) 
30.7 ± 3.0  
(101) 








Table 8. 1. Physical characteristics for the professional rugby union players (rugby group) and participants that had never played rugby or played recreational rugby 
(control group), as well as the forwards and backs sub-groups. 
Values are expressed as means ± standard deviations. The number of participants is in 
parentheses. Numbers in bold typeset are significant (p<0.05). BMI, Body Mass Index.  
a rugby group vs. control group. 
b forwards sub-group vs. control group. 
c backs sub-group vs. control group. 






Table 8.2. Genotype effects of COL3A1 rs1800255, COL5A1 rs12722, COL6A1 rs35796750 
and COL12A1 rs970547 on physiological characteristics of participants. 
Polymorphism 
p-values 
Age Height Weight 
COL3A1 rs1800255 0.189 <0.001 0.074 
COL5A1 rs12722 0.582 0.945 0.935 
COL6A1 rs35796750 0.932 0.808 0.735 
COL12A1 rs970547 0.778 0.369 0.935 
 
Numbers in bold typeset are significant (p<0.05). 
Table 8. 2. Genotype effects of COL3A1 rs1800255, COL5A1 rs12722, COL6A1 rs35796750 and COL12A1 rs970547 on 
physiological characteristics of participants. 
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8.3.2 Collagen Genes and Rugby Union Playing Level and Position 
 
There were no differences in genotype frequency distributions, for COL3A1 
rs1800255 (p=0.275), COL5A1 rs12722 (p=0.941), COL6A1 rs35796750 (p=0.883) 
or COL12A1 rs970547 (p=0.447), between the control and rugby groups (Figure 
8.1). When the forwards and backs sub-groups were analysed the COL3A1 
rs1800255 variant was associated with rugby union playing position (Figure 8.1A). 
Specifically, the COL3A1 rs1800255 GG genotype was significantly (p=0.047) under-
represented in the forwards sub-group (GG genotype: 39.6%, n=38) when compared 
to the control group (GG genotype: 53.5%, n=76) (Figure 8.1A). Furthermore, the 
COL3A1 rs1800255 GA genotype was significantly (p=0.046) over-represented in 
the forwards sub-group (GA genotype: 53.1%, n=51) when compared to the control 
group (GA genotype: 39.4%, n=56) (Figure 8.1A). No other significantly different 
genotype frequency distributions, for COL3A1 rs1800255 (backs sub-group 
p=0.962), COL5A1 rs12722 (forwards sub-group p=0.782, backs sub-group 
p=0.617), COL6A1 rs35796750 (forwards sub-group p=0.974, backs sub-group 
p=0.790) or COL12A1 rs970547 (forwards sub-group p=0.772, backs sub-group 
p=0.102), were identified between the forwards or backs sub-groups and the control 
group (Figure 8.1). 
 
Interestingly, when the smaller outside backs sub-group (playing positions 11, 14 
and 15, n=18) was analysed the COL12A1 rs970547 GG genotype was significantly 
over-represented in the outside backs sub-group (GG genotype: 23.5%, n=4) when 
compared to the control group (GG genotype: 5.8%, n=9, p=0.028), forwards sub-
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group (GG genotype: 8.6%, n=5, p=0.026) and all other positions (GG genotype: 
6.8%, n=10, p=0.043), respectively.  
 
The COL3A1 rs1800255 (rugby group p=0.141, control group p=1.000), COL5A1 
rs12722 (rugby group p=0.744, control group p=1.000), COL6A1 rs35796750 (rugby 
group p=1.000, control group p=0.742) and COL12A1 rs970547 (rugby group 

















Figure 8.1. Genotype frequency distributions between the control and rugby groups, as well 
as the forwards and backs sub-groups, for (A) COL3A1 rs1800255, (B) COL5A1 rs12722, 
(C) COL6A1 rs35796750 and (D) COL12A1 rs970547. Forwards sub-group, participants in 
playing positions 1-8, n=103. Backs sub-group, participants in playing positions 9-15, n=63. 
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8.3.3 Gene-gene Interactions and Rugby Union Playing Level and Position 
 
No significant associations were identified when inferred pseudo-haplotypes, 
constructed from COL3A1 rs1800255, COL5A1 rs12722, COL6A1 rs35796750 and 
COL12A1 rs970547, were investigated (Table 8.2).  
 
Closer inspection of the four-gene inferred pseudo-haplotypes showed a tendency 
for certain combinations which included the same COL5A1 rs12722, COL6A1 
rs35796750 and COL12A1 rs970547 alleles, such as T+T+G (A+T+T+G and 
G+T+T+G), to be over-represented in the backs sub-group. In addition there was at 
least a tendency for independent associations between these three collagen gene 
variants and the outside backs sub-group. Therefore inferred pseudo-haplotypes 
constructed from COL5A1 rs12722, COL6A1 rs35796750 and COL12A1 rs970547 
were further investigated (Figure 8.2). The C+C+G inferred pseudo-haplotype was 
significantly (p=0.030, OR=2.3, 95% CI 1.0-5.4 and p=0.042, OR=2.3, 95% CI 0.8-
6.1) under-represented in the control group (4.7%, n=8) when compared to the rugby 
group (10.1%, n=22) and backs sub-group (9.6%, n=9) (Figure 8.2). Furthermore, 
the T+T+G inferred pseudo-haplotype was significantly (p=0.029, OR=2.2, 95% CI 
1.0-5.2) over-represented in the backs sub-group (13.2%, n=12) when compared to 
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Table 8.2. Frequency distributions of inferred pseudo-haplotypes, constructed from COL3A1 
rs1800255 G/A, COL5A1 rs12722 T/C, COL6A1 rs35796750 T/C and COL12A1 rs970547 
























G+C+C+G 3.8 9.5 8.0 10.6 0.118 0.164 0.108 
G+C+C+A 8.0 12.0 13.2 10.4 0.267 0.380 0.524 
G+C+T+G 5.4 5.4 3.6 8.1 0.565 0.872 0.090 
G+C+T+A 17.0 8.5 8.9 6.7 0.089 0.304 0.065 
G+T+C+G 4.6 4.1 4.6 5.3 0.982 0.980 0.121 
G+T+C+A 11.5 10.1 4.1 12.8 0.885 0.959 0.311 
G+T+T+G 4.5 5.8 1.7 7.1 0.965 0.987 0.508 
G+T+T+A 18.4 17.3 24.1 16.2 0.344 0.811 0.210 
A+C+C+G 2.6 0.0 0.0 0.0 nd nd nd 
A+C+C+A 2.2 0.0 3.2 0.0 0.318 0.972 0.203 
A+C+T+G 0.8 1.8 6.2 0.0 0.555 0.114 0.349 
A+C+T+A 2.5 9.2 6.0 8.4 0.128 0.965 0.961 
A+T+C+G 0.0 0.0 0.0 0.0 nd nd nd 
A+T+C+A 8.7 6.8 10.1 3.1 0.112 0.490 0.103 
A+T+T+G 3.7 4.1 3.0 6.5 0.905 0.311 0.311 
A+T+T+A 6.4 4.3 2.0 4.7 0.786 0.078 0.133 
 
Values are expressed as percentages. nd, not determined. 
a control group vs. rugby group  
b control group vs. forwards sub-group  
c control vs. backs sub-group 
Table 8. 3. Frequency distributions of inferred pseudo-haplotypes, constructed from COL3A1 rs1800255 G/A, COL5A1 rs12722 T/C, COL6A1 rs35796750 T/C and COL12A1 rs970547, between the 










Figure 8. 2. Frequency distributions of inferred pseudo-haplotypes, constructed from COL5A1 rs12722 T/C, COL6A1 




Figure 8.2. Frequency distributions of inferred pseudo-haplotypes, constructed from 
COL5A1 rs12722 T/C, COL6A1 rs35796750 T/C and COL12A1 rs970547 A/G, between the 
control and rugby groups, as well as the backs sub-group. Numbers of participants are 
indicated above each column. 





The first novel main finding of this study is that the COL3A1 rs1800255 variant is 
independently associated with rugby union playing position. Specifically, the 
COL3A1 rs1800255 GG genotype was significantly under-represented in the 
professional rugby playing forwards sub-group (playing positions 1-8 characterized 
by intense and strenuous activities [167]) when compared to control participants that 
had played at a recreational level or had never played rugby before. The COL3A1 
rs1800255 variant was selected since the G to A transition at this locus is proposed 
to result in an alanine to threonine change at position 698 of the COL3A1 peptide, 
which is proposed to affect the tensile strength of type III collagen fibres [94]. 
Interestingly, previous studies in this thesis have shown that the rs1800255 A allele, 
as part of a pseudo-haplotype, was associated with reduced risk of chronic Achilles 
tendinopathy (Chapter 4), while the G allele was associated with increased 
endurance swimming and running performance (Chapter 6). Endurance and 
power/sprint phenotypes are often associated with the opposite alleles of the same 
gene variant [26], and this may explain the differences described above. 
 
Furthermore, the GA genotype was significantly over-represented in the professional 
rugby playing forwards sub-group when compared to the control group. It is possible 
that the heterozygous genotype was identified because the AA genotype is rare. 
Although rs1800255 is non-synonymous, these results do not exclude the possibility 
that this variant is tightly linked to an actual casual variant(s) within the COL3A1 
gene or a neighbouring gene. Future studies should investigate additional variants 
within this chromosomal region. No independent associations were identified for 
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COL5A1 rs12722, COL6A1 rs35796750 and COL12A1 rs970547 and rugby union 
playing position. 
 
Independent investigation of COL12A1 rs970547 in the smaller outside backs sub-
group (playing position 11, 14 and 15) revealed that the GG genotype was 
significantly over-represented in the outside backs sub-group when compared to the 
control group, forwards sub-group and all other playing positions, while the COL5A1 
rs12722 TT and COL6A1 rs35796750 TT genotypes showed similar trends. Caution 
needs to be taken when interpreting these results due to the small sample size of the 
outside backs sub-group. Further research is required to repeat these investigations 
in a larger cohort of professional outside back rugby union players. 
 
The second novel finding of this study was that COL5A1 rs12722, COL6A1 
rs35796750 and COL12A1 rs970547 interact to modulate rugby union playing 
position. The C+C+G inferred pseudo-haplotype was significantly over-represented 
in the rugby group and backs sub-group when compared to the control group. In 
addition, the T+T+G inferred pseudo-haplotype was also over-represented in the 
backs sub-group when compared to the control group. In addition, although this 
analysis was not included in the results section of this chapter, when the smaller 
outside backs sub-group (playing positions 11, 14 and 15) was analysed the 
expected C+C+A inferred pseudo-haplotype was significantly under-represented in 
the outside backs sub-group when compared to the control group, while the 
complementary T+T+G inferred pseudo-haplotype showed a tendency to be over-
represented in the outside backs sub-group when compared to the control group. 
Further research is required to repeat these investigations in a larger cohort of 
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outside back rugby union professional players. In addition, no independent variant 
analyses, or gene-gene interactions, investigated in this study were associated with 
playing professional rugby union (playing level; control group vs. rugby group).  
 
The main limitation of this study is the small sample sizes after dividing the rugby 
group into sub-groups such as backs or outside backs. This study has identified 
potential markers for rugby union playing position, however a larger cohort of 
professional players in required to accommodate larger sub-groups for these 
analyses. A second limitation to this study is the use of recreational rugby union 
players in the control group. These participants were added to increase the size of 
the control group to add statistical power, however this results in a less 
homogeneous control group which may have affected the ability of the study to 
determine small effects of the gene variants investigated. Additional studies should 
include a more homogeneous control group of participants with no history of ever 
playing rugby union. Finally, this study included only male participants. Despite the 
fact that rugby union is played predominantly by males, females also participate in 
the sport. Therefore future studies should investigate these gene variants in female 
cohorts to determine if the associations identified in this study may be gender-
specific, as shown when some of these variants were investigated in other exercise-
associated phenotypes [137;153;154] (Chapter 3). 
 
In conclusion, this study identified COL3A1 rs1800255 as a novel marker of rugby 
union playing position. Specifically, the COL3A1 rs1800255 GG genotype was 
significantly under-represented in the professional rugby playing forwards sub-group 
(playing positions 1-8) when compared to control participants that had never played 
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rugby or had played at a recreational level. Furthermore, the GA genotype was 
significantly over-represented in the forwards sub-group when compared to the 
control group. Additional variants within this gene, and neighbouring genes, should 
be explored as additional genetic markers. Further studies require a larger rugby 
cohort to investigate specific positional sub-groups or individual rugby union playing 
positions. A summary of the results of this chapter are presented in table 8.4. 
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Table 8.4. A continuing summary of the results of the chapters in this thesis. The results of 














Genotype not associated CC ♀ prev pub1 not associated 
AA ♀ 
prev pub2 






prev pub5 not associated 
not associated 
prev pub6 
Haplotype A C C nd 
ROM 
Genotype not associated CC prev pub7 not associated not associated 





Genotype not associated not associated not associated not associated 





Genotype not associated not associated TT not associated 





Genotype not associated TT prev pub8 not associated not associated 




Genotype not associated CC not associated not associated 




Genotype GG10 not associated not associated not associated 
Haplotype not associated T11 T11 G11 
Table 8. 4. A continuing summary of the results of the chapters in this thesis. The results of chapter 8, and all preceding chapters, are shown. 
Green shading indicates that the allele or genotype is associated with a reduced risk of injury, except for ROM, 
endurance performance and rugby union where it represents an increased ROM or endurance performance and 
an over-representation in a position sub-group. Red shading indicates that the allele or genotype is associated 
with an increased risk of injury, except rugby union where it represents an under-representation in a position sub-
group. Grey shading indicates no independent association. Prev pub, previously published. ♀, associations 
identified only in females. ACL, anterior cruciate ligament; ROM, range of motion; EAMC, exercise-associated 
muscle cramps; nd, not determined.  
1 independent association previously reported by Posthumus et al. [153]. 
2 independent association previously reported by Posthumus et al. [154], but not independently associated in this thesis. 
3 T+A pseudo-haplotype also associated with increased risk of female ACL ruptures when a Polish cohort was analysed [137]. 
4 no independent association previously reported by Saunders [170] 
5 independent association previously reported by Mokone et al. [131] and repeated by September et al. [179]. 
6 no independent association previously reported by September et al. [181] 
7 independent association previously reported by Brown et al. [28;29]. 
8 independent association previously reported by Posthumus et al. [151]  and repeated by Abrahams et al. [1]. 
9 only male participants were included in this study. 
10 Under-represented in the Rugby Union forwards sub-group in this thesis. 
11 Over-represented in the Rugby Union backs and outside backs sub-groups in this thesis. 





PRELIMINARY INVESTIGATION OF THE FUNCTIONAL EFFECTS OF 




As mentioned in chapter 2 of this thesis, the function of type VI collagen remains 
largely unknown. Although it is believed to play a role at the basement membrane, 
this has not been investigated [201]. The protein is expressed ubiquitously and is 
present in all connective tissue that contains types I and III collagen [106]. 
Furthermore it has been shown to interact with type V collagen in the fibril [190], and 
shows co-localisation with type III collagen in rat lung tissue [5]. As previously 
discussed a murine Col6a1 knockout model for myopathy revealed that the average 
weekly distance run by Col6a1 -/- mice was consistently less than the wildtype mice 
[21].  
 
The TT genotype of COL6A1 rs35796750 (C/T) is associated with increased risk of a 
number of multifactorial conditions, such as ossification of the posterior longitudinal 
ligament (OPLL) [191] and diffuse idiopathic skeletal hyperostosis (DISH) [197] in 
independent Japanese populations. In this thesis the T and C alleles, as part of a 
haplotype with COL5A1 rs12722, were significantly associated with reduced and 
increased risk of history of exercise-associated muscle cramps respectively (Chapter 
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7). In addition, the C allele was significantly over-represented in control participants, 
as part of a haplotype with the COL3A1 rs1800255 and COL5A1 rs12722 variants, 
when compared to participants with clinically diagnosed Achilles tendinopathy 
(Chapter 4). 
 
As hypothesised, the COL6A1 rs35796750 TT genotype was independently 
associated with increased endurance cycling performance in male ironman 
triathletes (Chapter 6). Consistent with this finding, the T allele, as part of a 
haplotype with COL3A1 rs1800255 and COL5A1 rs12722, was associated with 
increased endurance swimming performance during the ironman triathlon (Chapter 
6). Furthermore, the T allele, as part of a haplotype with COL5A1 rs12722 and 
COL12A1 rs970547, was significantly over-represented in male rugby union outside 
backs when compared to controls (Chapter 8). The C allele, on the other hand, was 
associated, as part of a haplotype with COL3A1 rs1800255, COL5A1 rs12722 and 
COL12A1 rs970547, with increased endurance running performance.  
 
The COL6A1 rs35796750 gene variant occurs near the branch site of intron 32 
where the cytosine to thymine transition is proposed to cause aberrant splicing of the 
COL6A1 mRNA [191]. Similarly to the previously published functional studies on 
COL5A1 rs12722 [107], it is important to determine the functional and biological 
mechanisms, of how COL6A1 rs3579750 may modulate exercise-related and other 
multifactorial phenotypes. The aim of this study was therefore to perform a 
preliminary investigation of the functional effects of COL6A1 rs35796750. 
Specifically, to determine if COL6A1 gene expression was different between the C 
allele and T allele of the rs35796750 varaint. 
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9.2 MATERIALS AND METHODS 
 
9.2.1 Bioinformatics Analysis of COL6A1 rs35796750 
 
A 601 bp sequence of the COL6A1 gene, containing rs35796750, was interrogated 
using a number of online bioinformatics tools, including TESS [173;187], ESEfinder 
[36] and JASPAR [30].  These databases identify conserved transcription factor 
[36;173;187] and splice factor [30] DNA-binding sites within the target sequence.  
 
9.2.2 Participants and Tissue Samples 
 
A total of six participants, with known COL6A1 rs35796750 (C/T) genotypes, were 
recruited for this preliminary study. Two participants were recruited with each 
genotype (TT, TC and CC). Primary skin fibroblasts were isolated and cultured from 
skin biopsy samples taken from these participants using methods described by 
Baumgarten [12]. Briefly, the dermis and epidermis were removed from the biopsy 
sample and washed with sterile phosphate buffered saline (PBS). This tissue was 
then finely sliced into approximately 1 mm by 1 mm pieces while covered in 
Dulbecco’s modified eagle medium (DMEM) (Highveld Biological, South Africa), 10% 
fetal calf serum (FCS) (Highveld Biological, South Africa), 200 units/ml penicillin and 
100 µg/ml streptomycin (complete medium). The sliced tissue fragments were then 
placed in 35 mm culture dishes and covered with sterile coverslips, thereby keeping 
the fragments in place and allowing them to attach to the dish surface. Furthermore, 
2.5 ml of complete medium were then added to each culture dish. The dishes were 
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the placed in a 37 oC humidified incubator (95% air, 5% CO2, 65% humidity). The 
medium was changed twice weekly until enough cells had grown out of the explants. 
Fibroblasts growing out form the explant can be seen in figure 9.1. 
 
Once the cells had grown out of the explants the coverslips were transferred, cell 
side up, into new 35 mm dishes. After approximately 2-3 weeks and the cells grown 
from the explants covered 70-90% of the culture area the medium was removed. The 
cells were then washed twice with PBS, then trypsinised using a 0.25% 
trypsin/EDTA solution and seeded in 50 ml culture flasks (passage one). Testing for 
mycoplasma was performed between passages on cells grown in antibiotic-free 
medium containing 10% FCS. Subcultures involved expansion of the fibroblast 
cultures into several flasks in complete medium. Stocks of fibroblasts from passage 
two and three were cryogenically preserved using 10% DMSO (Sigma-Aldrich, 
Munich, Germany) and stored in liquid nitrogen for further usage. The primary 
fibroblast cells obtained from early passages (Passages 3-6) were seeded at 2 X 105 
cells per ml in two 6 cm dishes per samples in 4 ml of complete DMEM. These cells 
were then incubated in a 37 oC humidified incubator (95% air, 5% CO2, 65% 











































Figure 9.1. Panels A and B show fibroblasts growing from the explant after 1 week under 
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9.2.3 Total RNA isolation and cDNA synthesis 
 
Total RNA was extracted from primary fibroblasts using a High Pure RNA Isolation 
Kit (Roche Diagnostics, Roche Applied Science, Mannheim, Germany), according to 
the manufacturer’s specifications with minor modifications to increase the 
concentration of the RNA yield. Briefly; primary fibroblasts were resuspended in 
100µl PBS. The samples were then vortexed for 15s following the addition of 400µl 
Lysis/-Binding Buffer. Each sample was then transferred to a High Pure Filter Tube, 
inserted into a Collection Tube, and centrifuged at 8000 x g for 15s. After 
centrifugation the flowthrough liquid was discarded. A total of 90µl DNase Incubation 
Buffer and 10µl DNase I was then added to each sample and they were left to 
incubate for 15 min at room temperature. Following this incubation step, 500µl Wash 
Buffer I was added to each sample and they were centrifuged for 15s at 8000 x g. 
Again the flowthrough liquid was discarded. 500µl of Wash Buffer II was then added 
and the samples were centrifuged at 8000 x g for 15s. After discarding the 
flowthrough liquid a final 200µl of Wash Buffer II was added to each sample. The 
samples were then centrifuged at 13 000 x g for 2min. Following this final wash step 
the High Pure Filter Tubes were transferred to sterile 1.5ml microcentrifuge tubes. To 
elute the RNA, 30µl of Elution Buffer was added to each sample and they were 
centrifuged at 8000 x g for 1min. The microcentrifuge tube then contained the RNA 
and was stored at -80oC for later analysis. 
 
Conventional reverse transcription was performed using the ImProm-II Reverse 
Transcription System (Promega Corporation, Madison, Wisconsin, USA), according 
to the manufacturer’s specifications. Briefly, 1µg of RNA per sample was added to 
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1µl of random and oligo(dT) primers in a final reaction volume of 5µl. These reaction 
tubes were then placed on a 70oC heating block for 5min before being chilled in ice-
water for at least 5min. While these samples were chilling a 15µl reverse 
transcription reaction mix was made containing; 6.1µl nuclease-free water, 4.0µl 
ImProm-II 5X Reaction Buffer, 2.4µl of MgCl2 (final concentration 3mM), 1µl of dNTP 
Mix (final concentration 0.5mM each dNTP), 0.5µl Recombinant RNasin 
Ribonuclease Inhibitor and 1.0µl ImProm-II Reverse Transcriptase. These 15µl 
aliquots were then added to the 5µl sample specific reactions made previously. The 
20µl reaction tubes were then placed on a heating block at 25oC for 5min, incubated 
at 42oC for 1 hour and then heated at 70oC for 15min to inactivate the reverse 
transcriptase enzyme. The cDNA samples were then stored at -20oC until analysed. 
 
9.2.4 Quantitative Real-Time PCR 
 
Quantitative Real-time PCR (qRT-PCR), to determine the relative content of 
COL6A1 and COL1A1 mRNA, was performed using the 7900 HT Fast Real-Time 
PCR System and SDS Software version 2.3 (Applied Biosystems, Foster City, CA, 
USA). Commercially available fluorescence-based custom Taqman® array assays 
were used (Appendix D) (Applied Biosystems, Foster City, CA, USA). Each sample 
was analysed in triplicate, in two separate experiments, using the following PCR 
conditions. A 10 min heat activation step (95ºC) followed by 40 cycles of 15 sec at 
92ºC and 1 min at 60ºC. Fluorescence data, indicative of the amount of PCR 
product, was captured at each cycle. The relative COL6A1 and COL1A1 mRNA 
concentrations were then calculated based on the cycle number that the threshold 
quantity of PCR product is obtained (Ct). Ct values for COL6A1 and COL1A1 were 
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normalised to values of an internal housekeeping gene, β-Actin, and expressed 
relative to this control [116]. The original and normalised Ct values are presented in 
Appendix C. Finally, at the end of the PCR, a melting curve was performed to 
confirm single melting peaks, indicative of a single PCR product, for each reaction. 
 
9.2.5 Statistical Analysis 
 
The same statistical tests were performed as described in chapter 3 section 3.2.4. 




9.3.1 Identified DNA-binding sits at rs35796750 
 
The results of the interrogation of the gene region containing COL6A1 rs35796750, 
using online bioinformatics tools [30;36;173;187], are shown in figure 9.2. 
Specifically, the DNA-binding domains for splice factor SRp55 (sequence TGCGCC) 
and the E2F transcription factor family (sequence GCGCC) were identified in the 
presence of COL6A1 rs35796750 C allele, while both sites are abolished in the 




















Figure 9.2. DNA-binding domains identified at the COL6A1 rs35796750 locus. The splice 
factor SRp55 (sequence TGCGCC) and the E2F transcription factor family (sequence 
GCGCC) were identified in the presence of the COL6A1 rs35796750 C allele, while both 
sites are abolished in the presence of the T allele, respectively. 
# - TGCGCC, SRp55 splice factor binding site. 
## - GCGCC, E2F transcription factor family binding site. 
 
 
9.3.2 Participant Characteristics 
 
The physical characteristics of the individual participants, as well as by COL6A1 
rs35796750 genotype group, are presented in table 9.1.  
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Table 9.1. General characteristics for the individual participants, as well as by COL6A1 
rs35796750 genotype group, recruited in this study.  












Weight (kg) Height (cm) 
TT1 47 73 173 M 
TT 36.5 ± 14.8 74.6 ± 2.1 178.0 ± 7.1 
TT2 26 76 183 M 
TC1 22 65 174 F 
TC 26.0 ± 5.7 72.5 ± 10.6 168.5 ± 7.8 
TC2 30 80 163 F 
CC1 24 96 179 M 
CC 25.0 ± 1.4 91.0 ± 7.1 176.5 ± 3.5 
CC2 26 86 174 F 
 
Where appropriate, values are expressed with mean ± standard deviation. M, male. F, 
female.  
a COL6A1 rs35796750 genotype groups 
Table 9. 1. General characteristics for the individual participants, as well as by COL6A1 rs35796750 genotype group, recruited 







9.3.3 Collagen Gene Expression Levels 
 
The individual gene expression, relative to participant CC1, for COL6A1 and 
COL1A1 are presented in figure 9.3. Individual differences between the relative 
expression levels for COL6A1 and COL1A1 were identified (Figure 9.3). Specifically, 
participant TT2 showed significantly (p=0.001) higher COL6A1 expression when 
compared to COL1A1 expression, while a similar tendency (p=0.088) for higher 
COL6A1 expression was also identified for participant TT1 (Figure 9.3). No other 
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significant differences between the individual participant expression levels of 
COL6A1 and COL1A1 were identified. 
 
Inter-individual differences in the relative expression of COL6A1 and COL1A1 were 
also identified. Participant TC1 showed a significant (p=0.016) 2.7 ± 1.5 fold increase 
in COL6A1 expression when compared to participant CC1, while a tendency 
(p=0.052) was observed for participant TT1 to have a higher COL6A1 expression 
(2.5 ± 1.2 fold change) when compared to participant CC1 (Figure 9.3). In addition, 
participant TC1 also showed a significant (p<0.001) 2.6 ± 1.1 fold increase in 
COL1A1 expression when compared to participant CC1 (Figure 9.3B). No other 
significant differences were identified for either COL6A1 or CO1A1 gene expression 


























Figure 9.3. The individual participant expression levels of COL6A1 (white bars) and 
COL1A1 (black bars) relative to participant CC1. The number of experimental replicates is 
shown above each column. p-values are presented above relevant columns. The star (*) 
indicates a significant (p=0.016) difference in the relative expression of COL6A1 between 
participants TC1 and CC1. The hash (#) indicates a significant (p<0.001) difference in the 
relative expression of COL1A1 between participants TC1 and CC1. 
COL6A1 
COL1A1 
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The expression levels of COL6A1 and COL1A1, after grouping participants 
according to their COL6A1 rs35796750 genotype, relative to the CC genotype group 
are presented in figure 9.4. When the relative expression levels of COL6A1 and 
COL1A1 were compared within the same COL6A1 rs35796750 genotype group a 
significant difference was identified for the TT genotype group. Specifically, the 
relative expression level of COL6A1 (1.89 ± 0.54) was significantly (p=0.003) higher 
when compared to that of COL1A1 (1.17 ± 0.41) (Figure 9.4). The relative 
expression levels of COL6A1 and COL1A1 were not different within the CC 
(p=0.304) and TC (p=0.830) genotype groups (Figure 9.4). 
 
Significant differences in COL6A1 expression were also identified between the three 
genotype groups. Specifically, the COL6A1 rs35796750 TT (1.89 ± 0.54) and TC 
(1.76 ± 0.84) genotype groups had significantly (p=0.005 and p=0.013) higher 
COL6A1 expression levels when compared to the CC (1.02 ± 0.21) genotype group, 
respectively (Figure 9.4). Similarly, significant differences in COL1A1 expression 
were also identified between the three COL6A1 rs35796750 genotype groups. 
Specifically, the COL6A1 rs35796750 TC (1.90 ± 1.10) genotype group had 
significantly (p=0.013) higher COL1A1 expression levels when compared to the CC 
(1.01 ± 0.16) genotype group (Figure 9.4), while the TT (1.17 ± 0.41) genotype 
showed a tendency (p=0.053) to be higher (Figure 9.4).  
 
 











Figure 9. 4. The COL6A1 rs35796750 genotype group expression levels of COL6A1 and COL1A1 relative to participants with 








Figure 9.4. The COL6A1 rs35796750 genotype group expression levels of COL6A1 (white 
bars) and COL1A1 (black bars) relative to participants with the COL6A1 rs35796750 CC 
genotype. The number of experimental replicates is shown above each column. p-values are 
presented above relevant columns. The star (*) indicates a significant (p=0.013) difference in 
the relative expression of COL6A1 between participants in the CC and TC genotype groups. 
The plus (+) indicates a significant (p=0.005) difference in the relative expression of COL6A1 
between participants in the CC and TT genotype groups. The hash (#) indicates a significant 
(p=0.013) difference in the relative expression of COL1A1 between participants in the CC 
and TC genotype groups. 
COL6A1 
COL1A1 





The novel preliminary results of this study showed that participants with the COL6A1 
rs35796750 TT and TC genotypes had significantly higher COL6A1 gene expression 
when compared to participants with the CC genotype, suggesting that individuals 
with at least one COL6A1 T allele have a higher type VI collagen gene expression.  
However analysis of COL1A1 gene expression between the COL6A1 genotype 
groups showed a similar COL1A1:COL6A1 expression ratio in individuals with the 
COL6A1 rs35796750 TC and CC genotypes, with a higher COL1A1:COL6A1 ratio in 
the participants with a COL6A1 TT genotype, suggesting that relative to type I 
collagen gene expression, type VI collagen might be higher in individuals with a 
COL6A1 TT genotype.  
 
Functional variants, such as the Sp1-binding site within intron 1 [81;126], within the 
COL1A1 gene alter its expression at an individual level. This could not be accounted 
for in this study. Despite this, it is interesting to note that the level of COL6A1 gene 
expression was higher when compared to COL1A1 gene expression in both the 
participants with a COL6A1 TT genotype. Although very speculative, this could 
suggest that the observed increased COL6A1 gene expression is due to the 
rs35796750 TT genotype and not due to altered COL1A1 gene expression. 
However, future studies with larger samples sizes should genotype participants for 
all known functional variants within the COL1A1 gene to eliminate altered COL1A1 
gene expression as a possible confounder. 
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Based on the results of this study two models can be proposed to explain the 
mechanism through which the rs35796750 variant may result in altered COL6A1 
gene expression. The first model assumes the altered binding affinity of the SRp55 
splice factor to COL6A1 at the polymorphic intronic DNA-binding domain containing 
the rs35796750 variant. The regulation of splicing by SR-proteins and their kinases 
has been extensively reviewed by Zhou and Fu [216]. Briefly, an SR-protein binding 
to an exonic DNA-binding site is positive for that exons inclusion during splicing, 
however binding to an intronic DNA-binding site will result in exon exclusion during 
splicing. For example, the SRp55 splice factor binds to the target sequence 
TGCGCC within intron 32 of COL6A1, in the presence of the rs35796750 C allele, 
which would result in exclusion of exon 33 during splicing (Figure 9.5). The binding 
site is abolished in the presence of the rs35796750 T allele which would result in 






Figure 9. 5. A schematic diagram showing alternative splicing of the COL6A1 gene as a result of the SRp55 splice factor 




Figure 9.5. A schematic diagram showing alternative splicing of the COL6A1 gene as a result of the 
SRp55 splice factor binding to the intronic region containing the rs35796750 variant. The last six 
exons (30-35) of the COL6A1 gene are indicated as black rectangles while introns are represented by 
the black line between exons. The SRp55 splice factor binds to the intronic DNA-binding domain, 
containing the rs35796750 C allele (in green), resulting in exclusion of exon 33 during splicing. The 
SRp55 splice factor does not bind in the presence of the rs35796750 T allele (in red) resulting in 
inclusion of exon 33 during splicing. 
3’ 5’ 
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Alternative α3(VI) collagen transcripts are known to vary in abundance, with no 
tissue-specification, in chick tissues [47]. Similar results for α3(VI) collagen 
transcripts of differing sizes have also been shown in a murine model [48]. It is 
therefore tempting to speculate that alternate splicing, as a result of rs35796750, 
may also result in varying abundance of the α1(VI) collagen transcript (Figure 9.6). 
Specifically, the binding of SRp55 to the DNA-binding domain in the presence of the 
rs35796750 C allele may result in exon exclusion and thereby lead to reduced α1(VI) 
mRNA abundance which may in turn lead to reduced COL6A1 gene expression 
(Figure 9.6). The inclusion of COL6A1 exon 33, as a result of the rs35796750 T 
allele and the abolishment of the SRp55 DNA-binding site, would then result in a 
larger α1(VI) collagen transcript which may lead to increased α1(VI) mRNA 
abundance which may in turn lead to increased COL6A1 gene expression (Figure 
9.6). 
  














Figure 9. 6. A schematic diagram of the proposed interaction between the intronic COL6A1 gene DNA-binding site, containing 





Figure 9.6. A schematic diagram of the proposed interaction between the intronic COL6A1 
gene DNA-binding site, containing rs35796750, and the SRp55 splice factor. In the left panel 
SRp55 binds to the DNA-binding site in the presence of the rs35796750 C allele (green) 
which may then lead to reduced α1(VI) mRNA abundance and corresponding COL6A1 gene 
expression. The right panel shows that the binding site is abolished in the presence of the 
rs35796750 T allele (red) resulting in increased α1(VI) mRNA abundance and corresponding 
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The second model that may explain the altered COL6A1 gene expression as a result 
of rs35796750 assumes the altered binding affinity of an E2F transcription factor to 
COL6A1 at the intronic DNA-binding domain containing the rs35796750 variant. The 
family of E2F transcription factors recognise and bind the target sequence GCGCC 
within intron 32 of the COL6A1 gene in the presence of the rs35796750 C allele. 
This DNA-binding site sequence is abolished in the presence of the rs35796750 T 
allele (Figure 9.7). E2F transcription factors act as activators (E2Fs 1-3) which 
promote gene expression or as inhibitors (E2Fs 4-8) which act as transcriptional 
repressors [8]. Therefore is may be proposed that an inhibitory E2F transcription 
factor binds to the intronic DNA-binding site in the presence of the rs35796750 C 
allele resulting in COL6A1 transcriptional repression thereby reducing COL6A1 gene 
expression (Figure 9.7). The presence of the rs35796750 T allele abolishes the E2F 
binding site thereby preventing transcriptional repression and resulting in increased 
COL6A1 gene expression (Figure 9.7).  
  












Figure 9. 7. A schematic diagram of the proposed interaction between the intronic COL6A1 gene DNA-binding site, containing 




Figure 9.7. A schematic diagram of the proposed interaction between the intronic COL6A1 
gene DNA-binding site, containing rs35796750, and the E2F transcription factor. In the left 
panel an inhibitory E2F transcription factor binds to the DNA-binding site in the presence of 
the rs35796750 C allele (green) which may then lead to transcriptional repression and 
corresponding reduced COL6A1 gene expression. The right panel shows that the binding 
site is abolished in the presence of the rs35796750 T allele (red) resulting in a lack of 
transcriptional repression and a corresponding increased COL6A1 gene expression. The 
DNA-binding site is underlined. 
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It is therefore possible that a continuum of associated phenotypes may also exist for 
the range of genetic variation within the COL6A1 gene, similar to that proposed for 
the COL5A1 gene in chapter 2 section 2.2  [41]. Mutations within a single copy of the 
COL6A1 gene will result in Bethlem myopathy and Ullrich congenital muscular 
dystrophy [109]. At this end of the continuum these severe disorders occur 
regardless of environmental exposure and independent of other non-genetic risk 
factors (Figure 9.8). At the opposite end of the continuum, functional common 
variants within COL6A1, such as rs35796750, contribute to more complex and less 
severe phenotypes, and do not result in disorders (Figure 9.8). These multifactorial 
phenotypes arise as a result of the interaction between genetic and non-genetic 
factors modifying physiological responses to environmental exposures [41]. 
 
A murine model has shown that Col6a1 -/- null mice have collagen fibrils with smaller 
diameters and greater density when compared to wildtype mice, accompanied by 
reduced tendon stiffness and maximal load [78]. Furthermore, the average weekly 
distance run by these Col6a1 -/- mice was consistently less than the wildtype mice 
[21], highlighting that these architectural changes may result in changes in 
biomechanics. Interestingly, analysis of COL6A1 rs35796750 C/T in this study has 
shown that participants with the TT genotype had significantly higher COL6A1 gene 
expression when compared to participants with the CC genotype. It may therefore be 
proposed that the increase in COL6A1 gene expression, as a result of the 
rs35796750 TT genotype, may result in an increased collagen fibril diameter and 
reduced fibril density, which in turn may increase the stiffness and maximal load of 
the type VI collagen containing tissue including tendons, ligaments and muscle 
(Figure 9.8). In contrast, the CC genotype may reduce COL6A1 gene expression 
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resulting in reduced collagen fibril diameter and a corresponding increase in fibril 















Figure 9. 8. A proposed genetic continuum for the COL6A1 gene, adapted from the general genetic continuum proposed by 






Figure 9.8. A proposed genetic continuum for the COL6A1 gene, adapted from the general genetic 
continuum proposed by Collins and Posthumus [41]. The black shading represents the severe 
disorders, including Bethlem myopathy and Ullrich congenital muscular dystrophy [109], due to 
mutations in the COL6A1 gene. At this end of the continuum a single mutation results in the disorder. 
Murine models have shown that Col6a1 null mice have aberrant changes to collagen fibril size or 
diameter and fibril density [78]. The white shading represents the most beneficial “versions” of the 
COL6A1 gene. At this end of the continuum variants within the gene collectively contribute to the 
aetiology of the phenotype. The COL6A1 rs35796750 variant is shown to be functional in this study. 
Furthermore, this thesis has shown this functional variant to associate with a number of 
musculoskeletal soft tissue injuries and other exercise-related phenotypes.  
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This suggests that participants with the rs35796750 TT genotype or T allele should 
have increased athletic performance and reduced risk of musculoskeletal soft tissue 
injury when compared to participants with the CC genotype or C allele. Some of the 
studies within this thesis agree with this proposal (Chapters 6-8) and it may also 
explain previously described genetic associations in which the C allele of COL6A1 
rs35796750 was associated with increased risk of both OPLL [191] and DISH [197] 
in independent Japanese populations. However contrasting results have also been 
identified (Chapters 4 and 6).  
 
These contrasting results may highlight tissue specific functions for this variant. 
Within phenotypes characterised by skeletal muscle involvement (endurance 
swimming and cycling, rugby union and EAMC) the associations identified fit the 
mechanism proposed above, the COL6A1 rs35796750 T allele is associated with 
increased performance and reduced risk. Similarly, for OPLL and DISH which are 
both characterised by ligament involvement, the C allele was associated with 
increased in independent Japanese populations [191;197]. Interestingly, however, 
phenotypes characterised by tendon involvement (chronic Achilles tendinopathy and 
endurance running) show opposite associations in that the C allele is associated with 
increased performance and reduced risk of injury. Future studies are required to 
further investigate these findings. Furthermore, these contrasting results may be the 
result of the multi-factorial and polygenic nature of the phenotypes investigated in 
this thesis which will be discussed in more detail in the final concluding chapter of 
this thesis. 
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One of the main limitations to this study is the small sample used. Larger samples 
sizes should be used to repeat this investigation to determine that the findings of this 
study are accurate for the COL6A1 rs35796750 genotype groups. Furthermore, this 
study was merely a preliminarily investigation of rs35796750 and further studies are 
required to determine exactly how this variant modulates COL6A1 gene expression. 
Two possible mechanisms have been proposed above however these remain 
speculative until further studies are conducted.  
  
This is the first study to show a functional effect on COL6A1 expression as a result of 
the rs35796750 gene variant. Specifically, participants with the TT genotype had 
significantly higher COL6A1 gene expression when compared to participants with the 
CC genotype. In addition, this study proposes a model to explain how the functional 
rs35796750 gene variant, and other COL6A1 gene variants, may result in altered 
exercise-associated phenotypes.   





SUMMARY AND PERSPECTIVES 
 
10.1 NOVEL FINDINGS OF THIS THESIS 
 
Genetic variants within collagen genes have been previously associated with 
musculoskeletal soft tissue injuries and other exercise-related phenotypes (Chapter 
2). Initially, the COL5A1 rs12722 gene variant was associated with risk of Achilles 
tendinopathy [131;179] and ACL rupture in females [153]. Since mutations within the 
COL5A1 gene cause classic type EDS [124], which is characterised by, among other 
characteristics, joint hypermobility and hyper-extensibility, additional studies 
investigated and identified associations between COL5A1 gene variants and ROM 
[1;28;29;40], and later endurance performance [1;151] (Chapter 2 Section 2.3.2). 
Furthermore, it was proposed that the relative content of type V collagen in tendons, 
ligaments and other tissues alters the fibril diameters and packing density within 
these tissues, and may alter their mechanical properties, and therefore their 
susceptibility to injury and other exercise-related phenotypes [41]. These studies 
highlighted the collagen component as a factor in the aetiologies of these 
phenotypes. Similarly to COL5A1, mutations within the COL3A1, COL6A1 and 
COL12A1 genes cause severe connective tissue disorders [17;109;140;186;218]. In 
addition, the collagens for which these genes encode, types III, VI, and XII, are 




Therefore, investigation of candidate variants in other collagen genes, such as 
COL3A1 rs1800255, COL6A1 rs35796750 and COL12A1 rs970547, was required to 
determine how they might modulate the aetiologies of these musculoskeletal soft 
tissue injuries and other exercise-related phenotypes. Furthermore, investigation of 
collagen gene variants in novel candidate exercise-related phenotypes was required 
to further determine the effects that these variants may have. In this concluding 
chapter, the novel findings, which address the aims of this thesis (Chapter 2 Section 
2.7) will be summarised and the perspective and future direction will be discussed. 
 
10.1.1 Primary Aim: To investigate the COL3A1 rs1800255 and COL6A1 
rs35796750 gene variants as risk factors for ACL ruptures and chronic Achilles 
tendinopathy 
 
The COL5A1 rs12722 gene variant has been previously associated with risk of 
anterior cruciate ligament (ACL) ruptures in females [153] and with chronic Achilles 
tendinopathy [131]. The COL12A1 rs970547 gene variant has also previously been 
associated with risk of ACL ruptures in females [154], but not with chronic Achilles 
tendinopathy [181]. Furthermore, the COL3A1 rs1800255 gene variant was not 
associated with risk of chronic Achilles tendinopathy [170]. The COL3A1 and 
COL6A1 genes have not been previously investigated for risk of ACL ruptures, and 
the COL6A1 gene has not been investigated for risk of chronic Achilles tendinopathy. 
Therefore, where appropriate, this thesis investigated the COL3A1 rs1800255 and 
COL6A1 rs35796750 gene variants as risk factors for these musculoskeletal soft 
tissue injuries. 
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The novel findings of this thesis were that the COL3A1 rs1800255 and COL6A1 
rs35796750 gene variants were not independently associated with risk of ACL 
ruptures. In addition, no significant gene-gene interactions between these variants 
and risk of ACL rupture were identified. These results therefore suggest that 
COL3A1 rs1800255 and COL6A1 rs35796750 are not risk factors for ACL ruptures. 
 
The novel findings of this thesis were that the COL6A1 rs35796750 variant was not 
independently associated with risk of chronic Achilles tendinopathy in a South 
African or Australian cohort in this thesis. However, a novel gene-gene interaction 
between COL6A1 rs35796750 and the previously investigated COL3A1 rs1800255 
variant [170] was shown to modulate the risk of Achilles tendinopathy.  
 
10.1.2 Secondary Aim: To investigate the COL3A1, COL6A1, and COL12A1 
genes for associations with range of motion and endurance performance 
 
Of the collagen genes investigated in this thesis, only the COL5A1 rs12722 variant 
was previously associated with endurance performance [151] and range of motion 
(ROM) [28;29]. Therefore, this thesis investigated the COL3A1, COL6A1, and 
COL12A1 genes for associations with these exercise-related phenotypes. 
 
The novel findings of this thesis were that the COL3A1 rs1800255, COL6A1 
rs35796750 and COL12A1 rs970547 variants were not independently associated 
with specific upper and lower body joint range of motion (ROM) measurements. 
Despite a lack of independent associations, the COL3A1 rs1800255 and COL6A1 




variation. These results implicate these genes in the aetiology of ROM for the first 
time. 
 
A further novel finding of this thesis was the identification of the COL6A1 rs35796750 
gene variant as a novel performance marker for the bike component of the South 
African Ironman triathlon. The COL6A1 rs35796750 TT genotype was associated 
with increased performance during the bike component of the South African Ironman 
triathlon. No independent associations were identified between COL3A1 rs1800255 
or COL12A1 rs970547 and time to complete any of the components of the Ironman 
triathlon. However, COL3A1 rs1800255 and COL6A1 rs35796750 were again shown 
to interact, with COL12A1 rs970547, to modulate endurance running performance.  
 
10.1.3 Tertiary Aim: The investigation of COL3A1 rs1800255, COL5A1 rs12722, 
COL6A1 rs35796750 and COL12A1 rs970547 in novel exercise-related 
phenotypes, namely exercise associated muscle cramps and rugby union 
playing level and position. 
 
Due to the previously mentioned associations between collagen genes and 
musculoskeletal soft tissue injuries and other exercise-related phenotypes, this 
thesis also investigated COL3A1 rs1800255, COL5A1 rs12722, COL6A1 
rs35796750 and COL12A1 rs970547 in novel exercise-related phenotypes, namely 
exercise associated muscle cramps (EAMC) and rugby union playing level and 
position. 
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A novel finding of this thesis was the identification of COL5A1 rs12722 as a marker 
for a past history of EAMC. Specifically, the COL5A1 rs12722 CC genotype was 
significantly over-represented in participants that reported never suffering from 
EAMC, when compared to participants that reported suffering from EAMC within 12 
months prior to the events. A significant novel interaction was also identified between 
the COL5A1 and COL6A1 genes and risk of past history of EAMC. These results 
highlight the COL5A1 rs12722 and COL6A1 rs35796750 gene variants as risk 
factors for EAMC. The COL3A1 rs1800255 and COL12A1 rs970547 gene variants 
were not implicated in the aetiology of EAMC.  
 
The novel findings of this thesis were that the COL3A1 rs1800255 variant was 
independently associated with rugby union playing position. Professional rugby union 
forwards had a significantly lower rs1800255 GG genotype frequency distribution 
when compared to control participants. No independent associations were identified 
between COL5A1 rs12722, COL6A1 rs35796750 or COL12A1 rs970547 and rugby 
union playing position. Despite this lack of independent associations, the COL5A1 
rs12722, COL6A1 rs35796750 and COL12A1 rs970547 gene variants were shown 
to interact to modulate individual inclination to a rugby union backs position. 
 
10.1.4 Final Aim: To investigate the expression of the COL6A1 gene in 
individuals with known rs35796750 genotypes. 
 
The COL6A1 rs35796750 gene variant occurs near the branch site of intron 32 
where the cytosine to thymine transition is proposed to cause aberrant splicing of the 




COL5A1 rs12722 [107], it is important to determine the functional and biological 
mechanisms of how COL6A1 rs3579750 may modulate exercise-related and other 
multifactorial phenotypes. This thesis therefore investigated the functional effects of 
COL6A1 rs35796750. 
 
This thesis showed for the first time that participants with the COL6A1 rs35796750 
TT and TC genotypes had significantly higher COL6A1 gene expression when 
compared to participants with the CC genotype, suggesting that individuals with at 
least one COL6A1 T allele have a higher type VI collagen gene expression.  
However analysis of COL1A1 gene expression between the COL6A1 genotype 
groups showed a similar COL1A1:COL6A1 expression ratio in individuals with the 
COL6A1 rs35796750 TC and CC genotypes, with a higher COL1A1:COL6A1 ratio in 
the participants with a COL6A1 TT genotype, suggesting that relative to type I 
collagen gene expression, type VI collagen might be higher in individuals with a 
COL6A1 TT genotype. These novel results show a functional effect on COL6A1 
expression as a result of the rs35796750 gene variant. 
 
As mentioned in each experimental chapter, there are limitations to the studies 
conducted in this thesis. Since these limitations may provide for false positive 
associations additional studies are required to replicate the results presented above. 
Despite this, the perspectives and future direction based on the results of this thesis 
will be discussed.  
 
 





A summary of the novel findings of this thesis, as well as the results of previously 
published studies, for each gene with regard to the investigated musculoskeletal soft 
tissue injuries and other exercise-related phenotypes is presented in table 10.1. The 
contributions of these findings, together with the results of previously published 
studies, to understanding the role that each gene variant may play in the aetiologies 





Table 10.1. A summary of the specific genetic associations identified in this thesis. Both 














Genotype not associated CC ♀ prev pub1 not associated 
AA ♀  
prev pub2 






prev pub5 not associated 
not associated 
prev pub6 
Haplotype A C C nd 
ROM 
Genotype not associated CC prev pub7 not associated not associated 





Genotype not associated not associated not associated not associated 





Genotype not associated not associated TT not associated 





Genotype not associated TT prev pub8 not associated not associated 




Genotype not associated CC not associated not associated 




Genotype GG10 not associated not associated not associated 
Haplotype not associated T11 T11 G11 
Table 10. 1. A summary of the specific genetic associations identified in this thesis. 
Green shading indicates that the allele or genotype is associated with a reduced risk of injury, except for ROM, 
endurance performance and rugby union where it represents an increased ROM or endurance performance and 
an over-representation in a position sub-group. Red shading indicates that the allele or genotype is associated 
with an increased risk of injury, except rugby union where it represents an under-representation in a position sub-
group. Grey shading indicates no independent association. Prev pub, previously published. ♀, associations 
identified only in females. ACL, anterior cruciate ligament; ROM, range of motion; EAMC, exercise-associated 
muscle cramps; nd, not determined.  
1 independent association previously reported by Posthumus et al. [153]. 
2 independent association previously reported by Posthumus et al. [154], but not independently associated in this thesis. 
3 T+A pseudo-haplotype also associated with increased risk of female ACL ruptures when a Polish cohort was analysed [137]. 
4 no independent association previously reported by Saunders [170] 
5 independent association previously reported by Mokone et al. [131] and repeated by September et al. [179]. 
6 no independent association previously reported by September et al. [181] 
7 independent association previously reported by Brown et al. [28;29]. 
8 independent association previously reported by Posthumus et al. [151]  and repeated by Abrahams et al. [1]. 
9 only male participants were included in this study. 
10 Under-represented in the Rugby Union forwards sub-group in this thesis. 
11 Over-represented in the Rugby Union backs and outside backs sub-groups in this thesis. 
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10.2.1 The COL5A1 rs12722 Gene Variant 
 
The associations between the rs12722 C/T variant within a functional region of the 
COL5A1 3’-UTR and these phenotypes, namely chronic Achilles tendinopathy, ACL 
ruptures in females, lower limb range of motion measurements and running 
endurance performance, have been previously described 
[1;2;28;29;40;131;151;153;156;179] and mechanisms for these associations have 
been proposed [41]. The novel findings that the COL5A1 rs12722 CC genotype and 
C allele, as part of an inferred pseudo-haplotype, were associated with a reduced 
risk of a history of exercise-associated muscle cramps (EAMC) and that the T allele, 
as part of inferred pseudo-haplotypes, was associated with increased risk of a 
history of EAMC and with the backs (playing positions 9-15) rugby union positions 
are agreement with these previous findings and the mechanisms proposed for this 
variant [41] (Table 10.1). Additional evidence for the type V collagen genotype and 
exercise-related phenotype relationships hypothesis [41] was recently published, 
where the combined WW+CC genotypes of the COL5A1 3’-UTR 
rs14774622/rs55748801 and rs12722 was reported to be associated with reduced 
risk of the occupational over-use injury, carpal tunnel syndrome [32]. Although there 
is a growing body of evidence that hypothesizes that variants within the functional 
COL5A1 3’-UTR alter fibril architecture and structure and, thereby, directly or 
indirectly the mechanical properties of musculoskeletal soft tissue, there are studies 






10.2.2 The COL3A1 rs1800255 Gene Variant    
 
The COL3A1 rs1800255 (G/A) variant was only independently associated with rugby 
union player position, while the A and G alleles were implicated in various collagen 
gene-gene interactions (Table 10.1). Specifically the rs1800255 GG genotype was 
shown to be under-represented in the forwards rugby union position sub-group, while 
the G allele was implicated in inferred pseudo-haplotype associations with increased 
endurance swimming and running performance (Table 10.1). In addition, the 
rs1800255 A allele was implicated in an inferred pseudo-haplotype associated with 
reduced risk of chronic Achilles tendinopathy. The non-synonymous COL3A1 
rs1800255 gene variant is proposed to be functional [94]. The guanine to adenine 
substitution results in an alanine to threonine change at position 698 of the COL3A1 
peptide which is proposed to affect the tensile strength of type III collagen fibres [94]. 
The hydroxyl side chain of threonine is more hydrophilic than that of alanine and may 
result in distortion and unwinding of the collagen triple helix of type III collagen [94]. 
Interestingly, increased levels of type III collagen have also been shown to reduce 
fibril diameter in a dose dependent manner [110]. Although the exact implications 
that these changes to type III collagen may have on fibrillogenesis are not yet 
known, it is tempting to speculate that the AA genotype or A allele of rs1800255, 
containing the less favourable threonine residue at position 698, results in 
conformational changes in the triple helix of the type III collagen molecules, which 
when incorporated into the collagen fibril will alter its mechanical properties (Figure 
10.1). Therefore, the presence of the more favourable GG genotype or G allele may 
grant endurance athletic benefits due to a more beneficial collagen fibril architecture 
and biomechanics, allowing for increased endurance swimming and running 
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performance (Figure 10.1). Although it is unclear how the incorporation of the type III 
collagen molecule with a “distorted and not properly wound” triple helix into the 
collagen fibril could be protective, the results of this thesis suggest that the G allele 
may increase the risk of musculoskeletal soft tissue injuries. This is highlighted by 
the association of the A allele with reduced risk of chronic Achilles tendinopathy 
(Figure 10.1). Furthermore, it cannot be discounted that this association is merely a 
consequence of the possible increased training volume, frequency and/or speed of 
endurance athletes who are able to perform better.    
 
This proposed mechanism does not explain the under-representation of the “normal” 
GG genotype in rugby union forwards players, however previous studies have shown 
contrasting genetic association results between power and endurance sports [26]. 
For example, the GG genotype of the PPARα rs4253778 G/C variant was under-
represented in power athletes (weightlifting and sprinting) and over-represented in 
endurance athletes (triathlons and cross-country skiing) when compared to 










Figure 10. 1. A proposed mechanism by which COL3A1 rs1800255 G/A may alter the collagen fibril to modulate the aetiology 




Figure 10.1. A proposed mechanism by which COL3A1 rs1800255 G/A may alter the 
collagen fibril to modulate the aetiology of musculoskeletal soft tissue injuries and other 
exercise-associated phenotypes. (A) The rs1800255 G allele results in an alanine amino 
acid at position 698 of the COL3A1 peptide. This results in a “normal collagen fibril” with 
beneficial architecture and biomechanics, allowing for athletic benefits. (B) The rs1800255 A 
allele results in a more hydrophilic threonine amino acid at the same position. The resulting 
conformational changes, distortion and unwinding, of the triple helix of the type III collagen 






These varying genetic association results could also indicate that these associations 
may be due to another variant within the COL3A1 gene or a neighbouring gene, 
such as COL5A2. Since COL5A2 encodes for the α2(V) chain of type V collagen, it is 
possible that functional changes to the expression of COL5A2 may affect type V 
collagen and the overall fibril in a similar manner as proposed for COL5A1 [41]. 
Although less common, rare mutations within COL5A2 have also been shown to 
cause the classical forms of EDS [122;124]. No individual variants within the 
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COL3A1 and downstream COL5A2 genes have however to date been reported to 
associate with chronic Achilles tendinopathy [170]. In addition, no inferred 
haplotypes constructed from these COL3A1 and/or COL5A2 variants have been 
reported to associate with Achilles tendinopathy [170]. It is possible that associated 
variants within the COL3A1/COL5A2 locus still need to be identified, and entire gene 
sequencing technologies and approaches could be considered for future studies.     
 
Further studies are also required to confirm the proposed functional effects of 
rs1800255, as well as any other associated variant that might eventually be identified 
within the COL3A1/COL5A2 locus, and how these variants may affect the 
biomechanical properties and architecture of type III collagen containing tissues. 
Furthermore, the associations identified with rs1800255 in this thesis were in male 
participants only and female participants should also be included in future studies.  
The possibility that rs1800255, and other COL3A1 variants, is an important 
modulator of specific phenotypes also needs to be considered and investigated.   
 
10.2.3 The COL12A1 rs970547 Gene Variant 
 
This thesis did not identify any independent associations between the COL12A1 
rs970547 gene variant and investigated exercise-related phenotypes. However, 
novel inferred pseudo-haplotype associations were identified between the COL12A1 
rs970547 A/G gene variant and endurance running performance and rugby union 
position, respectively (Table 10.1). Specifically, the rs970547 A allele was associated 
with increased running performance, while the G allele was over-represented in the 




the COL12A1 rs970547 AA genotype and A allele were previously associated with 
an increased risk of ACL rupture in females only [137;154]. It is interesting to note 
that, as reported for COL3A1, the opposite COL12A1 alleles were associated with 
the endurance and power sports. Similarly, the same allele was associated with both 
endurance performance and risk of injury. ACL ruptures are not a common injury for 
endurance running athletes [20;61], however rugby union player are at higher risk 
since the sport involves high risk activities for ACL ruptures, including the cutting, 
pivoting and landing [20;61;167]. 
 
Although the function of rs970547 is unknown, bioinformatic functional analysis has 
shown that the glycine (rs970547 G allele) to serine (rs970547 A allele) change is 
potentially damaging to the α1(XII) chain and may modulate the function of type XII 
collagen [105]. Increasing levels of the N-terminal NC-3 domain of type XII collagen 
reduces inter-fibrillar connections, which may make the matrix surrounding these 
fibrils more pliable in the absence of cellular stress or more rigid if these domains are 
able to facilitate cell-mediated alignment and concentration of banded fibrils [133], 
and these changes to the matrix may then result in fibrils with reduced or larger 
diameters, respectively [133]. Therefore, it is possible that the rs970547 A allele may 
produce an isoform of type XII collagen which could alter fibril diameter and the 
biomechanical properties and architecture of the tissue. Future studies are required 
to test this proposal. Based on the proposed function of the rs970547 and the pattern 
of reported associations of this variant with the various phenotypes, a simple 
mechanism could not be proposed. The data does suggest that this COL12A1 
variant might modulate the effect that the COL5A1 3’-UTR variants have on some of 
the phenotypes (Table 10.1), such as ACL rupture (Chapter 3) [154], endurance 
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running performance (Chapter 6) and rugby union position (Chapter 8). It also cannot 
be excluded that these associations are due to other nearby polymorphisms within 
this gene. As stated in chapter 2, one other COL12A1 variant (rs240736) was 
investigated for risk of chronic AT [181] and ACL ruptures [154], however no 
independent significant associations were observed. Future studies should 
investigate additional variants within this gene for associations with musculoskeletal 
soft tissue injuries and other exercise-associated phenotypes. Furthermore, 
additional studies should determine the mechanism through which types XII and V 
collagen may interact to modulate the aetiologies of these phenotypes.  
 
10.2.4 The COL6A1 rs35796750 Gene Variant 
 
Novel independent and haplotype associations were identified between the CO6A1 
rs35796750 C/T gene variant and musculoskeletal soft tissue injuries and other 
exercise-associated phenotypes (Table 10.1). Specifically, the TT genotype was 
independently associated with increased endurance cycling performance, while the T 
allele was implicated in inferred pseudo-haplotypes over-represented in the backs 
and outside backs rugby union position sub-groups and associated with increased 
endurance swimming performance and increased ROM, as well as, reduced risk of a 
history of EAMC, respectively (Table 10.1). In addition, the C allele was implicated in 
pseudo-haplotypes associated with increased endurance running performance, 
reduced risk of chronic Achilles tendinopathy and increased risk of a history of 





Furthermore, this thesis showed for the first time that the rs35796750 C/T variant is 
functional (Chapter 9). Specifically, preliminary investigation showed that the 
rs35796750 TT genotype increases COL6A1 gene expression, when compared to 
the CC genotype. Therefore, this thesis also proposed a genetic continuum for 
COL6A1, where common variants are associated with altered gene expression, 
similar to that proposed for the COL5A1 gene in chapter 2 section 2.2 (Chapter 9, 
Figure 9.8) [41]. Mutations within a single copy of the COL6A1 gene result in 
Bethlem myopathy and Ullrich congenital muscular dystrophy [109]. At the opposite 
end of the continuum, functional common variants within COL6A1, such as 
rs35796750, contribute to more complex and less severe phenotypes, and do not 
result in debilitating disorders (Chapter 9, Figure 9.8). A murine model has shown 
that Col6a1 -/- null mice have collagen fibrils with smaller diameters and greater 
density when compared to wildtype mice, accompanied by reduced tendon stiffness 
and maximal load [78]. Reduced COL6A1 gene expression, as a result of the 
rs35796750 CC genotype, may therefore result in a similarly reduced collagen fibril 
diameter and increased fibril density, which in turn may reduce the stiffness and 
maximal load of the type VI collagen containing tissue including tendons, ligaments 
and muscle (Chapter 9, Figure 9.8). In contrast, the TT genotype may increase 
COL6A1 gene expression resulting in increased collagen fibril diameter and a 
corresponding reduction in fibril density. A summary of the associations identified for 
the functional COL6A1 rs3579750 are presented in figure 10.2. 
  













Figure 10. 2. A proposed mechanism by which the functional COL6A1 rs35796750 C/T may alter the collagen fibril to modulate 




Figure 10.2. A proposed mechanism by which the functional COL6A1 rs35796750 C/T may 
alter the collagen fibril to modulate the aetiology of musculoskeletal soft tissue injuries and 
other exercise-associated phenotypes. (A) The rs35796750 T allele results in increased 
COL6A1 expression. This may result in an increased collagen fibril diameter and 
corresponding reduced density. (B) The rs35796750 C allele results in reduced COL6A1 





Interestingly, most of the associations identified for COL6A1 rs35796750 may be 
explained by this mechanism (Chapter 9 Figure 9.8) and are consistent with the 
model outlined for type V collagen (Chapter 2 Figure 2.15) [41]. A summary of these 
similar and consistent findings, as well as contrasting and unique findings are 










Figure 10. 3. A summary of the association results for COL5A1 rs12722 and COL6A1 rs35796750, with regard to their 









Figure 10.3. A summary of the association results for COL5A1 rs12722 and COL6A1 
rs35796750, with regard to their proposed modulation of the collagen fibril. (A) The COL5A1 
rs12722 C and COL6A1 rs35796750 T alleles are proposed to result in an increased fibril 
diameter and corresponding reduced density. (B) The COL5A1 rs12722 T and COL6A1 
rs35796750 C alleles are proposed to result in a reduced fibril diameter and corresponding 
increased density. The up arrow (↑) indicates that the alleles are associated with an 
increased risk of injury, increased performance or increased range of motion. In the case of 
rugby union it represents an over-representation of the allele. The down arrow (↓) indicates 
that the alleles are associated with a reduced risk of injury.  
a Only the COL6A1 rs35796750 T allele was associated with endurance cycling 
performance. 
b Only the COL5A1 rs12722 T allele was associated with risk of ACL rupture. 
c The COL5A1 rs12722 T allele was associated with increased risk of chronic Achilles 
tendinopathy while the COL6A1 rs35796750 C allele was associated with reduced risk.   
d The COL5A1 rs12722 T allele and contrasting COL6A1 rs35796750 T allele were over-
represented in the rugby union backs players.  
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Mutations within the COL6A1 gene result in Bethlem myopathy [17;109] and Ullrich 
congenital muscular dystrophy [17;109;140] highlighting the importance of type VI 
collagen within skeletal muscle. Furthermore, mutations within COL5A1 cause 
classic Ehlers-Danlos syndrome [124], suggesting a critical role for type V collagen 
in the extracellular matrix of musculoskeletal soft tissue. The COL5A1 rs12722 
(Chapter 2 Section 2.5.4) [107] and COL6A1 rs35796750 (Chapter 9) variants have 
been shown to be functional. Specifically, these variants may alter the collagen fibril 
diameter and corresponding density (Figure 10.3). The changes to the fibril 
architecture as a result of COL5A1 gene variants have been proposed to alter the 
soft tissue biomechanics, which may explain associations identified between these 
variants and musculoskeletal soft tissue injuries and other exercise-related 
phenotypes [41]. The aim of this thesis was to investigate collagen genes and 
variants, such as COL6A1 rs35796750, that may have a similar effect on the 
collagen fibril architecture and therefore the tissue biomechanics. Most of the 
associations identified for COL6A1 rs35796750 in this thesis support the model 
proposed by Collins and Posthumus (Figure 10.3) [41]. Interestingly, contrasting and 
unique associations were also identified. Specifically, contrasting association results 
were identified for risk of Achilles tendinopathy and for predisposition to the rugby 
union backs positions, while the COL6A1 rs35796750 variant was not associated 
with ACL ruptures but was uniquely associated with endurance cycling performance 
(Figure 10.3). It is tempting to speculate that these contrasting and unique 
associations may be the result of the skeletal muscle specific nature of type VI 
collagen. These findings suggest a minor role for altered skeletal muscle 
biomechanics in ACL ruptures and predisposition to the rugby union backs positions, 




endurance cycling performance. Further research is required to test these 
hypotheses. Furthermore, it cannot be discounted that these contrasting and unique 
findings are the result of the multifactorial and polygenic aetiologies of these 
phenotypes. 
 
10.2.5 The Multifactorial and Polygenic Nature of Musculoskeletal Soft Tissue 
Injuries and Other Exercise-Related Phenotypes 
 
All the phenotypes investigated in this thesis, including ACL ruptures [67], chronic 
Achilles tendinopathy [128], joint range of motion [6;11;70;119;204], endurance 
performance [26;198], EAMC [174;176] and rugby union playing level and position 
[157;158;167;185], have complex multifactorial and polygenic aetiologies as outlined 
in figure 10.4.  
 
  













Figure 10. 4. A summary of the multifactorial nature of the phenotypes investigated in this thesis. 
 
Figure 10.4. A summary of the multifactorial nature of the phenotypes investigated in this thesis, 
adapted from Tucker and Collins [198]. (1) The musculoskeletal soft tissue injuries and other 
exercise-related phenotypes investigated in this thesis have common predisposing intrinsic factors. 
These intrinsic factors include, among others, a common genetic component. Although range of 
motion (ROM) is a complex multifactorial phenotype it is also a common intrinsic factor in the 
aetiology of the other phenotypes investigated in this thesis. (2)  In addition to the common intrinsic 
factors shown, the musculoskeletal soft tissue injuries have specific intrinsic factors, for example a 
previous injury of the same type, a previous injury to the same tissue and even specific genetic 
markers. (3) Similarly, other exercise-related phenotypes, including endurance performance and 
rugby union position, also have specific intrinsic factors such as specific genetic markers. (4) 
Musculoskeletal soft tissue injuries may be intrinsic factors in determining athletic ability, while athletic 
ability may be an intrinsic factor for musculoskeletal soft tissue injuries. (5) All of these phenotypes 
also have common extrinsic factors that may increase injury susceptibility or highlight elite athletes. 
(6) Each of the musculoskeletal soft tissue injuries also has specific extrinsic factors which increase 
an individual’s susceptibility to that injury. An inciting event will then eventually result in injury. (7) 
Similarly, endurance performance and rugby union position also have specific extrinsic factors that 






As shown in figure 10.4, the aetiologies of each of the phenotypes investigated in 
this thesis have numerous intrinsic factors. Furthermore, many of these intrinsic 
factors are common to all these phenotypes. In addition some of these multi-factorial 
phenotypes may even be intrinsic factors for others. For example ROM is a risk 
factor for musculoskeletal soft tissue injuries [208] and is also associated with 
running economy [77]. It is therefore difficult to determine which intrinsic factors may 
be directly causative to a phenotype and which are merely associated due to their 
indirect effects. These limitations are true for the genetic component as well. This is 
highlighted by the fact that none of the associated inferred pseudo-haplotypes had 
the same allele combinations (Table 10.1). Two possible reasons for these 
discrepancies are that; (i) the associations identified in this thesis may indicate direct 
causative factors or may be the result of causative loci in the same, or a 
neighbouring, gene. Or that (ii) these associations may be the result of indirect 
associations due to the overlap between the investigated phenotypes. Future 
research is required to determine the functional effects of all associated gene 
variants in order to better understand the molecular mechanisms, direct or indirect, 
through which their proteins might interact to modulate the aetiology of 
musculoskeletal soft tissue injuries and other exercise-related phenotypes.    
 
This thesis has highlighted the role that collagens may play in the aetiology of 
exercise-related musculoskeletal soft tissue phenotypes. Collagen gene variants, 
namely COL3A1 rs1800255, COL5A1 rs12722, COL6A1 rs35796750 and/or 
COL12A1 rs970547, have been identified as markers for the phenotypes 
investigated in this thesis, although in some cases independent associations were 
not identified. Although large effect sizes have been reported for some of the 
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common collagen gene variants studied to date, for example rs12722 [131;156;179], 
the expected effect sizes of common variants have often been described as 
approximately 1.1-1.5 and this may explain a lack of independent associations [4]. 
The sample sizes for this thesis were calculated based on previous findings for large 
effect sizes [131;156;179]. Future studies should investigate independent 
associations and gene-gene interactions, with biological relevance, within larger 
cohorts to overcome this limitation of common variants with small effect sizes.  
 
The collagen genes chosen in this thesis all encode for collagens, which interact to 
have an impact on the structure and/or function of the collagen fibril. Therefore it 
may be hypothesised that minor changes to these collagens, as a result of the 
investigated common variants, may cumulatively modulate the collagen fibril thereby 
resulting in pseudo-haplotype markers for these phenotypes. This is evidenced by 
the association of multiple inferred pseudo-haplotypes with musculoskeletal soft 
tissue injuries and other exercise-associated phenotypes in this thesis, where 
independent associations were not identified for those variants. The biological 
significance of these inferred pseudo-haplotypes are however currently difficult to 
interpret.  
 
10.3 FUTURE DIRECTIONS 
  
The collagens investigated in this thesis have been identified in a number of tissues, 
including tendons, ligaments and skeletal muscle (Chapter 2, Table 2.5). It may be 
proposed that, due to the ubiquitous nature of these collagens, the number of 




collagens will be limited since they could potentially result in a number of anomalous 
changes to all the tissues containing these collagens. These anomalous changes 
may not be tolerated during development or may result in severe disorders. Further 
complicating this issue is the fact that environmental factors may interact with these 
collagen variants in a tissue specific manner [38]. Therefore, the expression of these 
ubiquitous collagens may be different within specific tendon, ligament and skeletal 
muscle structures. 
 
Unlike the collagens investigated in this thesis there are a number of known “lesser 
characterised” collagens which are not ubiquitous in nature, but rather are localised 
to particular tissues or to subdivisions within certain tissues (Table 10.2). The 
functions of these collagens within tendon, ligament and/or skeletal muscle tissues is 
largely unknown, however it is tempting to speculate that this expression specificity 
may result in reduced redundancy for specific functions performed by these 
collagens or that these collagens serve as redundancy for the ubiquitous collagens 
also expressed within these tissues. This lack of redundancy would mean that 
tolerated functional common variants within the genes that encode these “lesser 
characterised” collagens, which do not result in disorder but still alter the architecture 
and biomechanics of their containing tissues, are more likely to be independently 
associated with investigated phenotypes. In addition, the tissue specific nature of 
these “lesser characterised” collagens limits the confounding effects that 
environmental factors might have on their gene expression. Therefore the genes that 
encode these “lesser characterised” collagens are excellent candidates for future 
genetic association studies with musculoskeletal soft tissue injuries and other 
exercise-associated phenotypes. 






Table 10.2. A summary of “lesser characterised” or minor collagens that have been 






Midsub MTJ OTJ Endo Peri Epi 
Fibrillar        
XXVII     ? ? ? 
Non-fibrillar        
XIII  √   √   
XV     √ √ √ 
XIX     ? ? ? 
XX ? ? ?     
XXI     ? ? ? 
XXII  √      
XXIII ? ? ?     
Table 10. 2. A summary of “lesser characterised” or minor collagens that have been identified within tendons, ligaments and the 
connective tissue structures of skeletal muscle. 
The localisation of collagen types is indicated by “ticks”. The question marks (?) show where 
a collagen type has been identified in that tissue but details were not given for a particular 
portion or subdivision. The tendon is shown as three separate portions; the midsubstance 
(Midsub), the myotendinous junction (MTJ) and the osteotendinous junction (OTJ). The three 
separate connective tissue subdivisions of skeletal muscle are shown; the endomysium 
(Endo), the perimysium (Peri) and the epimysium (Epi). 
 
 
Type XXVII collagen is a fibrillar collagen that is mainly expressed in cartilage and at 
sites of transition from cartilage to bone but is also expressed in the skeletal muscle 
[23;74;144] (Table 10.2). The exact function of type XXVII within skeletal muscle is 
currently not known, however its specific localisation to this skeletal muscle tissue 
makes its encoding gene (COL27A1) an excellent candidate for genetic association 




exercise-associated phenotypes with skeletal muscle involvement, such as exercise-
associated muscle cramps, endurance cycling performance and rugby union level 
and position. Interestingly, Saunders et al. [171] recently investigated the COL27A1 
and TNC genes as risk factors for chronic Achilles tendinopathy. No independent 
associations were identified for the investigated COL27A1 rs946053, rs4143245, 
rs1249744 and rs753085 gene variants, however the rs946053 variant was 
implicated in a haplotype, with the TNC variants, associated with risk of chronic 
Achilles tendinopathy [171]. This study highlights that the COL27A1 rs946053 may 
be a good candidate for future genetic association studies investigating 
musculoskeletal soft tissue injuries and other exercise-associated phenotypes. 
 
Although little is known about their functions, a number of other “lesser 
characterised” non-fibrillar collagens, types XIII, XV, XIX, XXI and XXII collagen, are 
also specifically expressed within skeletal muscle and the myotendinous junction 
(Table 10.2). Type XV collagen is mainly derived from muscle cells and fibroblasts 
[68], and mice lacking type XV collagen suffer from skeletal myopathy highlighting 
the importance of this collagen within skeletal muscle [49]. In addition, types XIII and 
XXII collagen are expressed in the basement membrane of myotendinous junctions 
[72;99;189], and type XIII was also identified in the skeletal muscle endomysium 
[72;189]. Furthermore, types XIX and XXI collagen have also been identified within 
skeletal muscle [54;132]. As with type XXVII collagen the specific expression of 
these collagens makes their encoding genes excellent candidates for genetic 
association studies to determine novel markers for musculoskeletal soft tissue 
injuries and other exercise-associated phenotypes with skeletal muscle involvement.  
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Interestingly, the non-fibrillar types XX and XXIII collagen have been identified in 
tendons but not in ligaments or skeletal muscle [97;100] (Table 10.2). Type XX 
collagen has been identified as a FACIT while type XXIII collagen is a 
transmembrane domain collagen. The exact functions of these collagens have yet to 
be determined but high levels of type XXIII collagen in urine is a potential marker for 
lung cancer [188]. Further studies are required to determine the exact functions of 
these collagens and functional common variants within the COL20A1 (encodes type 
XX collagen) and COL23A1 (encodes type XXIII collagen) genes should be 
investigated for musculoskeletal soft tissue injuries and other exercise-associated 
phenotypes with tendon involvement, such as Achilles tendinopathy, endurance 
running performance, range of motion and rugby union playing level and position.  
 
To date none of the “lesser characterised” collagens have been identified in 
ligaments (Table 10.2). This highlights the necessity for future studies to determine 
the exact functions of these “lesser characterised” collagens. Ligaments and tendons 
have a similar hierarchical structure, however their organisational and molecular 
structure are quite different [75]. As a result it is possible that tendon specific 
collagens, such as types XX and XXIII collagen, may also be expressed in 
ligaments, however it is also possible that ligament specific collagen types exist that 
remain to be identified. Therefore, at present, the “well characterised” collagens are 
the only source of novel collagen candidate genes for musculoskeletal soft tissue 
injuries and other exercise-associated phenotypes with ligament involvement, such 
as anterior cruciate ligament rupture, endurance running performance, range of 
motion and rugby union playing level and position. Both types IV and XIV collagens 




variants within their encoding genes, the COL4A1-COL4A6 and COL14A1 genes 
respectively, should be investigated for associations with these musculoskeletal soft 
tissue injuries and other exercise-associated phenotypes. 
 
Finally, in addition to identifying novel variants within collagen genes which are 
associated with musculoskeletal soft tissue injuries and other exercise-associated 
phenotypes, future studies should determine the specific functions of these variants 
and the mechanisms through which they may have an effect on the collagen fibril 
and subsequent containing tissues. Of the collagen genes associated with 
musculoskeletal soft tissue injuries and other exercise-associated phenotypes only 
the COL5A1 rs12722 [107] and COL6A1 rs35796750 (Chapter 9) collagen gene 
variants have been investigated for their functional effects. Future studies should 
investigate the functional effects of those variants previously associated with 
musculoskeletal soft tissue injuries and other exercise-associated phenotypes, such 
as the COL12A1 rs970547 and COL27A1 rs946053 gene variants, and novel 
variants used in investigations for these phenotypes. Identifying the functional effects 
of these variants will provide understanding of the mechanisms through which these 
variants may affect the collagen fibril and thereby the collagen containing tissues. 
Furthermore, studies are also required to determine how the collagen molecules 
interact within the fibril and how changes to the fibril, resulting from collagen gene 
variants, may affect these interactions. These future studies would provide the data 
to develop accurate screening tools to determine individual susceptibility to 
musculoskeletal soft tissue injuries and other exercise-associated phenotypes. 
 





In conclusion, this thesis identifies a number of novel associations between collagen 
gene variants and various musculoskeletal soft tissue injuries and other exercise-
related phenotypes. Interestingly, the functional COL6A1 rs35796750 variant was 
associated with most of the phenotypes investigated in this thesis. Furthermore, as 
initially hypothesised, the mechanism for these associations is consistent with that 
previously proposed for COL5A1 rs12722 [41]. Future studies are required to 
investigate and understand the contrasting and unique results identified for COL6A1 
rs35796750. The COL3A1 rs1800255 variant was associated with a number of 
phenotypes, while no additional independent associations were identified for 
COL12A1 rs970547. In addition, varying gene-gene interactions were identified 
between the four variants and six phenotypes investigated in this thesis. The 
simplest interpretation of these findings is that the association between COL5A1 
rs12722 and the additional exercise-related phenotypes investigated in this thesis, 
namely exercise-associated muscle cramps and rugby union playing position, 
supports the previously described hypothesis that common variants within the type V 
collagen genes, especially COL5A1, are associated with seemingly unrelated 
musculoskeletal soft tissue phenotypes [41]. Furthermore, a similar genetic 
continuum may exist for type VI collagen. The results of this thesis however do not 
support the proposal that common variants, at least those investigated in this thesis, 
within the genes that encode other collagen types, namely III and XII, within or 
associated with the fibril are also associated with seemingly unrelated 
musculoskeletal soft tissue injuries. At best these other collagen variants appear to 




specific manner to modulate inter-individual variation. Further work is required to 
investigate the nature of these interactions and how they may modulate the 
aetiologies of these phenotypes. In addition, candidate variants within the genes that 
encode for “lesser characterised” collagens should be investigated in an attempt to 
identify additional independent markers for the phenotypes investigated in this 
thesis. These results highlight the complexity in identifying genetic, and other, 
markers for the inter-individual predisposition to musculoskeletal soft tissue injuries 
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2000/2001 South African Ironman triathlon informed consent form. 
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2006 Ironman Informed Consent 
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2007 Ironman triathlon Informed Consent 
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4. Participant questionnaires 
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Questionnaire used for the data collection for Chapter 5. Range of Motion 
 
 


























   
323 
 








   
326 
 
Questionnaire used at the 2000 and 2001 South African Ironman Triathlon. Data 
collected was used in Chapters 5-7. Range of Motion, Endurance Performance and 
Exercise-associated Muscle Cramps. 
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Questionnaire used at the 2006 and 2007 South African Ironman Triathlon. Data 
collected was used in Chapters 5-7. Range of Motion, Endurance Performance and 
Exercise-associated Muscle Cramps. 
 

























































































































   
373 
 



















































































   
388 
 




   
389 
 
(B) ALLELIC DISCRIMINATION METHODOLOGY 
 
1. PCR Conditions for COL1A1 rs1800012 G/T 
 
Primer pairs 
Primary reaction  
Forward Primer 5’-GGA AGA CCC GGG TTA TTG CT-3’ 
Reverse Primer 5’-CGC TGA AGC CAA GTG AAA TA-3’ 
Secondary reaction  
Forward Primer 5’-TAA CTT CTG GAC TAT TTG CGG ACT TTT TGG-3’ 
Reverse Primer 5’-GTC CAG CCC TCA TCC TGG CC-3’ 
The secondary reverse primer was designed to contain two mutated nucleotides (underlined in the 
primer sequence) which introduced a restriction site (TGG’CCA) for the restriction endonuclease MscI 
at the 3’ end of the 260 bp secondary PCR product when amplifying the T allele. 
 
PCR Conditions 
Polymerase Taq DNA Polymerase 
Primary Cycling 5 cycles 
Primary Annealing temperature 70oC 
Secondary Cycling 27 cycles 
Secondary Annealing temperature 58oC 
Mg2+ Concentration 2.0 mM 




Cutting site TGG’CCA 
Incubation temperature 37oC 
Fragment sizes G allele – 260 bp T allele – 242 bp, 18 bp 
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2. PCR Conditions for COL5A1 rs12722 T/C 
 
Primer pairs 
Forward Primer 5’-GAA GAC GTT TCT GGA GGA TC-3’ 
Reverse Primer 5’-GGA GGC ACC TGC AGA ATG AC-3’ 
 
PCR Conditions 
Polymerase Taq DNA Polymerase 
Cycling 35 cycles 
Annealing temperature 53oC 
Mg2+ Concentration 1.5 mM 




Cutting site CG’CG 
Incubation temperature 60oC 
Fragment sizes T allele – 351 bp, 316 bp C allele – 316 bp, 271 bp, 80 bp 
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3. PCR Conditions for COL12A1 rs970547 A/G 
 
Primer pairs 
Forward Primer 5’-GAG AAT CCA GAA CAG CTC CAC CAG-3’ 
Reverse Primer 5’-CAT GGC TAG TAT GGG ACA G-3’ 
The COL12A1 forward primer was designed to contain a mutated nucleotide (underlined in the primer 




Polymerase Taq DNA Polymerase 
Cycling 30 cycles 
Annealing temperature 58oC 
Mg2+ Concentration 2.0 mM 




Cutting site AG’CT 
Incubation temperature 37oC 
Fragment sizes G allele – 599 bp, 16 bp A allele – 460 bp, 139 bp, 16 bp 
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4. PCR Conditions for COL3A1 rs1800255 G/A  
 
PCR Conditions 
Taqman SNP Genotyping Assay (Applied Biosystems, Foster City, CA, USA).  
Assay ID: AHGJQCQ 
 
Primer pairs 
Forward Primer 5’- CGT GGA CCT CCT GGA TTG G -3’ 
Reverse Primer 5’- GAA TGC TGT GGA GTT ACC TTT CCT -3’ 
 
Probe sequences 
Allele 1 (G allele) 5’- TAG AGG TGG AGC TGG TC -3’ 













Figure B1. A typical allelic discrimination plot for rs1800255 using the Taqman SNP 
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5. PCR Conditions for COL6A1 rs35796750 T/C  
 
PCR Conditions 
Taqman SNP Genotyping Assay (Applied Biosystems, Foster City, CA, USA).  
Assay ID: AH89JPA 
 
Primer pairs 
Forward Primer 5’- GGC CTT GTC CCC AGA AAG AC -3’ 
Reverse Primer 5’- CCA CGG AGA CCA CCT GTG -3’ 
 
Probe sequences 
Allele 1 (C allele) 5’- TGT GGC GCA GCC TG -3’ 













Figure B2. A typical allelic discrimination plot for rs35796750 using the Taqman SNP 






   
394 
 
(C) SUPPLEMENTARY RESULTS 
 
1. Participant and family history of soft tissue injuries for the male and female 
participants. 
 
Male Participants CON (145) ACL (177) p-value
a
 NON (103) p-value
b
 
Participant previous ligament injury 40.0 (58) 44.1 (78) 0.462 41.7 (43) 0.076 
 Knee ligament injuryc 
4.1 (6) 11.9 (21) 0.010 8.7 (9) 0.134 
 Ankle ligament straind 
21.4 (31) 28.2 (50) 0.158 30.1 (31) 0.118 
Participant previous tendon injury 20.7 (2) 23.7 (42) 0.515 25.2 (26) 0.398 
Participant history of joint capsule disease 11.0 (16) 8.5 (15) 0.439 9.7 (10) 0.737 
Family history ligament injury 26.2 (38) 37.3 (66) 0.034 36.9 (38) 0.072 
 ACL injury 
2.1 (3) 15.3 (27) <0.001 15.5 (16) <0.001 
Family history tendon injury 6.2 (9) 10.7 (19) 0.151 8.7 (9) 0.582 
Female CON (90) ACL (65) p-value
a
 NON (33) p-value
b
 
Participant previous ligament injury 24.4 (22) 43.1 (28) 0.014 48.5 (16) 0.011 
 Knee ligament injuryc 
1.1 (1) 10.8 (7) 0.007 18.2 (6) <0.001 
 Ankle ligament straind 
22.2 (20) 30.8 (20) 0.230 36.4 (12) 0.113 
Participant previous tendon injury 18.9 (17) 15.4 (10) 0.570 27.3 (9) 0.313 
Participant history of joint capsule disease 7.8 (7) 15.4 (10) 0.135 24.2 (8) 0.013 
Family history ligament injury 27.8 (25) 44.6 (29) 0.030 54.5 (18) 0.006 
 ACL injury 
2.2 (2) 20.0 (13) <0.001 33.3 (11) <0.001 
Family history tendon injury 11.1 (10) 13.8 (9) 0.608 12.1 (4) 0.876 
Table C. 1. Participant and family history of soft tissue injuries for the male and female participants. 
Values are expressed as percentages with the number of participants (n) indicated in 
parentheses. Values in bold typeset are significant (p<0.05). CON, apparently healthy 
controls. ACL, anterior cruciate ligament. NON, non-contact mechanism of injury.  
a CON vs. ACL 
b CON vs. NON 
c includes the posterior cruciate ligament, the lateral collateral ligament and the medial 
collateral ligament.  
d includes the lateral and medial ankle ligaments.  
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2. Genotype frequency distributions when participants with a self-reported 
history of any previous ligament injury were excluded from the analysis. 
 
 COL3A1 rs1800255 Genotype 
n p-value 
 GG GA AA 
All Participants     
CON 53.5 (77) 37.5 (54) 9.0 (13) 144  
ACL 56.6 (69) 36.9 (45) 6.6 (8) 122 0.729
a
 
NON 55.9 (38) 36.8 (25) 7.4 (5) 68 0.901
b
 
Male Participants     
CON 54.6 (42) 36.4 (28) 9.1 (7) 77  
ACL 60.4 (55) 36.3 (33) 3.3 (3) 91 0.272
a
 
NON 59.3 (32) 35.2 (19) 5.6 (3) 54 0.721
b
 
Female Participants     
CON 52.2 (35) 38.8 (26) 9.0 (6) 67  
ACL 45.2 (14) 38.7 (12) 16.1 (5) 31 nd 
NON 42.9 (6) 42.9 (6) 14.3 (2) 14 nd 
Table C. 2. Genotype frequency distributions when participants with a self-reported history of any previous ligament injury were excluded from the analysis. 
Values are expressed as percentages with the number of participants indicated in 
parentheses. The total number (n) of participants genotyped in each individual or combined 
cohort is also indicated. Values in bold typeset are significant (p<0.05). All the ACL ruptures 
were diagnosed at surgery.  
nd, not determined. 
a CON vs. ACL 
b CON vs. NON 
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 COL6A1 rs35796750 Genotype 
n p-value 
 TT TC CC 
All Participants     
CON 34.9 (44) 46.0 (58) 19.1 (24) 126  
ACL subset 1 33.3 (19) 54.4 (31) 12.3 (7) 57 0.438
a
 
NON subset 1 31.3 (10) 56.3 (18) 12.5 (4) 32 nd 
Male Participants     
CON 37.5 (27) 41.7 (30) 20.8 (15) 72  
ACL subset 1 32.5 (13) 55.0 (22) 12.5 (5) 40 0.339 
NON subset 1 26.1 (6) 56.5 (13) 17.4 (4) 23 nd 
Female Participants     
CON 31.5 (17) 51.9 (28) 16.7 (9) 54  
ACL subset 1 35.3 (6) 52.9 (9) 11.8 (2) 17 nd 
NON subset 1 44.4 (4) 55.6 (5) 0.0 (0) 9 nd 
 
Values are expressed as percentages with the number of participants indicated in 
parentheses. The total number (n) of participants genotyped in each individual or combined 
cohort is also indicated. Values in bold typeset are significant (p<0.05). All the ACL ruptures 
were diagnosed at surgery.  
nd, not determined. 
a CON vs. ACL 
b CON vs. NON 
  




COL5A1 rs12722 Genotype 
n p-value 
TT TC CC 
Male Participants     
CON 31.4 (27) 54.7 (47) 14.0 (12) 86  
ACL 28.6 (26) 59.3 (54) 12.1 (11) 91 0.816
a
 
NON 29.6 (16) 59.3 (32) 11.1 (6) 54 0.832
b
 
Female Participants     
CON 29.4 (20) 41.2 (28) 29.4 (20) 68  
ACL 33.3 (11) 57.6 (16) 9.1 (3) 33 nd 
NON 23.5 (4) 58.8 (10) 17.7 (3) 17 nd 
 
COL12A1 rs970547 Genotype 
n p-value 
AA AG GG 
Male Participants     
CON 59.5 (50) 36.9 (31) 3.6 (3) 84  
ACL 58.6 (51) 34.5 (30) 6.9 (6) 87 0.614
a
 
NON 58.8 (30) 31.4 (16) 9.8 (5) 51 0.307
b
 
Female Participants     
CON 60.6 (40) 36.4 (24) 3.0 (2) 66  
ACL 60.6 (20) 27.3 (9) 12.1 (4) 33 nd 
NON 52.9 (9) 29.4 (5) 17.7 (3) 17 nd 
 
Values are expressed as percentages with the number of participants indicated in 
parentheses. The total number (n) of participants genotyped in each individual or combined 
cohort is also indicated. Values in bold typeset are significant (p<0.05). All the ACL ruptures 
were diagnosed at surgery.  
nd, not determined. 
a CON vs. ACL 
b CON vs. NON 
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3. A List of Reported Contact and Non-contact non-jumping and Non-
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4. COL3A1 rs1800255 and Achilles tendinopathy 
 
A comparison of the genotype and allele frequency distributions for COL3A1 
rs1800255 (G/A) between the South African and Australian Achilles tendinopathy 
groups and their respective control groups. Genotype and allele frequency 
distributions after combining the cohorts are also reported. Data taken from 
Saunders (2013) [170]. 








 GG GA AA 
SA TEN 56.7 (51) 35.6 (32) 7.8 (7) 90  25.6 (46)  
SA CON 54.9 (89) 34.6 (56) 10.5 (17) 162 0.781 27.8 (90) 0.590 
AUS TEN 63.3 (50) 30.4 (24) 6.3 (5) 79  21.5 (34)  
AUS CON 56.2 (109) 36.1 (70) 7.7 (15) 194 0.558 25.8 (100) 0.295 
All TEN 59.8 (101) 33.1 (56) 7.1 (12) 169  23.7 (80)  
All CON 55.6 (198) 35.4 (126) 9.0 (32) 356 0.606 26.7 (190) 0.296 
Table C. 3. A comparison of the genotype and allele frequency distributions for COL3A1 rs1800255 (G/A) between the South African and Australian Achilles tendinopathy 
groups and their respective control groups. 
Values are expressed as percentages with the number of participants indicated in 
parentheses. The total number (n) of participants genotyped in each individual or combined 
cohort is also indicated.  
SA, South African; AUS, Australia; All, South Africa and Australia; TEN, participants with 
diagnosed Achilles tendinopathy; CON, apparently healthy control participants. 
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5. COL5A1 rs12722 and Achilles tendinopathy 
 
A comparison of the genotype and allele frequency distributions for COL5A1 rs12722 
(T/C) between the South African and Australian Achilles tendinopathy groups and 
their respective control groups. Genotype and allele frequency distributions after 
combining the cohorts are also reported. Data taken from Mokone et al. and 
September et al. [131;179].  








 TT TC CC 
All Participants       
SA TEN 36.6 (34) 50.5 (47) 12.9 (12) 93  38.2 (71)  
SA CON 29.6 (47) 43.4 (69) 27.0 (43) 159 0.031 48.7 (155) 0.021 
AUS TEN 20.0 (17) 68.2 (58) 11.8 (10) 85  45.9 (78)  
AUS CON 35.2 (74) 40.5 (85) 24.3 (51) 210 <0.001 44.5 (187) 0.764 
All TEN 28.7 (51) 59.0 (105) 12.4 (22) 178  41.9 (149)  
All CON 32.8 (121) 41.7 (154) 25.5 (94) 369 <0.001 46.3 (342) 0.162 
Table C. 4. A comparison of the genotype and allele frequency distributions for COL5A1 rs12722 (T/C) between the South African and Australian Achilles tendinopathy 
groups and their respective control groups. 
Values are expressed as percentages with the number of participants indicated in parentheses. The 
total number (n) of participants genotyped in each individual or combined cohort is also indicated. 
Significant p-values are indicated in bold. 
SA, South African; AUS, Australia; All, South Africa and Australia; TEN, participants with diagnosed 
Achilles tendinopathy; CON, apparently healthy control participants.  
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6. COL12A1 rs970547 and Achilles tendinopathy 
 
A comparison of the genotype and allele frequency distributions for COL12A1 
rs970547 (A/G) between the South African Achilles tendinopathy and control groups. 
Data taken from September et al.  [181]. 








 AA AG GG 
SA TEN 44.7 (38) 47.1 (40) 8.2 (7) 85  31.8 (54)  
SA CON 45.3 (72) 47.8 (76) 6.9 (11) 159 0.932 30.8 (98) 0.838 
Table C. 5. A comparison of the genotype and allele frequency distributions for COL12A1 rs970547 (A/G) between the South African Achilles tendinopathy and control 
groups. 
Values are expressed as percentages with the number of participants indicated in 
parentheses. The total number (n) of participants genotyped in each individual or combined 
cohort is also indicated.  
SA, South African; TEN, participants with diagnosed Achilles tendinopathy; CON, apparently 
healthy control participants. 
   
 
 
7. Two-gene inferred pseudo-haplotypes constructed from COL3A1 rs1800255, COL5A1 























Figure C. 1. Two-gene inferred pseudo-haplotypes constructed from COL3A1 rs1800255, COL5A1 rs12722  and/or COL6A1 
rs35796750 and Achilles tendinopathy. 
 
Inferred pseudo-haplotype frequencies, constructed from COL3A1 rs1800255, COL5A1 
rs12722 and/or COL6A1 rs37596750, in South African and Australian participants with 
clinically diagnosed Achilles tendinopathy (TEN group) and apparently healthy controls 
(CON group). Numbers of participants are listed above each column. 
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8. Two-gene inferred pseudo-haplotypes constructed from COL3A1 rs1800255, COL5A1 


























Inferred pseudo-haplotype frequencies, constructed from COL3A1 rs1800255, COL5A1 
rs12722, COL6A1 rs37596750 and/or COL12A1 rs970547, between the High and Low SR-
ROM (sit-and-reach ROM) groups. Numbers of participants are listed above each column. 
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9. Three-gene inferred pseudo-haplotypes constructed from COL3A1 rs1800255, COL5A1 





















Figure C. 3. Three-gene inferred pseudo-haplotypes constructed from COL3A1 rs1800255, COL5A1 rs12722, COL6A1 
rs35796750 and/or COL12A1 rs970547 and Range of Motion. 
 
 
Inferred pseudo-haplotype frequencies, constructed from COL3A1 rs1800255, COL5A1 
rs12722, COL6A1 rs37596750 and/or COL12A1 rs970547, between the High and Low SR-
ROM (sit-and-reach ROM) groups. Numbers of participants are listed above each column.  
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10. Genotype Frequency Distributions for COL3A1 rs1800255, COL5A1 rs12722, COL6A1 
rs35796750 and COL12A1 rs970547 between the participants that had never played 
rugby and the recreational rugby players. 
 
 
COL3A1 rs1800255 Genotype 
p-value 
GG GA AA 
NR CON 54.2 (39) 38.9 (28) 6.9 (5) 
0.988 
Recreational 52.9 (37) 40.0 (28) 7.1 (5) 
 
COL5A1 rs12722 Genotype 
p-value 
TT TC CC 
NR CON 27.6 (21) 51.3 (39) 21.1 (16) 
0.152 
Recreational 41.0 (32) 46.2 (36) 12.8 (10) 
 
COL6A1 rs35796750 Genotype 
p-value 
TT TC CC 
NR CON 35.1 (26) 52.7 (39) 12.2 (9) 
0.469 
Recreational 32.5 (25) 48.1 (37) 19.5 (15) 
 
COL12A1 rs970547 Genotype 
p-value 
AA AG GG 
NR CON 57.7 (45) 39.7 (31) 2.6 (2) 
0.211 
Recreational 52.6 (40) 38.2 (29) 9.2 (7) 
 
Values are expressed as percentages. Numbers of participants are indicated in parentheses.  
NR CON, never played rugby before. 
Table C. 6. Genotype Frequency Distributions for COL3A1 rs1800255, COL5A1 rs12722, COL6A1 rs35796750 and 
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(D) Quantitative Real-Time PCR Methodology 
 
Primer pairs 
COL6A1 primers  
Forward Primer 5’- TCA GAA TAG TGA TGT GTT CGA CGT T -3’ 
Reverse Primer 5’- AGC AAC ATG GAT ATG GTT CAG AAA -3’ 
COL1A1 primers  
Forward Primer 5’- AGC CAG CAG ATC GAG AAC A -3’ 
Reverse Primer 5’- TCT TGT CCT TGG GGT TCT T -3’ 
β-Actin  primers  
Forward Primer 5’- CCT CGC CTT TGC CGA TCC G -3’ 




Cycling 40 cycles 
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